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ABSTRACT 
Wild-type transthyretin amyloidosis (ATTRwt) is a rare, sporadic protein misfolding 
disorder with no validated biomarkers or specific treatments. The disease is characterized 
by deposition of amyloid fibrils composed of wild-type transthyretin (TTR) in cardiac 
tissue, which leads to cardiomyopathy, heart failure, and death within 5 years. The 
hypothesis for the studies detailed in this dissertation was non-coding variants in the TTR 
gene regulatory regions impact expression and serum levels of the protein, thereby 
contributing to ATTRwt pathogenesis. Investigations included examination of 2 enhancer 
regions and the proximal promoter of the TTR gene for risk factors which could 
contribute to pathogenesis of ATTRwt amyloidosis. In total, 11 common and 20 rare 
variants were identified. The analyses demonstrated significant associations of 3 variants 
with increased disease risk and 4 variants with age at disease onset and/or survival. 
Functional studies using GFP and luciferase reporter assays in HepG2 cells were 
performed to examine the impact of nucleotide alterations in the TTR proximal promoter 
on reporter expression. Three ATTRwt-risk factors (rs3764479, rs72922940, rs3794885), 
  x 
caused significantly decreased reporter expression in both GFP and luciferase assays (p < 
0.02). Moreover, serum TTR levels, measured by immunoturbidity and analyzed along 
with ATTRwt clinical data, demonstrated that lower serum TTR concentrations were 
associated with worse survival (hazard ratio = 0.89, p = 0.003). Follow-up analysis of an 
ATTRwt subset treated with diflunisal, a TTR stabilizer, showed increased serum TTR (p 
= 0.002) and organ improvement as assessed by cardiac biomarkers (p = 0.043). 
Unexpectedly, our genetic sequencing data suggested that the TTR G6S variant was 
disease-protective. Analysis of the TTR G6S protein using circular dichroism and 
aggregation assay corroborated these findings by demonstrating a higher structural 
stability and a lower aggregation propensity compared to L55P and V122I, two unstable 
amyloidogenic TTR variants. In summary, the major findings of this work were: 1) 
identification of genetic variants that confer risk for ATTRwt amyloidosis through 
changes in expression, 2) evidence in support of serum TTR as a candidate for 
monitoring disease progression and response to treatment, and 3) evidence suggesting 
that TTR G6S may confer protection from ATTRwt by slowing the amyloid cascade. 
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CHAPTER 1. INTRODUCTION 
1.1 Amyloid and amyloidosis 
Amyloid deposits were first described by Rudolf Virchow in 1854, when he observed 
autopsy tissue that stained with iodine, a marker for starch; he thus termed these deposits 
“amyloid,” derived from the Latin word for starch, “amylum” (Virchow, 1854). It was 
determined in 1927 that these starch-like, or amyloid, deposits stained with Congo red 
dye, and exhibited a characteristic “apple-green” birefringence under cross-polarized 
light (Divry and Florkin, 1927). Congo red staining still remains the gold standard for an 
unequivocal diagnosis of amyloidosis (Maurer, 2015; Wechalekar et al., 2016). While 
amorphous in appearance by light microscopic examination, tissue-deposited amyloid 
was found to display an ordered ultra-structural appearance when studied at higher 
magnifications with electron microscopic techniques; these fibrils were described by 
many throughout the 1960s as filamentous, ordered, non-branching structures (Cohen et 
al., 1982; Gueft and Ghidoni, 1963; Shirahama and Cohen, 1967; Terry et al., 1964). 
Identification of the specific proteins which composed the amyloid fibrils followed 
throughout subsequent decades (Reviewed in Sipe and Cohen, 2000).  
From X-ray crystallographic analyses, we now know that amyloid fibrils display a 
non-branching, cross-beta sheet structure, described as mainly antiparallel in orientation; 
the fibrils are of varying lengths usually 7 – 13 nm in diameter (Bonar et al., 1969; 
Glenner and Terry, 1974; Sawaya et al., 2007; Sunde et al., 1997). Currently, more than 
30 separate human proteins have been identified as constituents of amyloid deposits or 
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“amyloidogenic” (Sipe et al., 2016); each amyloid protein has the intrinsic ability to 
misfold, aggregate, and form the characteristic Congophilic amyloid fibrils. 
Amyloid deposits can occur in one or multiple tissues and/or organ systems 
throughout the body, near to or remotely located from the site of amyloid protein 
expression. Loosely categorized as localized or systemic forms of amyloidosis, 
respectively, these diseases are a result of the damaging nature of the extracellular 
amyloid deposits. One of the most well-known localized amyloidoses is Alzheimer’s 
disease (Invernizzi et al., 2012; Stefani and Dobson, 2003). The systemic amyloidoses are 
a class of fatal protein misfolding diseases characterized by the extracellular deposition of 
ordered fibrils in the heart and other visceral organs (Falk and Skinner, 2000; Kisilevsky, 
1991; Merlini and Westermark, 2004; Wechalekar et al., 2016). Although mechanistic 
organ dysfunction arises from fibril deposition and tissue displacement (Hou et al., 2007; 
Pepys, 1995), cellular toxicity of pre-fibrillar forms has also been demonstrated (Merlini 
and Westermark, 2004; Reixach et al., 2004; Sousa et al., 2001; Stefani and Dobson, 
2003). Specifically, intracellular toxicity can be the result of a heat shock or unfolded 
protein response (UPR) (Reviewed in Stefani and Dobson, 2003). It is widely held that a 
“seeding” effect allows for fibril propagation and disease progression continues as pre-
fibrillar aggregates mature into ordered fibrils which deposit in the tissue (Invernizzi et 
al., 2012). Once the amyloid cascade is initiated it is both continuous and lethal, often 
within a short period of time, without intervention or treatment (Merlini and Westermark, 
2004; Stefani and Dobson, 2003; Wechalekar et al., 2016). 
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1.2 Transthyretin-associated amyloidosis 
One group of systemic amyloidoses is caused by fibrillar deposits of the liver-secreted, 
plasma protein transthyretin (TTR) (Felding and Fex, 1982; Mita et al., 1986). The TTR-
associated amyloid diseases, termed ATTR amyloidoses, can be inherited or sporadic. 
The inherited forms of ATTR (ATTRm) are caused by more than 120 pathologic coding 
variants in the TTR gene (Rowczenio et al., 2014). Patients with ATTRm amyloidosis 
generally present with symptoms of cardiac or neurologic amyloid, though many have 
TTR deposits in both heart and nerve tissues; previously, ATTRm featuring mainly 
cardiac or neurologic involvement was referred to as familial amyloidotic 
cardiomyopathy (FAC) or familial amyloidotic polyneuropathy (FAP) (Cornwell 3rd et 
al., 1995; Gertz et al., 2015a; Planté-Bordeneuve and Said, 2011). The sporadic form of 
ATTR is characterized by cardiac deposition of fibrils derived from wild-type TTR 
(ATTRwt) and was formerly known as senile systemic amyloidosis (SSA) and senile 
cardiac amyloidosis (SCA) (Cornwell 3rd et al., 1995; Gertz et al., 2015a, 2015b; Merlini 
and Westermark, 2004). ATTRwt amyloidosis is typically diagnosed in males over age 
60, and generally presents as cardiomyopathy with typical symptoms of heart failure, 
diastolic dysfunction, arrhythmias, and greater left ventricular wall thickness (Gertz et al., 
2015a; Merlini and Westermark, 2004); ATTRwt amyloidosis is the focus of the studies 
reported in this dissertation. 
1.3 Transthyretin and the amyloid cascade 
TTR is a circulating homotetrameric protein mainly produced and secreted by the liver 
(Felding and Fex, 1982; Jacobsson, 1989; Mita et al., 1986). Other sites of TTR 
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expression include the choroid plexus (Dickson et al., 1986; Herbert et al., 1986) and 
retina (Cavallaro et al., 1990). Normal serum concentrations are 18 – 45 mg/dL (Ritchie, 
ed., 1996); TTR levels in cerebral spinal fluid (CSF) are 10 – 40 μg/mL (Weisner and 
Roethig, 1983). Circulating TTR levels are higher in younger individuals, males 
(Buxbaum et al., 2008a; Caccialanza et al., 2013), and Caucasians compared to African 
Americans (Buxbaum et al., 2008a). In the blood pool, TTR functions as a minor carrier 
of thyroxine and binding partner to retinol-binding protein 4 (RBP4) (Rostom et al., 
1998). Interestingly, TTR in CSF may exhibit a neurologic protective function, 
preventing or delaying Alzheimer’s disease (Buxbaum et al., 2008b; Li et al., 2011a, 
2011b). 
The TTR protein is normally 55 kDa in size and composed of 4 identical 
polypeptide chains, each containing 127 amino acids (Kanda et al., 1974) (Figure 1.1). 
Each monomer is composed of 8 beta sheets, termed A through H, which form a flattened 
barrel structure (Blake et al., 1971, 1974, 1978; Hamilton et al., 1993). There is a small 
amount of alpha helix conformation and both the N- and C-termini are unstructured 
regions. The tetramer is formed by the association of two AB dimers, where monomers A 
and B have slightly different conformations (Hamilton et al., 1993). Two hydrophobic 
thyroxine-binding pockets are formed at the hourglass-shaped dimer interface (Blake et 
al., 1971; Foss et al., 2005), though only one binding region is usually occupied by the 
hormone (Raghu and Sivakumar, 2004). In addition, there are two binding sites for RBP4 
located on the outer surface of the TTR tetramer, though the plasma circulating molar 
ratio of TTR:RBP4-retinol is typically 1:1 (Raghu and Sivakumar, 2004). TTR and RBP4 
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are secreted from hepatocytes as a complex (Bellovino et al., 1996) and function in the 
serum as a carrier of vitamin A (Bartalena and Robbins, 1993). 
TTR is a highly thermodynamically stable protein; the native protein is resistant 
to thermal, acid, and urea denaturation (Hammarström et al., 2002; Hurshman Babbes et 
al., 2008; McCutchen et al., 1993, 1995). In fact, destabilization of the protein and 
amyloid formation (discussed below) requires an initial dissociation of the tetramer 
(Azevedo et al., 2013; Branch et al., 1972; Nilsson et al., 1975). The binding of thyroxine 
to TTR increases the stability of the native protein (Miroy et al., 1996). Moreover, 
interactions within the ternary complex of TTR-RBP4-retinol also stabilize the tetrameric 
structure of TTR (Raghu and Sivakumar, 2004; White and Kelly, 2001). Stabilization of 
the tetramer serves as the basis for several therapeutic agents currently being investigated 
(Adamski-Werner et al., 2004; Azevedo et al., 2013; Bulawa et al., 2012; Gertz et al., 
2015b; Johnson et al., 2012). 
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Figure 1.1. Ribbon diagram of tetrameric transthyretin. The abundant beta sheet 
structure of native tetrameric TTR is shown. The hourglass-shaped channel in the center 
of the protein serves as the binding site for T4 (3,3′-diiodothyroxine shown) molecules 
rendered in the figure as space-filling structures. The four conserved water molecules are 
also shown in CPK (Corey–Pauling Space Filling Models) format. Reproduced with 
permission from Greta J. Miroy et al. PNAS 1996;93:15051-15056 (Miroy et al., 1996), 
Copyright (1996) National Academy of Sciences.
1 
 
 
 
 
 
1Originally published as “Ribbon diagram of tetrameric TTR”; figure legend modified from original 
publication.  
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In order for TTR to form amyloid fibrils, the tetramer must dissociate into 
monomers; this is the rate-limiting step in a process that initiates an amyloid cascade 
mechanism (Hurshman et al., 2004) (Figure 1.2). It is widely held that subsequent to 
tetramer disassembly, TTR monomers become misfolded and exposure of normally 
buried hydrophobic regions of the polypeptide chains leads to self-aggregation. The 
process continues with the formation of high molecular weight (HMW) oligomers and 
pre-fibrillar structures that ultimately precipitate in the extracellular compartments of 
tissues and organs as amyloid fibrils (Azevedo et al., 2013; Johnson et al., 2012). Several 
stages in the amyloid cascade may be impacted in ATTR amyloidosis. Despite findings 
that amyloid-associated amino acid replacements do not significantly alter TTR 
tetrameric structure (Hörnberg et al., 2000), several studies have demonstrated that 
mutant proteins have decreased kinetic stabilities (Hammarström et al., 2002; Hurshman 
Babbes et al., 2008; McCutchen et al., 1993, 1995). Changes in the primary structure of 
TTR, encoded by point mutations in the gene, reportedly lowers the energy barriers 
required for disassembly of the native state (Sekijima et al., 2005). A variety of additional 
factors can impact the stability and misfolding of the native monomer including pH and 
post-translational modifications (Azevedo et al., 2013). 
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Figure 1.2. The transthyretin (TTR) amyloid cascade. Amyloid formation by TTR 
requires rate-limiting tetramer dissociation to a pair of folded dimers, which then quickly 
dissociate into folded monomers (upper right, shown in blue). Partial unfolding of the 
monomers yields aggregation-prone amyloidogenic monomers (lower right, shown in 
purple). Self-aggregation of misfolded monomers leads to formation of a variety of 
aggregate morphologies, including spherical oligomers, amorphous aggregates, and 
fibrils (shown in turquoise). The cascade can be inhibited with TTR tetramer stabilizing 
compounds that bind to the protein in the thyroxine channel as shown here with the drug, 
tafamidis (upper left). Reproduced with permission from Christine E. Bulawa et al. 
PNAS 2012;109:9629-9634 (Bulawa et al., 2012).
2
 
 
 
 
 
 
2Originally published as “The TTR amyloid cascade”; figure legend modified from original publication.  
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1.4 Mutant transthyretin and amyloidosis 
There are over 120 mutations reported to cause inherited forms of TTR-associated 
amyloidosis, ATTRm amyloidosis (Rowczenio et al., 2014). These hereditary amyloid 
diseases are characterized by fibril deposition in the peripheral nerves or cardiac tissue, 
usually dependent on the particular TTR mutation. In vitro studies have demonstrated a 
range of structural stabilities among amyloidogenic TTR variant proteins; these stability 
differences are thought to be related to variations in ages of disease onset and course. One 
of the most aggressive forms of ATTRm amyloidosis is associated with the least stable 
variant, TTR-L55P (Hurshman Babbes et al., 2008). ATTR L55P amyloidosis was 
described solely in one kinship and featured a very early onset of disease, occurring in the 
second decade of life (Jacobson et al., 1992; McCutchen et al., 1993). Conversely, other 
amyloidogenic TTR mutations feature amyloid disease symptoms that appear in later life 
and seem to have racial associations; two mutants usually associated with later onset (> 
60 years of age) amyloidotic cardiomyopathy are T60A, described mainly in Caucasians 
(Benson et al., 1987), and V122I, almost exclusively found in individuals of African 
descent (Gorevic et al., 1989; Jacobson et al., 1991). Interestingly, V30M has been 
described with widely variable ages of onset in Portuguese, Swedish, and Japanese 
populations. ATTR V30M disease symptoms in Portuguese and Japanese kinships 
usually occur prior to the fourth decade of life (Sousa et al., 1995), while onset in the 
Swedish population is usually past age 60 (Sousa et al., 1993). Previously referred to as 
familial amyloid polyneuropathy (FAP), ATTR V30M generally features symptoms of 
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peripheral neuropathy (Dwulet and Benson, 1983), though cardiac involvement can be 
observed in some patients. 
Variations in ATTRm amyloidosis disease onset, aggressiveness and penetrance, 
as well as differences in organ and tissue involvements are unexplained and have 
prompted investigations of gene and protein disease modifiers. Some studies suggest that 
disease course or aggressiveness is related to the stability of the TTR tetramer, while 
other reports have provided evidence indicating TTR monomeric structural instability is 
key (Hurshman Babbes et al., 2008; Jiang et al., 2001). The amyloid-forming propensity 
of a mutant TTR protein is undoubtedly dependent on the specific mutation present. 
However, other factors, extrinsic to TTR structure, may also play a role in modulating the 
formation and deposition of amyloid fibrils; for example, affinity for binding partners 
RBP4 or chaperone proteins such as clusterin may influence amyloid fibril formation 
(Greene et al., 2011, 2015; White and Kelly, 2001). Further, non-coding genetic 
modifiers have been suggested as factors contributing to the diverse penetrance of the 
V30M mutation (Olsson et al., 2010; Polimanti et al., 2013; Soares et al., 2004), and will 
be discussed further in Section 1.6. 
It is also important to note that several non-pathologic TTR variant proteins have 
been described (Rowczenio et al., 2014); these mutants contain amino acid replacements 
that have no destabilizing effect on TTR structure, and thus do not contribute to a disease. 
One such protein is the TTR G6S variant which was discovered at a frequency of 6% in 
the Caucasian population. Although G6S has been reported in patients with ATTRm 
amyloidosis, the mutant is always found along with another known pathologic TTR 
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mutation (Jacobson et al., 1995). Therefore, G6S has been widely accepted as a non-
amyloidogenic variant (Fitch et al., 1991). 
1.5 Wild-type transthyretin amyloidosis 
It is well established that many mutant forms of TTR are amyloidogenic, but the wild-
type protein can also form amyloid fibrils. In fact, amyloid fibril deposits from ATTRm 
tissues have been shown to be composed of both mutant and wild-type TTR as well as 
fragments of the proteins (Yazaki et al., 2000, 2003). ATTR associated with wild-type 
TTR, ATTRwt amyloidosis, is a progressive and fatal disease usually affecting the heart. 
Patients commonly present with symptoms of congestive heart failure resulting from the 
accumulation of wild-type TTR amyloid deposits in the left ventricular walls of the heart 
(Westermark et al., 1990). ATTRwt amyloidosis is recognized most often in elderly 
Caucasian men (Ng et al., 2005) and diagnosed as an infiltrative cardiomyopathy that 
continuously progresses with worsening organ function to death; typical survival from 
onset of heart failure symptoms to death is less than 5 years (Connors et al., 2011, 2016). 
Once thought to be a rare disease, ATTRwt amyloidosis has become increasingly 
recognized as a cause of heart failure in Caucasian men over the age of 60 with diastolic 
dysfunction (Dharmarajan and Maurer, 2012; Gertz et al., 2015a; Quarta et al., 2014). 
Autopsy studies have demonstrated that TTR amyloid fibrils can be found in the hearts of 
25% of elderly individuals over 80 years of age (Cornwell 3rd et al., 1983; Tanskanen et 
al., 2008; Westermark et al., 2003), suggesting that as many as 2.5 million Americans 
(US Census, 2012) could be at risk for this disease. Cardiomyopathy due to ATTRwt 
amyloidosis is likely under-recognized (Falk, 2012; Grogan et al., 2016; Liu and Smyth, 
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2016; Sawyer and Skinner, 2006), as the clinical diagnosis depends upon appropriate 
interpretation of echocardiography or cardiac magnetic imaging and a definitive 
pathologic diagnosis often requires an endomyocardial biopsy, which can pose significant 
risk in elderly patients (Maurer, 2015). We suspect that, as the aged population increases 
and recognition of ATTRwt amyloidosis improves (Dungu et al., 2012), this patient 
group will expand and may pose significant challenges to health care providers. 
The Boston University (BU) Amyloidosis Center follows a cohort of patients 
unequivocally diagnosed with ATTRwt amyloidosis (Connors et al., 2016), which at the 
time of this report totals 165 patients. We are especially interested in understanding the 
pathogenesis and mechanisms of disease. ATTRwt pathogenesis is poorly understood, 
and it is not known whether control of TTR production and secretion by the liver 
contributes to disease. Furthermore, no ATTRwt amyloid disease-specific biomarkers 
have been validated and clinical features of the disease frequently overlap with other 
forms of amyloidoses featuring cardiac involvement (Pinney et al., 2013; Rapezzi et al., 
2015), such as the more commonly recognized immunoglobulin light chain (AL) 
amyloidosis (Merlini and Westermark, 2004; Wechalekar et al., 2016). At our center, the 
majority (~80%) of patients who undergo evaluation are diagnosed with AL amyloidosis, 
while ATTRwt constitutes ~6% of the patient population. Causes and risk factors for 
ATTRwt amyloidosis are unknown, and there is currently no specific treatment for 
disease. Therefore, there is a pressing unmet need for improved recognition of ATTRwt 
amyloidosis and identification and validation of diagnostic markers; it is also essential to 
develop therapeutic options for patients with this disease. 
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1.5.1 Disease identification 
A definitive diagnosis of ATTRwt amyloidosis relies on several steps (Figure 1.3). First, 
the presence of amyloid must be confirmed by Congo red staining of a tissue biopsy and 
visualization of the characteristic apple-green birefringence by polarized light 
microscopy (Wechalekar et al., 2016) (Figure 1.3a). The affected organ may be biopsied 
or a subcutaneous fat biopsy may serve as a surrogate tissue which would indicate the 
presence of systemic amyloid disease. Secondly, the type of amyloidosis must be 
determined by identifying the aberrant protein present in the deposit. This can be done 
using immunohistochemistry, electron microscopy, or mass spectral techniques (Figure 
1.3b). Traditionally, a diagnosis of ATTR amyloidosis requires endomyocardial biopsy 
with biochemical proof of TTR present in the deposit. However, this proves problematic, 
especially in patients with ATTRwt amyloidosis, as endomyocardial biopsy poses 
significant risk in elderly heart failure patients. Thus, alternative diagnostic tools and 
measures have been investigated, including nuclear imaging and subcutaneous fat biopsy, 
though the latter is only positive in a small number (< 30%) of patients with ATTRwt 
amyloidosis (Connors et al., 2016). Finally, ATTRwt amyloidosis is distinguished from 
ATTRm amyloid disease with serum screening for TTR protein variants by isoelectric 
focusing (Connors et al., 1998) (Figure 1.3c) and TTR exonic sequencing to confirm the 
presence or absence of mutations (Connors et al., 2016) (Figure 1.3d). 
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Figure 1.3. Wild-type transthyretin amyloidosis diagnostic algorithm. The presence 
of amyloid fibrils in biopsied tissue is confirmed by Congo red histology and evaluation 
using polarized and fluorescent light microscopy (a). Amyloid fibrils stain red under 
bright field (not shown), exhibit apple-green birefringence under cross-polarized light, 
and display a bright red fluorescence under fluorescent microscopy. Follow-up 
identification of the protein present in the amyloid deposits is accomplished by 
immunohistochemistry (IHC), electron microscopy (EM), mass spectrometry, or western 
blot (b). The depicted western blot procedure shows microdissected tissue run on a 
reducing gel and stained with an anti-transthyretin (TTR) antibody. In ATTR cases, 
serum screening by isoelectric focusing detects wild-type TTR (ATTRwt) and variant 
forms (ATTRm) of the protein, if present, based on isoelectric point (pI) differences (c). 
Follow-up confirmation of wild-type and/or mutant TTR is completed by Sanger 
sequencing of all 4 TTR exons (d). Depicted is a heterozygous case with both wild-type 
and mutant TTR; ATTRwt exonic sequences display no deviation from the reference 
sequence, except in cases where the non-pathologic G6S variant is identified in exon 2.  
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Recently, several imaging techniques have emerged as additional tools with 
diagnostic and prognostic utility, particularly useful as an alternative to invasive biopsy 
procedures (Maurer, 2015). Radio-isotopes can identify ATTR amyloidosis with high 
sensitivity and specificity while ruling out similar conditions such as AL amyloid disease 
and similar cardiomyopathies (Bokhari et al., 2013; Glaudemans et al., 2014). Although 
not currently approved by the FDA, [99mTc]-DPD is commonly used for ATTR 
amyloidosis identification in Europe, and [99mTc]-PYP has been employed in the US 
(Maurer, 2015). 
1.5.2 Treatments 
Traditionally, liver transplantation has been used as a treatment for ATTRm amyloidosis, 
although in patients with cardiac involvement disease progression continues unabated 
(Hund et al., 2001). More recent therapeutic strategies have focused on simply 
eliminating the aberrant mutant TTR through the utilization of short interfering RNA 
(siRNA) and antisense oligonucleotide (ASO) techniques (Benson et al., 2011). Other 
approaches have centered on stabilizing the native tetrameric state of TTR with small 
molecules, thereby inhibiting amyloid fibril formation by preventing subunit dissociation. 
Two promising TTR stabilizers which have emerged from the ATTRm field are diflunisal 
and tafamidis, both small molecules which interact with TTR in the thyroxine binding 
pocket of the tetramer (Adamski-Werner et al., 2004; Bulawa et al., 2012; Coelho et al., 
2012; Johnson et al., 2012). Diflunisal was demonstrated to improve the symptoms of 
peripheral neuropathy in patients with ATTRm amyloidosis (Berk et al., 2013), though it 
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has yet to be determined whether the drug has a similar efficacy in TTR-associated 
amyloidotic cardiomyopathies such as ATTRwt disease. 
In ATTRwt amyloidosis, treatment regimens are currently limited mainly to 
managing the symptoms of heart failure. Diuretics are commonly prescribed, though their 
use can be complicated by high central venous pressure; additionally, implantable 
cardioverter-defibrillators and pacemakers can be used in some patients to limit risk of 
sudden death from bradyarrhythmia and electrical mechanical dissociation (Castaño et 
al., 2015; Gertz et al., 2015b). Common heart failure therapies such as beta blockers, 
digoxin, and calcium channel blockers are typically avoided due to disease-specific 
complications (Castaño et al., 2015; Gertz et al., 2015b). Liver transplantation is not a 
plausible option in ATTRwt patients since the amyloidogenic protein is the wild-type 
form. However, in rare cases, heart transplantation has been performed (Castaño et al., 
2015; Sher and Gertz, 2014). 
1.5.3 Biomarkers of disease 
For some time, the ATTR field has been focused on identification of disease-specific 
biomarkers, as well as the expansion of treatment options. Hereditary TTR (ATTRm) 
amyloidosis has the advantage over ATTRwt amyloid disease of having an identifiable 
gene mutation/protein variant which can serve as both a diagnostic agent and a 
therapeutic target. Cardiac amyloid disease progression in ATTR has conventionally been 
monitored with serum indicators of generalized myocardial damage, such as cardiac 
troponin (cTn-I) and B-type natriuretic peptide (BNP) (Gertz et al., 2015b). Several 
independent cohort studies have demonstrated associations of clinical and laboratory 
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findings at baseline evaluation with worse outcome in patients with ATTRwt 
amyloidosis. Pinney et al. reported decreased survival in patients with higher levels of  
troponin T (cTn-T), the presence of a pacemaker, and New York Heart Association 
(NYHA) class IV symptoms; additionally, N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) and age were associated with disease (Pinney et al., 2013). Moreover, BNP 
and cTn-I were significantly elevated in the Transthyretin Amyloid Outcomes Survey 
(THAOS) (Coelho et al., 2013). Recent studies have indicated age, BNP, NT-proBNP, 
uric acid, relative wall thickness (RWT), and left ventricular ejection fraction (LVEF) as 
factors predictive of survival (Connors et al., 2016; Grogan et al., 2016). 
The potential utility of serum TTR levels as a biomarker of disease has been 
investigated in both inherited and sporadic forms of ATTR. Several groups found 
consistently lower than normal concentrations in small cohorts of patients with ATTRm 
amyloidosis (Benson and Dwulet, 1983; Buxbaum et al., 2008a; Connors et al., 1984; 
Saraiva et al., 1983; Shoji and Nakagawa, 1988; Skinner et al., 1985; Westermark et al., 
1985). A meta-analysis of data from these studies showed that serum TTR concentrations 
in ATTRm (N = 154) were significantly different from healthy controls (168 vs. 220 
μg/mL, p = 0.005) (Buxbaum et al., 2010); the majority of cases in the combined dataset 
were ATTR V30M amyloidosis. One study examining serum TTR levels in a small group 
of ATTRwt cases (N = 40) found only slightly lower amounts of the protein in patients 
compared to controls (248 vs. 250 μg/mL); the difference was not significant (Buxbaum 
et al., 2008a). However, it is important to note that the ATTRwt sera used in this analysis 
were provided by our laboratory and obtained from patients identified by clinical, and not 
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biochemical diagnosis. Recent advances in diagnostic strategies and techniques, 
including confirmation of TTR in the amyloid deposit, have led to the exclusion of a 
majority of these previously studied cases from the “biochemically proven” ATTRwt 
cohort used in this dissertation research. Thus, the issues of an unconfirmed diagnosis 
and small sampling size represent limitations in the previous study findings of Buxbaum 
et al. (Buxbaum et al., 2008a) and leave unanswered the question of whether serum TTR 
concentrations are truly unchanged in ATTRwt amyloidosis. 
1.6 Implications for altered gene control in the transthyretin amyloidoses  
It is not known whether lower levels of serum TTR in ATTRm amyloidosis are simply a 
reflection of the protein deposition process or a manifestation of altered gene control. It 
has been suggested that non-coding variants in cis-regulatory regions may impact 
expression of the TTR gene in ATTRm amyloidosis (Nie et al., 2016; Olsson et al., 2010; 
Polimanti et al., 2013; Soares et al., 2004). This cis-regulatory hypothesis is offered as an 
explanation for variability in penetrance, age at onset, and disease severity in different 
ATTR V30M patient populations. Whether this theory may account for the lower serum 
TTR levels measured in FAP compared to healthy controls is unknown (Buxbaum et al., 
2008a, 2010; Skinner et al., 1985). 
One study investigating genetic variation in non-coding regions of the TTR gene 
implicated a specific haplotype containing upstream and downstream single nucleotide 
polymorphisms (SNPs) as a potential modulator of early disease onset in the Portuguese 
ATTR V30M amyloidosis population (Soares et al., 2004), where disease development 
occurs prior to the 4th decade of life (Sousa et al., 1995). A later study found the T allele 
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of SNP rs62093482 to be associated with Swedish ATTR V30M amyloidosis (Olsson et 
al., 2010), where disease onset is usually reported after age 60 (Sousa et al., 1993). The 
SNP was located in a predicted miRNA binding site and the authors proposed that the 
presence of the T allele in this location acted as a protective factor, potentially explaining 
the observed late-onset penetrance of disease in the Swedish population. However, this 
suggested mechanism has not been confirmed by functional studies (Norgren et al., 
2012). Another study determined significant ethnic differences in non-coding SNPs 
surrounding the TTR gene, particularly between haplotypes present in Africans and non-
Africans (Polimanti et al., 2013). The authors proposed that some of these SNPs may be 
located in cis-regulatory regions and, therefore, may affect TTR gene function. 
Interestingly, a predicted binding site for a cardiac transcription factor, TEAD1, was 
identified which may be disrupted by the presence of SNP rs1791228 in cardiac muscle. 
The proposed ATTRm modifiers have potential implications in ATTRwt amyloidosis as 
well, where an unexplained destabilization of the TTR tetramer leads to misfolding and 
fibrilization, and the disease is observed in a selective subset of the population.  
Further implications for altered gene control in ATTRwt amyloidosis are based on 
the high degree of sexual dimorphism that has been described in patients diagnosed with 
this disease; several reports detailing disease characteristics have suggested that patients 
were most frequently male (Coelho et al., 2013; Connors et al., 2016; Grogan et al., 2016; 
Rapezzi et al., 2008). Recent studies have shown that ATTRwt amyloid disease is 
characterized by significantly more severe amyloidotic cardiomyopathy in men than 
women, despite post-mortem studies citing the presence of TTR deposits in equal 
  21 
numbers of men and women (Cornwell 3rd et al., 1983; Rapezzi et al., 2008; Tanskanen 
et al., 2008; Westermark et al., 2003). Moreover, serum TTR levels were reported to be 
higher in men, suggesting a relationship between TTR expression and androgen serum 
levels (Buxbaum et al., 2008a; Caccialanza et al., 2013; Han et al., 2011; Labrie et al., 
2003). 
Thus far, there have been no genetic studies in ATTRwt amyloidosis. Considering 
the ethnic and gender differences, as well as the regulatory SNPs identified in ATTRm, it 
seems plausible that TTR gene function and expression play an important role in 
ATTRwt pathogenesis. 
1.7 Current understanding of the human transthyretin gene  
The human TTR gene, located on chromosome 18, is approximately 10 Kb in length and 
contains a proximal promoter, 4 exons, and 3 introns (Sasaki et al., 1985; Tsuzuki et al., 
1985) (Figure 1.4). Some elements of the proximal promoter have been described, 
including both TATA and CAAT binding boxes (Sakaki et al., 1989; Sasaki et al., 1985; 
Tsuzuki et al., 1985). There is high a degree of homology between the human and mouse 
TTR genes, both in coding (Wakasugi et al., 1985) and regulatory regions. In the mouse 
gene, an enhancer and promoter have been well characterized and key transcription 
factors binding at these sites have been identified (Costa and Grayson, 1991; Costa et al., 
1986, 1988a, 1988b, 1989, 1990; Courtois et al., 1988; Grayson et al., 1988; Qian et al., 
1995; Samadani et al., 1996) (Figure 1.4a). While there are little data detailing 
regulatory regions in the human TTR gene, it is known that the proximal promoter region 
spans approximately -50 to -190 b upstream from the transcription start site; this region 
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was found to be highly conserved with the mouse gene and reported to contain several 
binding sites crucial for hepatocyte-specific expression, including HNF-1, C/EBP, HNF-
3, and HNF-4 (Costa et al., 1989; Sakaki et al., 1989) (Figure 1.4b). Enhancer elements 
in the human TTR gene have been incompletely characterized (Martinho et al., 2013; 
Sakaki et al., 1989). A possible homolog to the mouse enhancer was identified 
approximately 3.5 Kb upstream from the transcription start site, and found to contain an 
intact HNF-4 binding site (Sakaki et al., 1989). In addition, several transcription factor 
binding sites located in regions upstream to the human TTR gene have been reported on 
ENCODE (Meyer et al., 2013), though most have not been confirmed experimentally. 
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Figure 1.4. Regulatory regions and transcription factor binding sites upstream of 
the transthyretin (TTR) gene reported in the literature. Transcription factor binding 
sites are depicted for the mouse (a) and human (b) genes (not to scale). Ap-1 is depicted 
as a red triangle and C/EBP as a purple rectangle. The HNF family is depicted as ovals, 
with coloring as follows:  HNF1 in medium blue; HNF3 light blue; and HNF4 dark blue. 
On the gene map, the non-coding regions are shown in green, exons are shown in gray, 
and untranslated regions in light blue. The stop codon location is indicated by a red line, 
and the poly-A location by a dark blue line. The transcription start site is indicated with 
an arrow, and CAAT and TATA binding sites are depicted in green lettering. (Costa and 
Grayson, 1991; Costa et al., 1986, 1988a, 1988b, 1989, 1990; Courtois et al., 1988; 
Sakaki et al., 1989; Sasaki et al., 1985; Tsuzuki et al., 1985)  
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The TTR gene region that lies 500 b immediately upstream of the transcription 
start site has been shown to be sufficient to drive liver expression in transgenic mice, 
although only at approximately 10% of endogenous expression levels (Yamamura et al., 
1987). These data suggest that liver expression can be driven by a minimal number of 
elements, which likely are present within the 500 b immediately upstream from the 
transcription start site in the human TTR gene. However, maximal expression in HepG2 
cell reporter models has been shown to require both the mouse TTR upstream enhancer 
and promoter regions (Costa et al., 1986, 1988b). Similar levels of expression were 
observed in HepG2 cells containing mouse gene elements, including the 100 b enhancer 
located at -202 to -70 b, and the entire region 3 Kb upstream of the transcription start site 
(Costa et al., 1989). Moreover, in vivo experiments demonstrated that a construct 
containing minimal regulatory elements, i.e. the 200 b promoter and 100 b enhancer, as 
well as a construct with 3 Kb of the immediate upstream region, were both sufficient to 
induce TTR expression at endogenous levels (Yan et al., 1990). 
1.8 Specific aims 
ATTRwt amyloidosis is a disease typically diagnosed as congestive heart failure in 
elderly Caucasian men and characterized by endomyocardial deposits of wild-type TTR 
amyloid fibrils. The pathobiology of the disease mechanism is unclear, there are currently 
no validated disease-specific biomarkers, and treatment options are mainly focused on 
managing the symptoms of congestive heart failure. Further, it is not known whether the 
control of TTR production and secretion by the liver contributes to disease. The research 
detailed in this dissertation is based on the following hypotheses: non-coding genetic 
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variation in TTR gene regulatory regions is associated with ATTRwt amyloidosis; and 
disease-specific nucleotide alterations directly impact TTR expression, causing an 
imbalance of serum concentrations which contributes to disease pathogenesis. 
Conversely, the non-amyloidogenic TTR G6S variant codes for an amino acid 
replacement that acts to stabilize tetrameric TTR and inhibit the amyloid cascade, 
thereby delaying or ameliorating the ATTRwt amyloid disease process. To test our 
hypotheses, we proposed the following 3 specific aims: 
 
Specific Aim 1: Define TTR genetic risk factors for ATTRwt amyloidosis onset and 
progression.  
a) Identify non-coding TTR genetic risk variants specific to ATTRwt amyloidosis. 
b) Correlate genetic data to clinical features of disease onset and progression. 
c) Measure and compare serum TTR levels in ATTRwt and ATTRm patient groups, 
and matched healthy controls. Evaluate TTR impact on survival, determine 
cutoffs, and establish biomarkers for diagnosis and monitoring. 
Specific Aim 2: Investigate the functionality of non-coding TTR gene risk factors 
identified in aim 1 and their role in ATTRwt disease course.  
a) Design two complimentary reporter assays in HepG2 cells which can serve as a 
model for disease. 
b) Based on disease associations and functional predictions, select key non-coding 
genetic risk variants and evaluate the effect of each on TTR expression using 
reporter assays. 
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c) Analyze the relationship between serum TTR levels, genetic risk factors, and 
markers of disease progression in the context of reporter assay results.  
Specific Aim 3: Examine the disease-protective potential of the advantageous coding 
TTR gene variant, TTR G6S.  
a) Determine the occurrence of G6S in ATTR and control groups, and correlate its 
presence with risk factors and markers of disease progression. 
b) Analyze the stability of G6S tetramers, compare to wild-type TTR and unstable 
variants, and evaluate the role and stability of G6S during the aggregation process 
using in vitro techniques. 
1.9 Significance 
The investigations detailed in this dissertation focus on ATTRwt disease-specific genetic 
variation in the context of altered TTR expression which may lead to a more 
comprehensive understanding of the mechanisms driving this disease, and possibly other 
TTR-related amyloidotic cardiomyopathies. Our unique access to cross-sectional and 
longitudinal patient specimens, as well as clinical data from a large ATTRwt amyloidosis 
cohort (N = 165), allows investigation of potential disease risk factors, or conversely, 
examination of the protective nature of a coding variant. The aims of this dissertation, 
based on recent reports from the ATTRm amyloidosis field, were developed with the goal 
of identifying useful metrics of ATTRwt amyloidosis, such as genetic variants or serum 
TTR concentration, which could improve diagnosis, allow close monitoring of disease 
progression, and measure response to treatment. Furthermore, results from these 
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proposed studies have the potential to contribute invaluable data to understanding 
ATTRwt disease pathogenesis at the cellular level. 
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CHAPTER 2. METHODS 
2.1 Genetic analyses 
2.1.1 Genetic study groups  
The ATTRwt cohort consisted of 108 self-identified Caucasian males with biopsy proof 
of ATTRwt, referred to the BU Amyloidosis Center Clinic for evaluation between 1994 
and 2014. Informed consent for data and sample collection was obtained from patients 
with the approval of the Boston University Medical Campus Institutional Review Board 
(IRB) in accordance with the Declaration of Helsinki. Clinical, laboratory, and 
echocardiography data were obtained from an IRB-approved database of amyloidosis 
patients. An initial diagnosis of amyloidosis was made by Congo red staining of a tissue 
biopsy from the affected organ(s) that demonstrated fibrils with apple-green birefringence 
by polarized light microscopy. The diagnosis of ATTRwt amyloidosis was based on 
biochemical or immunochemical proof of TTR as the major component of the amyloid 
deposit; all ATTRwt patients in this study had TTR-positive amyloid fibrils. Complete 
exonic sequencing of the TTR gene was performed to rule out the presence of a 
pathologic TTR mutation in both the ATTRwt and control groups. Except for the 
presence of the non-pathologic G6S polymorphism (Fitch et al., 1991) in several 
ATTRwt and control cases, only wild-type TTR was present. Cardiac involvement, 
identified in the majority of ATTRwt patients, was defined by an interventricular septal 
wall thickness (IVST) > 12 mm on echocardiogram and serum B-type natriuretic peptide 
(BNP) > 100 pg/mL. Extracardiac involvement was determined through biopsy of the 
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affected tissue, i.e. bladder, stomach, or antrum, and the presence of associated bladder or 
gastrointestinal symptoms. 
The control group consisted of 118 healthy individuals who were matched by 
ethnicity, sex, and age to ATTRwt patients. Clinical data for control subjects were not 
available; however, to limit the possibility of confounders, we requested the provider 
select only blood samples from Caucasian males over age 60, with no history of heart 
disease, no family history of Alzheimer’s disease, and a general assessment of “healthy.” 
Using the Genetic Power Calculator (http://pngu.mgh.harvard.edu/~purcell/gpc/), we 
determined that this sample size was sufficient to detect a single SNP association with a 
large effect (90% power for a SNP with a relative risk of 2 and a minor allele frequency 
of 0.10). 
An additional patient group consisting of 30 male patients with ATTRm 
amyloidosis was selected and used for comparative analyses. All cases had a confirmed 
diagnosis of amyloidosis based on positive Congo red staining of a tissue biopsy, and 
verification of a pathologic TTR mutant by serum isoelectric focusing (IEF) and exonic 
sequencing (Connors et al., 1998). The TTR proximal promoter region was evaluated in 
all ATTRm cases, as this was the region where ATTRwt risk variants were identified. 
2.1.2 Microdissection-western blot diagnostics 
Histological samples (N = 12) were collected from patients with biochemically 
unconfirmed ATTRwt amyloidosis. Of the 12 samples, 10 were fat aspirates and the 
other 2 were pelvic node and heart tissue biopsy material. The fat aspirates were 
previously prepared by squeezing the fat aspirate between two slides; the pelvic node and 
  30 
heart biopsy materials were formalin-fixed, paraffin-embedded samples that were cut 
with a microtome to 8 μm thick sections and placed on microscope slides. All tissues 
were pre-stained with Congo red prior to storage. A scoring system, developed in our 
laboratory and based on the amount of observed Congo red (CR) staining, was used to 
grade the relative abundance of amyloid present in the samples; tissues are graded CR+ 
or CR-, and in the CR+ category, a scale from 1-3+ is used with 1+ indicating trace 
amounts of amyloid and 3+ representing a large amyloid load. For the fat samples, 8 had 
small amounts of amyloid (CR 1+) and 2 showed more abundant levels (CR 2+, CR3+). 
The pelvic node and heart samples were graded 3+ and 2+, respectively, indicating ample 
amyloid material was available for extraction. Each slide was imaged under fluorescent 
light using a Nikon Eclipse TS100 microscope and Nikon Digital Sight camera (Tokyo, 
Japan). The fat aspirate biopsy material was scraped off the slides with a razor blade after 
imaging, and collected in an eppendorf tube with approximately 50 μL 70% ethanol. The 
pelvic node and heart biopsy samples which had highly abundant amounts of amyloid 
were individually extracted using a MicroDissector with a Transferman NK2 
micromanipulator (Eppendorf, Hamburg, Germany) under approximately 50 μL 70% 
ethanol. Samples were centrifuged at 25000 x g, 4 °C for 1 hour. The tissue pellet was re-
suspended in 30 μL extraction buffer (20 mM Tris-HCl, pH 8.0, 2% SDS, 200 mM DTT) 
and heated at 95 °C for 20 minutes, then 80 °C for 1 hour. Samples were resolved on a 
20% reducing SDS-PAGE gel and transferred to a nitrocellulose membrane for western 
blot using the PhastSystem for 30 minutes
 
(GE Healthcare Life Sciences, Little Chalfont, 
UK). Membranes were blocked in 5% milk in tris-buffered saline with tween (TBST) for 
  31 
45 minutes and washed for 5 minutes in TBST three times. TTR was probed using a 
1:20,000 dilution of primary rabbit anti-human prealbumin (TTR) antibody (Dako 
A0002, Carpinteria, CA) in 1% milk in TBST overnight, followed by three 5 minute 
washes in TBST. The membranes were probed with a 1:10,000 dilution of goat anti-
rabbit secondary antibody (Santa Cruz Biotechnology SC-2054, Dallas, TX) in 5% milk 
in TBST for 30 minutes and washed for 5 minutes in TBST three times. Samples derived 
from fat aspirates were also probed for haptoglobin to confirm that the presence of TTR 
in the sample was due to deposition and not blood contamination from the procedure. A 
serum sample was diluted 100X to serve as a positive control. The primary antibody was 
mouse anti-human haptoglobin (Santa Cruz SC-69783) at 1:1,000 dilution; the secondary 
antibody was goat anti-mouse (Santa Cruz SC-2005) at 1:10,000 dilution and the same 
procedure outlined above was followed. Western blots were developed using the Pierce 
ECL Plus chemiluminescent method (Thermo Fisher Scientific, Waltham, MA) and 
visualized on an ImageQuant LAS 4000 (GE Healthcare Life Sciences).  
2.1.3 Genetic target region selection 
Specific regions located near the TTR gene were selected for study based on strong 
evidence of potential cis-regulatory capabilities either by prediction programs or 
literature reports (Figure 1.4). While little is known about the regulatory regions of the 
human gene, the mouse TTR gene has been studied more extensively and found to be 
highly homologous to the human gene. Thus, it seemed reasonable and necessary to base 
much of our reasoning on the mouse literature, including the selection of enhancer and 
promoter locations to study. In total, four target non-coding regions were selected to 
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cover approximately 7 Kb in cumulative length encompassing predicted regulatory 
regions up- and down-stream of the TTR gene and spanning a total length of 20 Kb 
(Sikora et al., 2015) (Figure 2.1). 
Two predicted enhancer target regions were chosen, located approximately -10.6 
Kb to -9.9 Kb and -3.8 Kb to -2.6 Kb upstream of the TTR gene transcription start site; 
these were designated predicted enhancer 1 and 2, respectively (Figure 2.1). Predicted 
enhancer 1 was selected for its homology to the mouse enhancer (Costa et al., 1989) as 
determined by a CLUSTALW (https://www.ebi.ac.uk/Tools/msa/clustalw2/) nucleotide 
sequence alignment. The selection of predicted enhancer 2 was based on the 
identification of a sequence homologous to the mouse enhancer (Costa et al., 1989) with 
an intact HNF-4 binding site (Sakaki et al., 1989) in the region (Figure 1.4), as well as a 
high density of predicted transcription factor binding sites by ENCODE (Meyer et al., 
2013), Matinspector (Cartharius et al., 2005) (http://www.genomatix.de/online_ 
help/help_matinspector/matinspector_help.html), and MATCH (Wingender, 2008) 
(http://www.gene-regulation.com/pub/programs.html#match) programs.  
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Figure 2.1. Target transthyretin (TTR) gene non-coding regions selected for analysis 
(Sikora et al., 2015). Segments spanned a 20 Kb region and totaled 7 Kb in sequencing 
length; depiction is to scale. The upstream regions, denoted predicted enhancer 1 and 2, 
encompassed two distal predicted enhancers, shown in green. Predicted enhancer 1 was 
determined by CLUSTALW sequence alignment to the mouse enhancer (Costa et al., 
1989), and predicted enhancer 2 was determined by Sakaki, et al. (Sakaki et al., 1989). 
The proximal promoter region incorporated approximately 2 Kb immediately upstream of 
the gene, in green, along with the 5’ untranslated region (UTR), in light blue. The 
downstream segment, termed 3’ region, included approximately 1 Kb immediately 
downstream of the gene which encompassed the 3’ UTR, in light blue, and the proximal 
near gene region. Red indicates the location of the stop codon; dark blue is the location of 
the poly-A signal at the end of the 3’ UTR. Exons are shown in gray and numbered. The 
transcription start site is indicated with an arrow. 
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The proximal promoter target encompassed approximately 2 Kb immediately 
upstream of the gene, consisting of the 5’ untranslated region (UTR), the promoter, and 
some of the 5’ near gene non-coding region (Figure 2.1); this region is highly 
homologous to the mouse promoter (Costa et al., 1989), and several transcription factor 
binding sites in this region have been confirmed including HNF and C/EBP (Sakaki et al., 
1989) (Figure 1.4). In addition, several transcription factor binding sites in this region 
have been predicted by ENCODE (Meyer et al., 2013), Matinspector (Cartharius et al., 
2005), and MATCH (Wingender, 2008). 
The downstream target, termed the 3’ region, spanned approximately 1 Kb 
immediately downstream of the TTR gene; this stretch encompassed the 3’ UTR and the 
proximal near gene region (Figure 2.1). Selection of this area was based on a report 
implicating the 3’ UTR as a modulator of ATTR V30M amyloidosis (Olsson et al., 
2010).  
2.1.4 Genomic DNA isolation 
Whole blood was obtained from patients at initial visit to the Amyloidosis Center Clinic, 
and after a 1500 rpm spin for 10 minutes, approximately 250 μL of buffycoat was 
removed and stored at -80 °C in 1.5 mL RNAlater (Life Technologies, Grand Island, 
NY). Control blood clots, purchased from StemExpress (Placerville, CA) and 
Bioreclamation (Westbury, NY), were also stored at -80 °C. Genomic DNA was 
extracted using a Qiagen (Venlo, Netherlands) Blood and Body Fluids DNA Extraction 
kit, and subsequently stored at -20 °C. 
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Control blood clots (collected in red-top tubes) were homogenized on ice with a 
TissueRuptor (Qiagen) in the presence of 200 – 400 μL phosphate-buffered saline (PBS), 
depending on the size of the clot. Samples were centrifuged at 1500 x g for 5 minutes, 
then at 12000 x g for 5 min. The pellet was re-suspended in 200 μL PBS, and this served 
as the starting material for the DNA Extraction kit protocol. 
2.1.5 Transthyretin gene sequencing and genotyping 
Individual primer sets, designed to encompass exons 1 – 4 and the 4 target regions (Table 
2.1), were used for amplification by polymerase chain reaction (PCR). Nucleotide 
sequencing of each and all reaction products was performed in both forward and reverse 
directions using the Sanger (Sanger et al., 1977) method (Genewiz, South Plainfield, NJ). 
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Table 2.1. Primers for target region and exon amplification 
Target region Upstream primer Downstream primer 
Fragment 
size, Kb 
Predicted enhancer 1 GAGCCTGAGTTGTAGGTCAATC
a 
GGTTAAGAACCTGGACACAGAG 1 
Predicted enhancer 2 TTGTGGATACATAGTAGGTGTA CCAAATAGACATTCCCACTTCT 1.3 
Proximal Promoter
b CACAGGGTCTACAAGAGATG 
CAGCAAGTTTGGTTCTGTC (S) 
AAAGCTGGAAGGAGTCAC 
TCCTGAGCTCAAGCAATC (S) 
2.3 
1.2/1.3 
3’ region GTGGTATTCACAGCCAACGA CCTGAGTTGCTGCAGGTGTA 1 
Exon 1 TCAGATTGGCAGGGATAAG AAAGCTGGAAGGAGTCAC 0.3 
Exon 2 TCTGGAGGCAGAAACCGTTC CTTGCCAAAGACGGAGGTCT 0.5 
Exon 3 CCTACTTCTGACTTAGTTGAG ACTGTGCATTTCCTGGAATGC 0.3 
Exon 4 GGACTTCCGGTGGTCAGT TGCCTGGACTTCTTCTAACATAGC 0.3 
aPrimers are listed in the 5’ to 3’ direction. Primers were designed to be used for polymerase chain reaction (PCR) amplification of 
the target regions and subsequent sequencing. 
b
As the proximal promoter PCR product was sufficiently large to prevent sequencing coverage in both directions using the 
amplification primers alone, internal sequencing primers were designed to appropriately cover the entire 2 Kb region in both 
directions. These internal sequencing primers are labeled with (S). 
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A Taq PCR Master Mix kit (Qiagen) was used to amplify all PCR products using 
the primers outlined in Table 2.1. Similar protocols were employed for each non-coding 
target region and consisted of the following basic format: melting at 95 °C for 30 
seconds; annealing at 62 °C for 45 seconds with a decrease of 0.5 °C per cycle for 20 
cycles followed by an additional 25 cycles at 52 °C; and extension at 72 °C for 30 – 90 
seconds based on the size of the desired fragment. Amplifications of exonic regions were 
completed using the following protocol: melting at 94 °C for 30 seconds; annealing at 
57.6 °C for 60 seconds; and extension at 72 °C for 35 cycles. All PCR products were 
purified using the ExoSAP-IT procedure from Affymetrix (Santa Clara, CA) prior to 
sequencing. 
Nucleotide sequence chromatograms were analyzed for genotypes using Mutation 
Surveyor (State College, PA) (Figure 2.2). Nucleotide variations in ATTRwt and control 
cases were identified by comparison to published data on dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/). All SNPs were tested for Hardy-Weinberg 
equilibrium (HWE) in the control group. 
The presence of rare variants was confirmed with a second set of primers (Table 
2.2) that were designed to encompass the same regions, but were located in different 
areas than the original primers. Amplification reactions, sequencing, and analyses were 
performed using the protocols described in the preceding paragraphs.   
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Figure 2.2. Chromatographs of seven common variants found in the wild-type 
transthyretin amyloidosis and control groups. At the top, a map of the TTR gene 
shows non-coding target regions in green, untranslated regions in light blue, and exons in 
gray, with the stop codon indicated by a red line, and the poly-A location indicated by a 
dark blue line. Variant locations are depicted on the gene map by color-coded lines 
corresponding to the colored box around the chromatographs for each variant. A 
representative example of each genotype is shown for each variant, with the variant 
shown as the middle base in the chromatographs. Chromatograph coloring is as follows: 
black indicates a guanine base; blue cytosine; red thymine; and green adenine. The 
identifying number for each variant is shown at the bottom of the chromatographs in 
color coding by variant. 
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Table 2.2. Primers for rare variant verification 
Target region Upstream primer Downstream primer 
Fragment 
size, Kb 
Predicted enhancer 1 CAGAGGGATGAAGCAGATCAA
a
 TGGCTGTAATCGAATGGAATCT 0.9 
Predicted enhancer 2 AGGCATGCAATGTGAAATAAGG CAGCATCCCGAACTTCTTT 1.1 
Proximal Promoter 
AAGGCTCTCTATCCAGGTTCT 
CCCAATGCAGAAGAGTCAGTAA 
CCCTGAAATACAGAGAACCAAATC 
CTGCTTATCCCTCGGAATCT 
1.0 
0.9 
3’ region GAAGTCCAGGCAGAGACAATAA TAGACCAGCCTAGCCAACAT 0.5 
a
Primers are listed in the 5’ to 3’ direction. Designed for polymerase chain reaction (PCR) amplification of target regions and 
subsequent sequencing. 
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2.1.6 Genetic statistical analyses 
Only SNPs with 5% minor allele frequency (MAF) or higher were analyzed. Single-
marker associations with ATTRwt disease were determined using the allele test, with 
significance determined by the chi-square (χ2) test for independence, and computed in 
PLINK (Purcell et al., 2007) (version 1.07, http://pngu.mgh.harvard.edu/purcell/plink/). 
Multiple testing was computed using PLINK’s max(T) permutation procedure; this 
analysis calculates an adjusted significance (pcorrected) based on the number of variants and 
the linkage disequilibrium (LD; i.e. non-independence) between the variants. Regression 
analysis in PLINK considered specific alleles as covariates to explore whether or not 
significant SNP effects were independent or a result of LD. Haplotypes were computed 
between the common SNPs using HaploView (Barrett et al., 2005) and PLINK; the latter 
program calculated haplotypes using variant groups of two, three, and four. An 
association graph was computed using LocusZoom (Pruim et al., 2010) 
(http://csg.sph.umich.edu/locuszoom/); LD information presented in the plot was based 
on 1000 Genomes reference data. 
Correlations between SNPs and clinical features were examined within the 
ATTRwt group using a regression analysis computed with PLINK. Clinical features 
included ages at disease onset and diagnosis, and survival measured from date at onset or 
diagnosis to death. In addition, several markers of cardiac involvement obtained at  
baseline clinical evaluation were examined; these included serum levels of BNP and 
cardiac troponin (cTn-I), and echocardiographic measures of IVST, left ventricular (LV) 
end-diastolic (LVEDD) and end-systolic diameters (LVESD), LV ejection fraction 
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(LVEF), and LV mass index (LVMI). Box plots were generated with the use of R 
software, version 3.0.3 (R Foundation for Statistical Computing, Vienna, Austria) and 
tertile analysis was executed in Microsoft Excel (Redmond, WA). 
2.1.7 Functional predictions 
The potential functionality of each SNP found to be associated with ATTRwt amyloid 
disease was assessed using the is-rSNP database (Macintyre et al., 2010) 
(http://bioinformatics.research.nicta.com.au/software/is-rsnp/) which predicts 
transcription factor binding sites that are disrupted by one allele of a SNP. Transcription 
factor binding profiles from the JASPAR database (Mathelier et al., 2014) 
(http://jaspar.genereg.net/) were utilized for comparison of each SNP and the surrounding 
sequence on each allele as a tool to further support is-rSNP results. 
2.2 Serological analyses 
2.2.1 Serum study groups 
Biological samples and data from patients with ATTRwt amyloidosis were obtained from 
the BU Amyloidosis Center clinical specimens repository and patient database with 
approval from the IRB at the Boston University Medical Campus (BUMC) as described 
in Section 2.1.1. Clinical data included details of history, physical examination, 
laboratory testing, and echocardiographic studies. Sera and clinical data were selected 
from an ongoing longitudinal ATTRwt cohort evaluated at our center between January 
2009 and January 2016 (Figure 2.3). A portion of this series has been described 
previously (Connors et al., 2016). An unequivocal diagnosis of ATTRwt amyloid disease 
was verified as described (Section 2.1.1). Of 111 patients with ATTRwt amyloidosis, 95 
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were included in this study based on male sex, age ≥ 60 years at initial visit, cardiac 
involvement at baseline (as defined by an IVST ≥ 12 mm on echocardiogram and serum 
BNP > 100 pg/mL), and no amyloid disease-related treatment at the time of initial 
evaluation. Cases with incomplete data for laboratory parameters being studied or lacking 
serum samples adequate for TTR analysis were also excluded. In addition, the study 
included sub-analyses of 23 patients who returned for follow-up evaluation at 1-year; 7 
were treated with the TTR-stabilizer drug, diflunisal (Adamski-Werner et al., 2004), 
started after initial visit, and 16 remained untreated. A 2-year follow-up evaluation 
included 2 diflunisal-treated and 5 untreated patients.  
For comparative analyses, an additional patient group (ATTRm) and healthy 
controls were studied. The ATTRm group consisted of 29 male patients ≥ 60 years of age 
with biopsy-proven amyloidosis and cardiac involvement as a major feature of disease. 
Amyloidogenic TTR mutants represented in the ATTRm group were detected by serum 
isoelectric focusing (IEF) and identified by TTR exonic sequencing (Connors et al., 
1998). Thirty control sera samples from healthy Caucasian males over age 60 years were 
purchased from Bioreclamation (Westbury, NY).   
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Figure 2.3. Schematic of wild-type transthyretin amyloidosis (ATTRwt) patient 
groups for serological studies. Of 111 patients with biopsy proof of ATTRwt amyloid 
disease and initial evaluations between January 2009 and January 2016, 95 with adequate 
repository samples and complete laboratory data were included in baseline studies. 
Twenty-three patients returned for evaluation at 1-year and in this group, 7 were treated 
with diflunisal and 16 received no treatment during the interval from initial to follow-up 
evaluations. Two treated and 5 untreated patients returned for 2-year evaluation. 
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Clinical, laboratory, and echocardiographic data were chosen for this study based 
on our previous report detailing the natural history of ATTRwt amyloidosis (Connors et 
al., 2016). Serum concentrations of cTn-I, BNP, total protein, albumin, creatinine, uric 
acid, C-reactive protein (CRP) or sensitive CRP, and sedimentation rate were measured 
as part of routine laboratory testing. The CRP and sensitive CRP values were converted 
to dichotomous variables since measurements for each variable were not available in all 
patients. Specifically, serum CRP values were obtained between January 2009 and 
February 2011 (ATTRwt, n = 31; ATTRm, n = 7), and sensitive CRP in the interval from 
May 2011 to January 2016 (ATTRwt, n = 60; ATTRm, n = 21). Echocardiographic 
values IVST, LVEF, LVMI, and relative wall thickness (RWT) were determined from 
echocardiograms which were interpreted by researchers blinded to patient diagnosis as 
described (Connors et al., 2016). 
2.2.2 Serum transthyretin measurements 
Serum TTR concentrations were measured at the Boston Medical Center Pathology 
Department Laboratory using an immunoturbidimetric assay with coefficients of 
variation (CV) < 5.5% (Abbott Laboratories, Abbott Park, IL). Patient and control serum 
samples were stored at ≤ -20 °C prior to analysis or assessed immediately as part of the 
clinical workup. 
2.2.3 Serological statistical analysis 
Analyses of patient data from initial and follow-up evaluations, plot generation, and 
associated p-value calculations were obtained using GraphPad Prism software (GraphPad 
Software, Version 5.02, La Jolla, CA). Deviations of data from normal distribution were 
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assessed using the Shapiro-Wilk test for continuous variables. P-values describing 
differences in baseline characteristics and serum TTR levels between patient groups were 
determined by two-sided, unpaired t-test with Welch’s correction for normally distributed 
variables, and the Mann-Whitney test for skewed variables. 
Correlations between TTR and laboratory parameters were assessed using the 
Pearson’s or Spearman’s test for continuous variables, depending on data normality, and 
a two-sided unpaired t-test with Welch’s correction for dichotomous variables. P-values 
describing follow-up analyses were determined by paired, one-sided t-test or Wilcoxon 
signed-rank test depending on whether the data were normally distributed or skewed. P-
values describing differences between treated and untreated groups at a particular visit 
were determined by unpaired, one-sided t-test with Welch’s correction or Mann-Whitney 
test. All t-tests were performed with a type I error rate set at α = 0.05.  
Cox regression and related survival analyses were performed with the use of R 
software, version 3.2.3 (R Foundation for Statistical Computing). Three patients with 
ATTRwt amyloidosis who were enrolled in a clinical trial were excluded from survival 
analyses as their treatment status was unclear. Univariate analyses were performed in 
both ATTRwt and ATTRm groups to identify factors associated with survival and the 
models were adjusted to control for age, body mass index (BMI), and New York Heart 
Association (NYHA) class at the time of initial evaluation. All variables presented in the 
ATTRwt univariate analysis with a p-value < 0.1 were included in a multivariate 
proportional hazards regression model. No multivariate analysis was performed on the 
ATTRm group due to small group size. A value of p < 0.05 was considered statistically 
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significant. To assess potential bias introduced by treatment, a separate Cox regression 
model was generated that excluded 7 ATTRwt patients treated with diflunisal. This 
analysis yielded no major differences between the two Cox models. The sensitivities, 
specificities, and area under the receiver-operating characteristic (ROC) curve for serum 
TTR, cTn-I, and LVEF in the ATTRwt group at 3 years were calculated using the 
Nearest Neighborhood Estimator approach by Heagerty et al. accounting for censoring in 
the survival data (Heagerty et al., 2000). 
Overall survival (OS) curves based on TTR levels were estimated with the 
Kaplan-Meier method and compared using a log rank test. A threshold value of 18 mg/dL 
was considered to be the lower limit of the normal reported range for serum values of 
TTR (Ritchie, ed., 1996); curves using this cutoff value were generated and tested for 
significance. The survival time was measured from the date of positive biopsy (diagnosis) 
to death. Follow-up ended in January 2016 and patients who survived beyond the study 
period were censored. 
2.3 Transthyretin gene expression reporter assays 
2.3.1 HepG2 cells 
HepG2 cells were acquired as a generous gift from Dr. George Murphy’s laboratory. The 
cells were maintained at 37 °C with 5% CO2 in Dulbecco’s modified Eagle medium 
(DMEM) containing 4.5 g/L glucose and phenol red (Cellgro, Manassas, VA), and 
supplemented with 10% fetal bovine serum (FBS) (Optima, Flowery Branch, GA), 50 
IU/mL pennicillin (MP Biomedicals, Santa Ana, CA), 50 μg/mL streptomycin (MP 
Biomedicals), 2 mM L-glutamine (Hy-Clone, Pittsburgh, PA), and 0.1 mM non-essential 
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amino acids (NEAA) (Gibco, Waltham, MA). Cell lines were maintained in 75 cm
2
 and 
25 cm
2
 flasks (Corning, Corning, NY). 
Cells were passaged by trypsinization at 70% confluency with 0.25% trypsin-
EDTA (Gibco) as described by ATCC. Briefly, 3 mL of trypsin were added to the flask 
of cells and incubated at 37 °C for 5 to 10 minutes; cells were washed and agitated by 
pipetting up and down with 7 mL fresh media in the flask and split 1:5 by adding 2 mL 
suspended cells into 13 mL fresh media in a new flask. Images of cells were captured 
using the Nikon microscope and camera described in Section 2.1.1. Mycoplasma 
contamination was ruled out prior to transduction using the LookOut Mycoplasma PCR 
Detection kit (Sigma-Aldrich, St. Louis, MO). 
2.3.2 Cloning 
Vectors for reporter assays were designed on the pHAGE lentiviral backbone, a gift from 
Dr. Murphy’s laboratory in the BU Center for Regenerative Medicine (CReM) (Wilson et 
al., 2008). Two pHAGE plasmid backbones were used: 1) a destabilized GFP reporter 
(DR1) with an internal ribosomal entry site (IRES) for a puromycin resistance gene 
allowing selection (denoted pHAGE-DR1-IRES-puro; Figure 2.4a), and 2) a luciferase 
construct (denoted pHAGE-luciferase; Figure 2.4b). The pHAGE vector contains 
components of the HIV virus for lentiviral generation and infection, as well as NotI and 
SpeI restriction sites encompassing the promoter region for easy manipulation of the 
backbone. 
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Figure 2.4. pHAGE vector maps. Vector maps for DR1 (a) and luciferase (b) reporters 
on the pHAGE backbone are illustrated. The lentivirus is based on HIV for lentiviral 
packaging and infection, and contains HIV components in gray: the 5’ and 3’ long 
terminal repeats (LTR), ψ packaging element (PSI), envelope (env), and WHP post-
transcriptional regulatory element (WPRE). An ampicillin resistance gene, in blue, allows 
for bacterial selection, and the origin of replication (ORI) is shown in purple. The 
reporter genes, destabilized GFP (DR1) and luciferase, are shown in gold (the IRES-puro 
portion for selection in the DR1 reporter is indicated in yellow). The transthyretin (TTR) 
promoter is shown in green.   
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We chose to target the 2 Kb proximal promoter region (Figure 2.1) for insertion 
into the two expression reporter vectors. From previous reports, the minimal length of 
human promoter element required for observable in vivo TTR expression should be the 
500 b located immediately upstream from the transcription start site (Yamamura et al., 
1987). In vivo studies have demonstrated 10% expression with the 500 b human construct 
(Yamamura et al., 1987) and 100% expression with a 3 Kb mouse promoter construct 
both in vivo (Yan et al., 1990) and in HepG2 cells (Costa et al., 1989). Based on these 
data, we anticipated that the 2 Kb human proximal promoter sequence would drive a 
measurable level of reporter expression.  
Figure 2.5 details the cloning process which was followed to develop the vectors 
illustrated in Figure 2.4. Genomic DNA from an ATTRwt patient with a wild-type 
proximal promoter region was used as the template in the Taq PCR Master Mix kit 
(Qiagen) to amplify the promoter region. Primers for the amplification reaction were 
designed to incorporate the TTR proximal promoter, the target area located in the region 
from -2 Kb to the transcription start site (Figure 2.1). The forward primer contained the 
SpeI site, underlined in the following 5’ – 3’ sequence: TGCGCGACTAGTACATATCT 
ATGGGCTGATGGC. The reverse primer contained the NotI site, underlined in the 
following 5’ – 3’ sequence: TAATTAGCGGCCGCATGAGTGGACTTCTGTGATGG. 
For amplification, the following 40 cycle protocol was employed: melting at 95 °C for 30 
seconds, annealing at 60 °C for 45 seconds, and extension at 72 °C for 2 minutes. The 
PCR product was purified using a QIAquick PCR Purification kit (Qiagen).   
  50 
 
Figure 2.5. Schematic of reporter assay vector design. Genomic DNA from an 
ATTRwt patient with a proximal promoter wild-type sequence is depicted showing the 
gene region and the upstream site of interest. Exons are shown in gray, untranslated 
regions in blue, non-coding regions in green, and the transcription start site is indicated 
by an arrow. The targeted proximal promoter is outlined in red. The proximal promoter 
insert was ligated into two reporter vectors, pHAGE-DR1-IRES-puro and pHAGE-
luciferase, where the backbone is depicted in blue, the reporter gene for destabilized GFP 
(DR1) in gray, and the luciferase gene in gold. Introduction of the desired promoter risk 
variants into the vectors is depicted by lines at approximate locations in the promoter and 
coloring as follows: blue for rs3764479, red for rs72922940, and orange for rs3794885.  
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Double-digestion was performed separately on 4 μg of backbone (7.7 Kb for 
pHAGE-DR1-IRES-puro, and 7.4 Kb for pHAGE-luciferase) and 550 μg TTR promoter 
insert (2.2 Kb) using 10 U each of the restriction enzymes, SpeI and NotI (Roche 
Diagnostics, Indianapolis, IN). Reactions were carried out in Buffer H (Roche) for 1 hour 
at 37 °C; digestion products were resolved on a 1.5% agarose gel and isolated using a 
QIAquick Gel Extraction kit (Qiagen). The insert was ligated into both DR1-IRES-puro 
and luciferase backbones (Roche Diagnostics), transformed into DH5α E. coli using the 
heat shock method, and plated on Luria-Bertani broth (LB)-agar containing 100 μg/mL 
ampicillin. DNA from seven colonies was isolated using a Qiagen Mini-prep kit. 
Diagnostic digests with SpeI and NotI enzymes (as described above) allowed for 
selection of vectors containing backbone and insert in both the pHAGE-TTR-DR1-IRES-
puro and pHAGE-TTR-luciferase constructs. The TTR proximal promoter sequence was 
confirmed by Sanger sequencing using the previously described primers (Table 2.1) 
(Genewiz), and cell stocks were frozen in 18% glycerol at -80 °C.  
Desired risk variants, rs3764479, rs72922940, and rs3794885, were separately 
introduced into the proximal promoter by site-directed mutagenesis (Quikchange II XL, 
Agilent Technologies, Santa Clara, CA). Forward primers used in these studies, listed in 
the 5’ - 3’ direction with the a box surrounding the nucleotide at the mutation site, were: 
GAACTTCCAAATATTT G TGATTCATAGCCAGAGAAAAGGCTCTC for 
rs3764479; CATAATTTCTGGACTTGT G TTAATAAGTCGGCCAGGAGG for 
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rs72922940; and C(A16) T GGAAGGAAAAAAGGAAGGAAGGAAGGGAGGG for 
rs3794885.  
The reverse complement to each primer was used as the reverse primer for the 
amplification. The presence of each mutation was verified by Sanger sequencing using 
the previously described primers (Table 2.1) (Genewiz). XL-10 gold competent E. coli 
(from Quikchange kit) containing each construct were grown up for plasmid purification 
by streaking cells from a frozen glycerol stock onto LB-agar plates containing 100 μg/mL 
ampicillin and incubating overnight at 37 °C. An individual colony was chosen from each 
plate and used to inoculate a 5 mL LB starter culture containing 100 μg/mL ampicillin 
which was shaken (250 rpm) for approximately 8 hours at 37 °C. Subsequently, the 
starter culture was used to inoculate a pre-warmed 200 mL LB culture containing 100 
μg/mL ampicillin and shaken overnight. The large culture was used the next day as the 
starting material for a Purelink HiPure Maxi-prep kit (Invitrogen, Carlsbad, CA). Plasmid 
yields were between 1 – 2 mg/mL; samples were stored in sterile water for use in 
lentivirus generation. 
2.3.3 Lentiviral generation and transduction 
Lentiviral constructs for each risk variant (rs3764479, rs72922940, rs3794885), as well as 
the wild-type promoter, were generated in both pHAGE-TTR-DR1-IRES-puro and 
pHAGE-TTR-luciferase backbones as described (Wilson et al., 2008). Transduction of 
HEK-293T cells (approximately 2.5 x 10
7
 cells at 80% confluency) was performed by 
adding TransIT transfection reagent (Mirus Bio, Madison, WI) to DMEM, which was 
vortexed and incubated at room temperature for 10 minutes. Each backbone (24 μg) was 
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added to DMEM along with 2.4 μg of the envelope glycoprotein of vesicular stomatitis 
virus (vsv-g) and 1.2 μg each of several vectors containing HIV genes required for 
packaging. Specifically, the vectors included HIV genes for trans-activator of 
transcription (tat), regulator of expression of virion proteins (rev), group-specific antigen 
(gag), and reverse transcriptase (pol). The supplemented media was vortexed and 
incubated at room temperature, then added drop wise onto cells in fresh media. 
Beginning on day 3, media was collected every 12 hours for a total of 5 collections; the 
total amount was then filtered through a 0.45 mm pore filter, and spun for 90 minutes at 
16500 rpm. Supernatant was poured off and virus was collected from the bottom of the 
centrifuge tube. 
A titer procedure on FG293 cells, described by the same group whose protocol for 
generating lentiviral constructs in pHAGE-TTR-DR1-IRES-puro and pHAGE-TTR-
luciferase backbones is detailed in the preceding paragraph (Wilson et al., 2008), did not 
yield results; thus, no titer was available for transduction. Therefore, equal volumes (50 
μL) of each virus were used to transduce cells in 6-well tissue culture (TC)-treated plates 
at 60% confluency in the presence of described media (Section 2.3.1) supplemented with 
5 μg/mL polybrene (Sigma-Aldrich). Culture media was changed after 24 hours; and cells 
were passaged after 2 days. Fresh media containing 2.5 μg/mL puromycin (Thermo 
Fisher Scientific) was added on day 3 to cells containing HepG2-pHAGE-TTR-DR1-
IRES-puro. The puromycin concentration required for selection was determined using a 
kill curve prior to transduction. The range of puromycin concentrations tested was 0.5 – 
2.5 μg/mL, based on findings from several groups (Huang et al., 2008; Jia et al., 2007; 
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Kim et al., 2008). HepG2-pHAGE-TTR-DR1-IRES-puro cells were grown in the 
presence of puromycin for 10 days to allow for selection. 
2.3.4 FACS analysis 
Immediately following selection, HepG2-pHAGE-TTR-DR1-IRES-puro cell lines 
containing wild-type promoter or one of the three variants of interest were split into 
triplicate cultures, grown up to 70% confluency, counted as described, and harvested for 
fluorescence-activated cell sorting (FACS) analysis on the FACSCalibur (BD 
Biosciences, Franklin Lakes, NJ). Cells were re-suspended at a density of 1 x 10
6 
cells/mL in PBS with 0.5% BSA and measured for GFP fluorescence. Mean fluorescence 
intensity (MFI) was graphed in GraphPad Prism and p-values were determined by two-
sided unpaired t-test. 
2.3.5 Luciferase assay 
HepG2-pHAGE-TTR-luciferase cells containing either the wild-type TTR promoter or a 
promoter with one of the three variants of interest were counted using a haemocytometer 
and negative trypan blue staining. A cell number titration was performed to ensure that 
each cell line had comparable virus copy numbers. Each line was titrated from 1 x 10
4
 
cells/well to 1 cell/well on a 96-well TC-treated plate and analyzed in replicates of 6 
(Corning) to establish titration curves. For analysis, cells were seeded in a 96-well TC-
treated plate (Corning) at a density of 1 x 10
5
 cells per well and allowed to adhere for 3 
hours. Cells were lysed with 100 μL Glo Lysis buffer (Promega, Madison, WI) and 100 
μL Bright-Glo substrate (Bright-Glo Luciferase Assay System, Promega) was added to 
each well. Luciferase signal was quantified in white polystyrene 96-well plates (Costar, 
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Corning, NY) with the Synergy2 multifunction plate reader (Bio-Tek Instruments, 
Winooski, VT). Three plates were run with each construct measured in triplicate per 
plate; this experiment was repeated on three separate days. The background signal from 
no-virus control cells was averaged and subtracted from the signal for each variant and 
wild-type, and corrected values were compared using an unpaired two-sided t-test 
(Graphpad Prism). 
2.3.6 Quantitative PCR 
Three million HepG2 cells from each cell line (both DR1 and luciferase backgrounds) 
and no-virus controls were harvested, washed in PBS, and lysed for RNA purification 
with a Qiagen RNeasy mini plus kit. The protocol was modified to accommodate a 
DNase1 clean-up (Qiagen) step which was performed on-column between wash steps. 
Specifically, DNase1 was added to buffer RDD; 80 μL of the solution was placed on the 
column and incubated on the benchtop for 15 minutes before washing and continuing the 
extraction protocol. Reverse transcriptase (RT)-PCR was performed to generate cDNA 
using a QuantiTect Reverse Transcription kit (Qiagen). For each vector, 500 ng of 
purified RNA was incubated with gDNA wipeout buffer at 42 °C for 2 minutes; this step 
was followed by addition of reverse transcriptase and primers, and incubation at 42 °C 
for 15 minutes and 95 °C for 3 minutes. The cDNA yield was 25 ng/μL. 
A SYBR Green PCR Master Mix kit (Applied Biosystems, Foster City, CA) was 
used for qPCR analysis. Primers were designed for targets DR1 and luciferase; GAPDH 
was used as the reference gene (Table 2.3). The starting cDNA amount was 6.25 ng, and 
3.75 pmol of both forward and reverse primers were used. Each sample was run in seven 
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replicates on a MicroAmp Fast 96-well reaction plate with optical adhesive covers 
(Applied Biosystems) in a Bio-Rad C1000 thermal cycler (Bio-Rad, Hercules, CA). No-
RT controls were run in duplicate to verify the absence of genomic DNA contamination. 
The program was as follows: 95 °C for 10 minutes, 40 cycles of 95 °C for 15 seconds, 
and 60 °C for 1 minute; a plate read followed each cycle. A melt curve was generated by 
heating at 95 °C for 5 minutes, then a gradient heat cycle from 65 °C to 95 °C in 0.5 °C 
increments; a plate read was performed at each temperature increase. Data were analyzed 
using the comparative Ct (ΔΔCt) method, where the cells with wild-type TTR promoters 
in their reporter vectors served as the calibrator sample (Livak and Schmittgen, 2001). 
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Table 2.3. Primers for qPCR 
Target gene Forward primer Reverse primer 
Fragment 
size, b 
DR1 CCCAGGACATCGTCGACTACTTCAA ACTCGTGGTACATGCAGTTCTCCT 144 
Luciferase AGAGGTTCCATCTGCCAGGTATCA CCAGATCCACAACCTTCGCTTCAA 144 
GAPDH CGGAGTCAACGGATTTGGTCGTATTG GCCATGGGTGGAATCATATTGGAACA 145 
a
Primers are listed in the 5’ to 3’ direction. Designed for quantitative polymerase chain reaction (qPCR) amplification of target 
genes 
  58 
2.3.7 Electrophoretic mobility shift assay 
Ten million HepG2 cells were washed in 10 mL PBS and centrifuged at 2000 rpm for 5 
minutes, then lysed in 1 mL of low salt buffer (20 mM HEPES, pH 7.4, 10 mM KCl, 2 
mM MgCl2, 0.5% IGEPAL CA-360) on ice for 10 minutes. After a 2000 rpm 
centrifugation, the pellet was washed twice by re-suspending in 800 μL low salt lysis 
buffer (without IGEPAL CA-360) and centrifuged at 4000 rpm after each wash step. The 
pelleted nuclei were incubated in 100 μL high salt nuclear extract buffer (20 mM HEPES, 
pH 7.4, 10 mM KCl, 2 mM MgCl2, 500 mM NaCl) for 10 minutes with occasional 
vortexing. Supernatant was collected as the nuclear extract after a 13000 rpm 
centrifugation. The protein concentration was determined by Pierce bicinchoninic acid 
(BCA) assay (Thermo Fisher Scientific), then diluted to 1 mg/mL for storage at -80 °C. 
DNA probes for the wild-type and variant sequences were generated from 
oligomers previously used as primers in the site-directed mutagenesis experiments, 
detailed in Section 2.3.2. Wild-type probe sequences were as follows: 
GAACTTCCAAATATTTATGATTCATAGCCAGAGAAAAGGCTCTC for the 
sequence at rs3764479; CATAATTTCTGGACTTGTATTAATAAGTCGGCC 
AGGAGG for the sequence at rs72922940; and C(A17)GGAAGGAAAAAAGGAAGG 
AAGGAAGGGAGGG for the sequence at rs3794885. Wild-type and variant (Section 
2.3.2) oligomers were incubated with their reverse complements in equimolar 
concentrations of buffer containing 10 mM tris base, pH 8.0, 1 mM EDTA, and 50 mM 
NaCl at 95 °C for 5 minutes and allowed to cool slowly while on the heat block. 
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Nuclear extracts, in the range of 400 ng – 1.3 μg total protein, were incubated at 
room temperature for 30 minutes with 2 μg DNA probe in buffer containing 10 mM tris, 
150 mM KCl, 0.1 – 0.3 mM EDTA (depending on presence of probe), 0.1 mM DTT, 
10% glycerol, and 11 – 27.5 mM NaCl (from lysate and probe buffers), this was 
performed in triplicate for each wild-type/variant probe set. The reactions were resolved 
on 3-12% gradient Bis-Tris gels (1.0 mm thick, 15-well) using the blue native (BN)-
PAGE method (NativePAGE Novex Bis-Tris gel system, Life Technologies). The 
NativePAGE running buffer (Life Technologies) had a final concentration of 0.02% 
Coomassie G-250 (Bio-Rad); 1% G-250 was added to samples along with native sample 
buffer prior to electrophoresis. Gels were pre-run at 4 °C and 150 V for 45 – 60 minutes; 
samples were then quickly loaded into the wells. Electrophoresis was continued at 150 V 
for 1 hour and subsequently increased to 250 V for 20 – 30 minutes until the dye front 
was approximately 1 cm from the bottom of the gel. Gels were stained with 3 mg/mL 
ethidium bromide in Tris/Borate/EDTA (TBE) for 1 hour and visualized on the 
ImageQuant LAS 4000 (GE Healthcare). The ImageQuant TL program (GE Healthcare 
Life Sciences) was used for densitometric analysis of the bands, which allowed for 
plotting of the relative band intensities. Band intensities between wild-type and variant 
probes were compared using a two-sided unpaired t-test (GraphPad Prism). 
2.4 Transthyretin G6S stability 
2.4.1 Transthyretin expression and purification 
Recombinant TTR G6S was designed by utilizing site-directed mutagenesis (Quikchange 
II, Agilent Technologies) to modify the expression vector described in Kingsbury, et al. 
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(Kingsbury et al., 2007). Forward and reverse primers spanning the appropriate region in 
exon 2 were designed; the sequence of the forward primer, shown in the 5’ – 3’ direction, 
with a box surrounding the nucleotide at the mutation site, was: 
GGTCCGACCGGTACC A GTGAATCCAAATGCCCG. The reverse primer was the 
reverse complement of this sequence. TTR G6S was expressed and purified as outlined in 
Kingsbury, et al., and protein was stored at -150 °C until required for analysis. 
Comparative studies of wild-type, V122I, and L55P TTR were performed with 
recombinant proteins previously derived using the same protocol and available from 
laboratory stocks. All proteins were stored at -150 °C until used. 
2.4.2 Thermal stability 
Separate mixtures of G6S with wild-type, V122I, or L55P TTR in ratios of 1:3, 1:1, and 
3:1 for each protein combination were incubated at room temperature for 7 days prior to 
thermal unfolding experiments. This incubation period was previously shown to be 
sufficient for complete interchange of subunits within the tetrameric forms of TTR 
(Robinson and Reixach, 2014). Structural studies of the individual proteins and 
heterologous mixtures were conducted using circular dichroism (CD) spectroscopy to 
monitor the thermal unfolding of each protein alone and in the presence of wild-type or 
other variants. Sample solutions were prepared using 0.2 mg/mL total protein in the 
presence of 20 – 30% PBS, 1 mM EDTA, and 4.5 M urea. Tetrameric TTR is normally 
an extremely stable protein and obtaining a complete set of melting curve data is 
challenging. Thus, in these experiments, TTR proteins were semi-denatured with urea, 
immediately prior to thermal unfolding, in order to partially destabilize the tetramer and 
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generate melting curves reflecting fully unfolded proteins. CD signal was measured at 
220 nm (far-UV) through a 1 cm quartz cuvette at 1 minute intervals, while heating each 
sample from 25 – 95 °C on a Jasco J-815 spectropolarimeter (Jasco Inc, Japan); data were 
plotted as a function of temperature to construct melting curves. Melting temperature 
(Tm) for each protein sample was calculated from the maximum value of the first 
derivative of the melt data; however, melt curves were incomplete due to the high 
stability of the proteins and therefore the Tm presented for the curves are only estimates. 
2.4.3 Aggregation assay 
Recombinant wild-type, G6S, V122I, and L55P TTR were used to prepare 0.5 mg/mL 
solutions of each protein in PBS. Protein solutions were incubated at 80 °C with shaking 
(500 rpm) for 0 – 48 hours in 50 μL reaction volumes. Proteins were cross-linked with 
4% glutaraldehyde, resolved on a reducing 4-15% PHAST gel (GE Healthcare Life 
Sciences), and visualized with GelCode blue stain (Thermo Fisher Scientific) on the 
ImageQuant LAS 4000 (GE Healthcare Life Sciences). A non-cross-linked sample was 
also electrophoresed on each gel for comparison to the cross-linked samples. 
Densitometric analysis of gel bands was conducted using the ImageQuant TL program 
(GE Healthcare Life Sciences); results were used to generate aggregation curves by 
calculating the percent of the tetramer from total protein present in each lane; only the 
soluble portion of the mixtures was used for calculations. 
2.4.4 Transthyretin G6S structure 
TTR G6S and wild-type structures were downloaded from the Protein Data Bank (PDB, 
http://www.rcsb.org/pdb/home/home.do) and manipulated in Chimera (Version 1.9, 
  62 
[Pettersen et al., 2004]) for desired display. The PBD structures used were as follows: 
PDB #1BZD for TTR G6S; PDB #1TTA for wild-type TTR (Hamilton et al., 1993); PDB 
#3D2T for wild-type TTR complexed with diflunisal (Adamski-Werner et al., 2004); 
PDB #1TTR for TTR V122I (Damas et al., 1996); and PDB #3DJZ for TTR L55P 
(Cendron et al., 2009). 
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CHAPTER 3. GENETIC VARIATION OF THE TRANSTHYRETIN GENE IN 
WILD-TYPE TRANSTHYRETIN AMYLOIDOSIS 
3.1 Introduction 
ATTRwt amyloidosis is increasingly recognized as the cause of heart failure in older 
Caucasian men with diastolic dysfunction (Dharmarajan and Maurer, 2012; Quarta et al., 
2014). The ethnic and gender disparities observed in this disease (Coelho et al., 2013; 
Connors et al., 2016; Givens et al., 2013; Rapezzi et al., 2009) call to question whether 
there may be an underlying genetic impact which contributes to pathogenesis. Unlike 
ATTRm amyloidosis, where disease onset can be linked to a destabilizing amino acid 
mutation, ATTRwt amyloid disease is characterized by wild-type TTR deposits 
(Westermark et al., 1990); therefore, any genetic influence on the syndrome would be 
found either in coding regions of other contributing genes, or in the regulatory (or non-
coding) regions of any causal gene. We chose to focus our study on the non-coding 
regions of the TTR gene to assess the potential impact of TTR gene regulation on 
ATTRwt amyloidosis. 
It has recently been suggested that non-coding variants in cis-regulatory regions 
may impact expression of the TTR gene in ATTRm amyloidosis (Olsson et al., 2010; 
Polimanti et al., 2013; Soares et al., 2004). This cis-regulatory hypothesis is offered as an 
explanation for varying levels of penetrance, age at onset, disease severity, and sex 
differences observed in the inherited disease. Specifically, one haplotype was implicated 
as a potential modulator of early disease onset in the Portuguese V30M ATTRm 
population (Soares et al., 2004), where disease development occurs in the 3
rd
 and 4
th
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decades of life (Sousa et al., 1995). Another study found a SNP located in a predicted 
miRNA binding site to be associated with Swedish V30M ATTRm (Olsson et al., 2010), 
where disease onset is usually reported after age 60 (Sousa et al., 1993). The different 
non-coding SNPs found in these two populations may begin to describe the differences in 
disease onset ages, despite the presence of the same coding mutation. Furthermore, a 
study determining significant ethnic differences in non-coding SNPs surrounding the 
TTR gene found that the largest differences were between haplotypes present in Africans 
and non-Africans (Polimanti et al., 2013). 
Observed genetic differences in these populations may correlate with differences 
in serum TTR levels (Buxbaum et al., 2008a, 2010). Particularly, several studies have 
reported decreased serum TTR levels in ATTRm (Buxbaum et al., 2010; Connors et al., 
1984), and lowered concentrations of circulating TTR was also reported in older 
individuals (aged > 60 years), females, and African Americans (when compared to 
Caucasians), indicating there could be a genetic impact on TTR expression. 
Investigations into serum TTR concentrations in ATTRwt amyloidosis will be discussed 
in Chapter 4. 
The ethnic and gender differences featured in ATTRwt amyloidosis, along with 
the identification of potential regulatory SNPs explaining these disparities in ATTRm 
amyloid disease, make it plausible that TTR gene regulation plays an important role in 
ATTRwt pathogenesis. Thus far, there have been no ATTRwt genetic studies, and we 
hypothesized that we would find cis-regulatory factors in the TTR near-gene regions that 
could impact TTR expression. This investigation was aimed at identifying candidate non-
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coding variants that might impact the development of ATTRwt amyloid disease through 
cis-regulatory mechanisms. Results from this study represent the first characterization of 
TTR gene non-coding regions in ATTRwt amyloidosis (Sikora et al., 2015). 
3.2 Diagnosis of wild-type transthyretin amyloidosis 
A microdissection-western blot technique was employed as a method to establish 
biochemical proof of ATTRwt diagnosis in several cases lacking immunohistochemical, 
electron microscopic, or mass spectral verification of TTR amyloid deposits. This 
allowed for expansion of the ATTRwt group number used in the genetic study, as criteria 
for an unequivocal diagnosis was established biochemical proof of disease. Biopsy 
samples from 12 patients were analyzed; 10 were fat aspirates and the other 2 samples 
were pelvic node and heart tissue biopsy material. Congo red staining of the samples 
indicated that amyloid was present in all samples, mostly in minimal or trace amounts 
(CR1+) for fat aspirates; 2 fat samples showed more abundant amyloid deposits and were 
graded CR2+ and CR3+. The pelvic node sample was almost entirely infiltrated by 
amyloid (CR3+) and the heart biopsy showed ample Congo red staining in the 
insterstitium and blood vessels (CR2+). Amyloid material extracted from eight fat 
samples demonstrated visible TTR bands on western blot; TTR from blood 
contamination was ruled out as no haptoglobin bands were observed. Representative 
images of these analyses are shown in Figure 3.1 for case 2009020. A fat aspirate stained 
with Congo red exhibited the characteristic apple-green birefringence and bright red 
fluorescence under polarized and fluorescent light shown respectively in the left and right 
figure panels of Figure 3.1a. The circled region of amyloid fibrils in the tissue was 
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excised and analyzed by western blot, which revealed the presence of TTR in the tissue 
(Figure 3.1b). The serum was positive for haptoglobin, but there was no evidence of the 
serum protein in the fat (Figure 3.1c), indicating that TTR in the tissue sample was from 
the deposited amyloid and not due to residual blood in the specimen. This procedure 
confirmed a biopsy diagnosis of ATTR amyloidosis in case 2009020 and results from 
TTR gene mutation analysis established ATTRwt amyloid disease; 7 other tissues were 
positive for TTR in the amyloid deposits as determined by western blot analysis. 
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Figure 3.1. Microdissection-western blot diagnosis of wild-type transthyretin 
amyloidosis. A representative stained fat aspirate from case 2009020 shows the typical 
apple-green birefringence observed with Congo red staining of amyloid when viewed 
under polarized light (left panel), and bright red fluorescence via fluorescence 
microscopy (right panel); both views were at 20X magnification (a). The tissue is labeled 
as CR2+, the histological grade assigned by the evaluating pathologist and indicating 
moderate amyloid infiltration of the tissue by Congo red (CR) staining. The circled 
amyloid fibrils were excised using a tissue microdissector and resolved on a 20% SDS-
PAGE gel for western blot analysis, where the presence of transthyretin (TTR) was 
observed in the tissue, and the lack of haptoglobin indicated no blood contamination 
occurred during the procedure (b). Samples corresponding to 2009020 are outlined in red 
boxes on the western blots, including a serum sample, which stained positive for 
haptoglobin. kDa indicates kilodalton.  
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3.3 Wild-type transthyretin amyloidosis and control group characteristics 
The ATTRwt group consisted of 108 self-identified Caucasian males with biopsy proof 
of wild-type TTR amyloidosis (Table 3.1) (Sikora et al., 2015). A control group used in 
the study consisted of 118 healthy individuals who were matched to the ATTRwt group 
by ethnicity, sex, and age. The median age at onset of ATTRwt symptoms, as reported by 
the patient upon initial visit to the BU Amyloidosis Clinic, was 73.1 years with a range of 
58.8 – 86.6 years (Table 3.1a). The median (range) age at diagnosis was 75.1 years (59.0 
– 87.5). Molecular testing of TTR gene coding regions in all patients demonstrated no 
pathologic mutations; the non-pathologic G6S substitution (Fitch et al., 1991) was found 
to be present on one allele in 8 ATTRwt cases. In the control group, no amyloid-
associated mutations were detected, but 15 controls had the non-pathologic G6S 
substitution of which 11 were heterozygotes and 4 were homozygotes (Table 3.1b). 
The majority (105/108, 97%) of the cohort presented with dominant cardiac 
involvement. Of note, 3 cases had no evidence of cardiac amyloid; these patients 
exhibited symptoms of extracardiac amyloid with biopsies of bladder, stomach, or antrum 
demonstrating congophilic deposits composed of TTR fibrils. Other clinical and 
laboratory data on these 3 patients were representative of the entire group, including age 
at onset and survival; one patient in this group was found to be heterozygous for the G6S 
mutation. Results of single-marker analysis excluding these 3 cases were similar to those 
reported for the entire cohort of 108 patients.  
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Table 3.1. Genetic study group characteristics (Sikora et al., 2015)  
a. Demographics 
ATTRwt 
(N = 108) 
Control 
(N = 118) 
Normal 
Values 
Age at onset, y median (range) 73.1 (58.8 – 86.6) above 60  
Age at diagnosis, y median (range) 75.1 (59.0 – 87.5) 
 
 
Sex, n male 108 118  
Ethnicity, n Caucasian 108 118  
b. Clinical and Laboratory Features 
  
 
Congo red positive biopsy, n 
 
108 
 
 
TTR biochemical proof in 
biopsy, n  
108 
 
 
TTR gene variant, n (%) G6S heterozygotes 8 (7.4) 11 (9.3)  
 
G6S homozygotes 
 
4 (3.4)  
Organ involvement, n (%) cardiac 105 (97.2) 
 
 
 
extracardiac 3 (2.8) 
 
 
Deceased, n (%) 
 
66 (61.1) 
 
 
Survival (onset to death), y median (range) 4.8 (1.5 – 12.7) 
 
 
Survival (diagnosis to 
death), y 
median (range) 3.1 (0.3 – 8.9) 
 
 
c. Markers of Cardiac Involvement, median (range) 
 
 
BNP, pg/mL 
 
411 (52 – 1756) 
 
0 – 72.3 
cTn-I, ng/mL 
 
0.127 (0.020 – 1.198) 
 
0 – 0.049 
IVST, mm  16 (9 – 25)  < 11 
LVMI, g/m
2
 
 
150.4 (57.9 – 308.5) 
 
< 131 
LVEF, % 
 
49 (10 – 70) 
 
55 – 75 
LVEDD, mm 
 
45 (28 – 57) 
 
< 57 
LVESD, mm 
 
34 (21 – 50) 
 
21 – 40 
ATTRwt indicates wild-type transthyretin amyloidosis; N, group number; y, years; TTR, 
transthyretin; G6S, glycine to serine at the 6th amino acid position; BNP, B-type natriuretic 
peptide; cTn-I, cardiac troponin; IVST, interventricular septal thickness; LVMI, left ventricular 
mass index; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic 
diameter; and LVESD, left ventricular end systolic diameter 
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Median (range) survival of the ATTRwt group, measured from onset of heart 
failure symptoms to death, was 4.8 years (range, 1.5 – 12.7 years); median survival 
measured from diagnosis to death was 3.1 years, ranging from 0.3 to 8.9 years. Median 
(range) values for measures of cardiac involvement including B-type natriuretic peptide 
(BNP) and interventricular septal thickness (IVST), were 411 pg/mL (52 – 1756) and 16 
mm (9 – 25), respectively (Table 3.1c). Additional measures of cardiac structure and 
function listed in Table 3.1c include cardiac troponin (cTn-I), left ventricular (LV) mass 
index (LVMI), LV ejection fraction (LVEF), LV end diastolic diameter (LVEDD), and 
LV end systolic diameter (LVESD). For these data, all medians were outside the normal 
values and indicated cardiac involvement in the ATTRwt group. 
3.4 Genetic variation in wild-type transthyretin amyloidosis 
Genetic analysis of ATTRwt and control groups demonstrated the presence of 38 
previously reported variants in the non-coding target regions (Figure 2.1), of which 10 
were common (minor allele frequency [MAF] > 5%) (Sikora et al., 2015). In addition, 
one common coding variant was identified in both groups, rs1800458. All variants were 
within Hardy-Weinberg equilibrium (HWE) in the control group except for rs1800458 (p 
< 0.0001), a G to A nucleotide change in exon 2 corresponding to the non-pathologic 
TTR G6S protein variant (Fitch et al., 1991). Of the 11 common variants identified, 9 
were single nucleotide variations, one was a single nucleotide duplication (rs34047090), 
and one was a CA repeat (rs71383038) (Supplemental Table 1). Three SNPs had 
significant p-values and odds ratios (OR) greater than 1, indicating the minor alleles were 
risk factors (Table 3.2); these were rs4799581 (p = 0.019, OR = 1.56 [1.07 – 2.27]), a T 
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to C substitution located in predicted enhancer 1; rs72922940 (p = 0.013, OR = 2.05 
[1.15 – 3.63]), an A to G substitution located in the proximal promoter; and rs3794885 (p 
= 0.044, OR = 1.47 [1.01 – 2.15]), an A to T substitution located in the proximal 
promoter. The non-pathologic SNP corresponding to the TTR G6S protein variant, 
rs1800458, was predicted to be a protective factor with near-significance (p = 0.051, OR 
= 0.44 [0.19 – 1.03]). No single-marker associations survived a p-value cutoff of pcorrected 
< 0.05 after correction for multiple testing; however, one SNP, rs72922940, remained 
under the significance level of pcorrected < 0.10 (pcorrected = 0.083). 
3.5 Rare variants present in wild-type transthyretin amyloidosis 
A total of 20 rare variants were identified in 7 ATTRwt patients and 9 controls (Table 
3.3) (Hanson et al., 2016). All rare variants had an MAF < 1%. Six previously unreported 
variants were identified, and are listed in Table 3.3 sequentially in the 5’ to 3’ direction 
to uniquely identify the variants. Nearly all unreported variants were present in the 
control group; exceptions include Unreported 05, found in one ATTRwt case and located 
in the proximal promoter region, and Unreported 06, found in 3 ATTRwt patients and 
located downstream of the poly-A site at the 3’ end of the gene. 
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Table 3.2. Summary of common variants having nominally significant (p < 0.05) 
associations with disease (Sikora et al., 2015) 
 
SNP 
Location, 
Chr 18
a 
Minor 
(Common) 
Alleles 
ATTRwt, 
MAF 
Control, 
MAF 
Odds Ratio 
(95% CI) 
P Pcorrected 
rs4799581 29161511 C (T) 0.49 0.38 
1.56 
(1.07 – 2.27) 
0.019 0.12 
rs72922940 29170698 G (A) 0.17 0.09 
2.05 
(1.15 – 3.63) 
0.013 0.083 
rs3794885 29171123 T (A) 0.44 0.35 
1.47 
(1.01 – 2.15) 
0.044 0.24 
SNP indicates single nucleotide polymorphism; Chr, chromosome; ATTRwt, wild-type 
transthyretin amyloidosis; MAF, minor allele frequency; CI, confidence interval; C, cytosine; 
T, thymine; G, guanine; and A, adenine 
a
Assembly GRCh37.p13 
Color coding corresponds to gene map shown at the top of the table 
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Table 3.3. Rare variants identified within the wild-type transthyretin amyloidosis 
(ATTRwt) and control groups (Hanson et al., 2016)  
Variant 
Location, 
Chr 18
a
 
Target 
Region 
Nucleotide 
change
a
 
Sequence (5’ to 3’) ATTRwt, 
n 
Control, 
n 
rs77695939 29161208 Enhancer 1 G>A   1 
rs16962173 29161292  G>A  1  
Unreported 01 29161390  T>C tcagtttact[t/c]ggatgttact  1 
rs185571777 29161528  C>A  1  
Unreported 02 29161528  C>T gctattagtc[c/t]ttgctcaaca  1 
rs1791187 29161836  G>A   2 
rs76629170 29161903  G>T  1  
rs1667245 29168118 Enhancer 2 C>G   2 
rs35197841 29168225  TAG> Del   2 
rs187975096 29168237  T>C   1 
Unreported 03 29168894   A>G taaccatatc[a/g]aggatcaag  1 
rs1667246 29170013 
Proximal 
promoter 
G>A 
 
 2 
Unreported 04 29170423   A>G atctgactct[a/g]tcagttatg  1 
Unreported 05 29170986   C>T ctcaggagtt[c/t]gagaccagcc 1  
rs562861594 29171041   C>G  1  
rs566196517 29171096   G>T  1  
rs556327750 29178829 3’ region C>T  1  
rs558643749 29179072  T>C   1 
Unreported 06 29179241  C>T catgccacca[c/t]gcctagctca 3  
rs148515176 29179245  T>G  1  
ATTRwt indicates wild-type transthyretin amyloidosis; Chr, chromosome; G, guanine; A, 
adenine; T, thymine; and C, cytosine 
a
Assembly GRCh37.p13  
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3.6 Variant association with wild-type transthyretin amyloid disease characteristics 
The 9 common non-coding SNPs were tested for association with ATTRwt clinical and 
laboratory features, and measures of cardiac involvement (Table 3.1b,c) (Sikora et al., 
2015). The clinical features tested were ages at onset and diagnosis, survival, BNP, cTn-I, 
IVST, LVMI, LVEF, LVEDD, and LVESD. Age at disease onset was found to be 
significantly associated with SNPs rs4799581 (p = 0.047), rs3764479 (p = 0.035), 
rs3764478 (p = 0.036), and rs3794885 (p = 0.031); likewise, survival measured from 
onset of symptoms to death was linked to SNPs rs4799581 (p = 0.033), rs3764479 (p = 
0.031), rs3764478 (p = 0.026), and rs3794885 (p = 0.031) (Table 3.4). For these variants, 
a positive trend was observed with age at onset, and a negative trend was observed with 
survival. Results for rs3794885 are representative of the other associated SNPs and 
shown in Figure 3.2. The remaining association graphs can be found in Supplemental 
Figure 1. A conditional analysis of survival on age at onset decreased the significance to 
a small degree in each SNP (rs4799581, p = 0.083; rs3764479, p = 0.076; rs3764478, p = 
0.059; and rs3794885, p = 0.076), suggesting that the associations with age at onset and 
survival might be partially, but not entirely, due to the correlation between these two 
variables. Further, the effect estimates were comparable in the conditional and 
unconditional analyses of survival (rs4799581, -0.77 and -0.63; rs3764479, -0.79 and       
-0.65; rs3764478, -1.14 and -0.97; and rs3794885 -0.79 and -0.65). A graph comparing 
average survival to age at onset by tertile within each genotype for rs3794885 (Figure 
3.2c) demonstrates the negative relationship between the two variables. Having a T allele 
resulted in decreased survival within each age at onset tertile, with the greatest effect in 
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the two higher tertiles. We observed that as age at onset increases, the average survival 
for each genotype decreases, along with overall average survival. Furthermore, the 
number of individuals having the TT genotype increases with age at onset, while the 
number of individuals having the AA genotype decreases. No significant associations 
were observed between SNPs and any of the other variables that were tested. 
Interestingly, the SNP most associated with ATTRwt amyloidosis by the allele test, 
rs72922940, was not associated with any clinical features.  
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Table 3.4. Summary of common variants having nominally significant (p < 0.05) 
associations with clinical variables (Sikora et al., 2015) 
 
SNP 
Location, 
Chr 18
a 
Minor 
(Common) 
Alleles 
ATTRwt, 
MAF 
Control, 
MAF 
Clinical features 
Age at onset 
Survival 
from onset 
Effect 
estimate 
P 
Effect 
estimate 
P 
rs4799581 29161511 C (T) 0.49 0.38 1.57 0.047 -0.77 0.033 
rs3764479 29169825 G (A) 0.43 0.34 1.66 0.035 -0.79 0.031 
rs3764478 29170483 T (G) 0.12 0.13 2.36 0.036 -1.14 0.026 
rs3794885 29171123 T (A) 0.44 0.35 1.69 0.031 -0.79 0.031 
SNP indicates single nucleotide polymorphism; Chr, chromosome; ATTRwt, wild-type 
transthyretin amyloidosis; MAF, minor allele frequency; C, cytosine; T, thymine; G, guanine; and 
A, adenine 
a
Assembly GRCh37.p13 
Color coding corresponds to gene map shown at the top of the table 
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Figure 3.2. Representative clinical association plots for rs3794885 (Sikora et al., 
2015). Box plots showing rs3794885 association with age at onset (a) and survival from 
onset (b) by genotype show a general positive and negative trend, respectively. Each plot 
shows the common genotype first, with the addition of minor alleles following from left 
to right. The relationship between age at onset and survival from onset by genotype is 
depicted (c) to illustrate the relationship between the two associations. Genotype is 
represented by color as shown in the key. The average was calculated by genotype per 
tertile as defined on the horizontal axis. The number of cases having each genotype 
within the tertile which contributed to the calculated average is shown at the top of each 
bar. 
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3.7 Linkage disequilibrium across the transthyretin gene region 
Haplotypes were determined for the 9 common SNPs identified within the target regions 
using HaploView (Barrett et al., 2005) (Figure 3.3) and PLINK (Purcell et al., 2007) 
programs. The dark shading in the diagram indicated a moderate level of linkage 
disequilibrium (LD) across the TTR gene region, particularly at the furthest upstream 
areas that were sequenced. Interestingly, the SNP corresponding to the G6S variant, 
rs1800458, had the greatest recombination rate compared with the other variants. 
Variants rs2420813, rs4799581, rs3764479 and rs3794885 showed the largest degrees of 
LD with one another (D’ = 78 – 95); in contrast, risk variant rs72922940 showed a 
greater degree of recombinance with the other risk variants (D’ = 2 – 22). No haplotypes 
identified by HaploView or PLINK programs were more significantly associated with 
ATTRwt than the single-marker analysis of rs72922940. 
The common ATTRwt-associated variants identified as nominally significant (p < 
0.05; rs4799581, rs72922940, and rs3794885) were shown to be in varying levels of LD 
as determined by HaploView, PLINK, and LocusZoom (Pruim et al., 2010) (Figure 3.4). 
The variant rs72922940 was in moderate LD with rs4799581 (r
2
 = 0.192) and rs3794885 
(r
2
 = 0.224), while the latter two were in higher LD with one another (r
2
 = 0.786). A 
conditional analysis supported the LD results. When conditioned on rs72922940, 
significance only slightly diminished for both rs4799581 (p = 0.16) and rs3794885 (p = 
0.35); however, when rs4799581 and rs3794885 were conditioned on one another (p = 
0.22, p = 0.82), significance diminished more than when rs72922940 was conditioned on 
the two (p = 0.10, p = 0.081).  
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Figure 3.3. Haplotypes present in the wild-type transthyretin amyloidosis cohort. 
Haplotypes containing the 9 single nucleotide polymorphisms (SNPs) were determined 
by HaploView (Barrett et al., 2005). The gene map is shown at the top of the figure, with 
locations of each SNP depicted and coloring as follows: upstream non-coding target 
regions in green, exons in gray, stop codon location in red, 3’ untranslated region (UTR) 
in light blue, and the poly-A location in dark blue. A shaded map below depicts the level 
of linkage disequilibrium (LD) between the SNPs by r
2
 value, with strong evidence of LD 
in dark gray, and strong evidence of recombination in white. Moderate levels of LD are 
shown in shades of gray. The number shown in each square represents D’. The chart 
below displays the most common haplotypes within the cohort and their associated 
frequencies and p-values. Kb indicates kilobases.   
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Figure 3.4. Linkage disequilibrium plot of common single nucleotide polymorphisms 
(SNPs) associated with wild-type transthyretin amyloidosis (Sikora et al., 2015). A 
plot comparing associations from this study with 1000 Genomes data was created using 
LocusZoom (Pruim et al., 2010). SNPs are plotted along the horizontal axis by location 
on the chromosome (a map of the gene is shown at the bottom). The entire length of the 
horizontal axis spans 20 Kb both up- and down-stream of the transthyretin (TTR) gene. 
The vertical axis reflects the significance and shows the recombination rate along the 
blue line. Shading for each SNP reflects r
2
 as indicated by the key. Mb indicates 
megabase, and cM/Mb indicates recombination rate. 
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3.8 Inherited transthyretin amyloidosis non-coding genetic variation 
An ATTRm group (N = 30) was selected for proximal promoter region sequencing to 
determine whether the ATTRwt-associated risk variants were present at different rates in 
the TTR-related diseases. As with the ATTRwt cohort, the ATTRm group was entirely 
male, and mainly Caucasian (67%) (Table 3.5). ATTRm-associated mutations included 
V122I (36.7%), T60A (30%), V30M (10%), L58H (6.7%); 16.7% of the group was 
composed of individuals with the very rare TTR mutants, F64L, I68L, A81V, S77Y, and 
one compound heterozygous case of F44S and G6S. Average ages at onset and diagnosis 
in the ATTRm group were younger than the ATTRwt cohort, 63.9 vs. 73.1 years (p < 
0.0001) and 64.8 vs. 75.1 years (p < 0.0001), respectively. As in the ATTRwt group, 
markers of myocardial status were consistent with cardiac amyloid involvement. 
The ATTRm-associated variant, rs3764479 (p = 0.004), was not associated with 
ATTRwt amyloidosis by the allele test, despite being identified as a clinically-associated 
variable in ATTRwt (Table 3.6). The allele frequencies were significantly different 
between the patient groups (p = 0.0001) with the minor allele occurring more frequently 
in ATTRwt (MAF = 0.43 vs. 0.12). ATTRwt-associated variant, rs72922940, was not 
associated with ATTRm and there was no difference between the MAF in the disease 
groups. Variant rs3794885 was associated with both ATTRwt (p = 0.044) and ATTRm (p 
= 0.014), though the risk allele was different for each group, causing the minor allele to 
be more frequent in ATTRwt amyloidosis (MAF = 0.44 vs. 0.18, p = 0.0003). 
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Table 3.5. Inherited transthyretin amyloidosis (ATTRm) group 
characteristics 
a. Demographics 
ATTRm 
(N = 30) 
Age at onset, y median (range) 63.9 (42.2 – 79.4) 
Age at diagnosis, y median (range) 64.8 (45.0 – 79.5) 
Sex, n Male 30 
Ethnicity, n Caucasian 20 
b. Clinical and Laboratory Features 
 
Congo red positive biopsy, n 
 
30 
TTR biochemical proof in biopsy, n 
 
30 
TTR gene variant, n (%) V122I 11 (36.7) 
 
T60A 9 (30) 
 
V30M 3 (10) 
 
L58H 2 (6.7) 
 
Other
a 
5 (16.7) 
Cardiac involvement, n (%) cardiac 26 (86.7) 
c. Markers of Cardiac Involvement, median (range) 
 
BNP, pg/mL 
 
373 (25 – 2552) 
cTn-I, ng/mL 
 
0.109 (0.010 – 0.695) 
IVST, mm  15 (7 – 25) 
LVMI, g/m
2
 
 
132.4 (63.5 – 224.8) 
LVEF, % 
 
54 (21 – 75) 
ATTRm indicates inherited transthyretin amyloidosis; N, group number; y, 
years; TTR, transthyretin; G6S, glycine to serine at the 6
th
 amino acid position; 
BNP, B-type natriuretic peptide; cTn-I, cardiac troponin; IVST, interventricular 
septal thickness; LVMI, left ventricular mass index; LVEF, left ventricular 
ejection fraction 
a“Other” consists of one patient with each of the following mutations: F64L, 
I68L, A81V, S77Y, and one individual with both F44S and G6S 
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Table 3.6. Summary of proximal promoter variants found in inherited transthyretin amyloidosis 
(ATTRm) compared to wild-type transthyretin amyloidosis (ATTRwt) 
 
   
ATTRwt (N = 108) 
(Table 3.2, Table 3.4)  
ATTRm (N = 30) 
 
ATTRwt 
vs. 
ATTRm, 
P 
SNP 
Location, 
Chr 18
a 
Minor 
(Common) 
Alleles 
MAF 
OR 
(95% CI) 
P 
 
MAF 
OR 
(95% CI) 
P 
rs3764479 29169825 G (A) 0.43 
1.45 
(0.99 – 2.12) 
ns 
 
0.0.12 
0.26 
(0.10 – 0.68) 
0.004  0.0001 
rs72922940 29170698 G (A) 0.17 
2.05 
(1.15 – 3.63) 
0.013 
 
0.08 
0.93 
(0.34 – 2.58) 
ns  0.108 
rs3794885 29171123 T (A) 0.44 
1.47 
(1.01 – 2.15) 
0.044 
 
0.18 
0.42 
(0.21 – 0.85) 
0.014  0.0003 
SNP indicates single nucleotide polymorphism; ATTRm, inherited transthyretin amyloidosis; ATTRwt, wild-type 
transthyretin amyloidosis; Chr, chromosome; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; 
G, guanine; A, adenine; T, thymine; and ns, not significant 
a
Assembly GRCh37.p13 
Color coding corresponds to gene map shown at the top of the table 
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3.9 Functional predictions 
Several of the identified common ATTRwt risk variants may potentially disrupt predicted 
transcription factor binding sites, most of which are highly expressed in the liver (Table 
3.7, Figure 3.5) (Sikora et al., 2015). A C/EBP binding site was predicted to be strongly 
disrupted by rs2420813 using both is-rSNP (p < 0.02) and JASPAR prediction strategies 
(Macintyre et al., 2010; Mathelier et al., 2014). Despite is-rSNP prediction of specific 
binding factors at particular locations, the developers of the program caution that there is 
more confidence in suggesting a member of an identified family binds to the site, due to 
similarities in binding recognition sites within families (Macintyre et al., 2010). The 
binding affinities of HNF3A, HNF3B, and AP-1 (either Fos or JunD subunits) were 
potentially disrupted by rs3764479; interference of the HNF (FOX) family binding site  
(p < 0.03) was confirmed by both prediction techniques, though the AP-1 disruption was 
only predicted by a comparison of the DNA sequence to the transcription factor binding 
profile from JASPAR. The is-rSNP program predicted the disturbance of an HNF family 
site by rs3764478 (p < 0.03) which could not be confirmed by JASPAR comparison. 
Another HNF family binding site was predicted to be disrupted by rs72922940 (p < 0.05) 
using both methods. Interference of an HNF family binding site may also occur when 
rs3794885 is present, as predicted by is-rSNP (p < 0.04). The previously reported 
disruption of a cardiac transcription factor, TEAD1, binding site by rs1791228 (Polimanti 
et al., 2013) (p < 0.02) was also confirmed by both prediction programs used in this 
study. 
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Table 3.7. Common variants 
disrupting predicted transcription 
factor binding sites (Sikora et al., 
2015) 
SNP 
Transcription 
Factor 
Adjusted 
P-value
a
 
rs2420813  C/EBP-beta  0.00741  
 C/EBP  0.0165  
rs3764479  FOXP1  0.0214  
rs3764478  HNF1  0.00552  
 HNF1  0.0164  
 HNF1  0.0234  
 AR 0.0264 
 AR 0.0410 
rs72922940  HNF6  0.00915  
 HNF-4alpha  0.0231  
 HNF4  0.0415  
 C/EBP  0.0393  
rs3794885  HNF6  0.0336  
 HNF4alpha1  0.0364  
rs1791228  TEAD1  0.0120  
a
Adjusted p-values were determined by is-
rSNP (Macintyre et al., 2010) 
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Figure 3.5. Transcription factor binding sites potentially disrupted by transthyretin 
common non-coding single nucleotide polymorphisms (SNPs) (Sikora et al., 2015). 
Binding profile diagrams from JASPAR (Mathelier et al., 2014) were matched manually 
to the gene sequence surrounding the indicated SNP, shown below the transcription 
factor binding profile. The SNP alleles are shown in red with the common allele listed 
first. SNP alleles that differ from taller letters in the binding profile have the largest 
potential impact. 
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Transcription factor binding site predictions were also determined for the rare 
variants identified in our study, many of which were liver transcription factor and sex 
hormone responsive elements (Table 3.8, Figure 3.6) (Hanson et al., 2016). Both is-
rSNP and JASPAR predicted that binding sites for a sex hormone receptor (p < 0.002) 
and/or C/EBP (p < 0.02) would be disturbed by rs16962173, a SNP found in one 
ATTRwt patient (Table 3.3) and located in enhancer region 1. Unreported SNP 02, 
located in enhancer region 1 and present in one control subject, was predicted by both 
programs to interfere with HNF binding at this site (p < 0.004). Unreported SNP 03, 
found in the enhancer region 2 of a control subject, likely disturbs an HNF binding site (p 
< 0.02), as predicted by both methods. 
Sex hormone receptor binding sites were predicted to be disrupted for many of the 
rare variants, including all 9 variants listed in Table 3.8. This finding is in contrast to the 
transcription factor binding disruptions predicted to occur with common variants, located 
mainly in liver transcription factor binding sites. Only one common variant, rs3764478, 
was predicted to disturb an androgen receptor (AR) binding site (p < 0.05), though this 
site was not confirmed manually by the JASPAR prediction method. 
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Table 3.8. Rare variants predicted to disrupt transcription factor binding sites 
(Hanson et al., 2016) 
SNP 
Transcription 
Factor 
Adjusted 
P-value 
 
SNP 
Transcription 
Factor 
Adjusted 
P-value 
rs16962173 PR 0.00242  rs1667245 C/EBPbeta 0.00679 
 
ER 0.00322   AR 0.00761 
 
HNF4 0.00290  Unreported 03 HNF-4alpha 0.00102 
 
HNF4alpha1 0.00549   HNF4 0.00132 
 
HNF4-alpha 0.00711   HNF4alpha1 0.00903 
 
C/EBP 0.0113   AR 0.0153 
 
C/EBP 0.0117   ER 0.0158 
Unreported 01 FOXP1 0.00403   HNF4 0.0173 
 
FOXP3 0.00439  rs1667246 HNF-4alpha 0.00149 
 
C/EBPbeta 0.00738   HNF4 0.00232 
 
AR 0.00846   HNF3A 0.00376 
Unreported 02 HNF3alpha 0.00102   ER 0.00408 
 
FOX 0.00145   ERalpha 0.00701 
 
HNF-3beta 0.00238  Unreported 04 HNF1 0.00284 
 
HNF3beta 0.00350   ER 0.00418 
 
AR 0.00678   HNF6 0.0117 
 
C/EBP 0.00970  Unreported 05 FOXP1 0.00268 
 
FOXP1 0.0108   AR 0.00358 
rs1791187 PR 0.00180   AP-1 0.00359 
 
AR 0.00199   AP-1 0.00487 
 
GR 0.00238   AR 0.00573 
 
PR 0.00341   C/EBP 0.00904 
 
CEBPE 0.00366   C/EBPgamma 0.0110 
 
C/EBP 0.00397   C/EBPdelta 0.0110 
 
AR 0.00466   AP-1 0.0113 
 
C/EBPdelta 0.00903  aAdjusted p-values were determined by is-
rSNP (Macintyre et al., 2010) 
 
GR 0.0127  
 
ERR1 0.0139  
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Figure 3.6. Transcription factor binding sites potentially disrupted by transthyretin 
gene rare non-coding variants (Hanson et al., 2016). Binding profile diagrams from 
JASPAR (Mathelier et al., 2014) were matched manually to the gene sequence 
surrounding the indicated single nucleotide polymorphism (SNP), shown below the 
transcription factor binding profile. The SNP alleles are shown in red with the common 
allele listed first. SNP alleles that differ from taller letters in the binding profile have the 
largest potential impact. 
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3.10 Summary and conclusions 
In this first genetic study of a large, well-characterized ATTRwt cohort, 11 common 
variants in 4 non-coding target regions and one encoded mutant of the TTR gene were 
identified. The single-marker association tests identified 3 SNPs (rs4799581, enhancer 1; 
rs72922940 and rs3794885, proximal promoter) that were associated with ATTRwt, 
although only rs72922940 remained near significance after a multiple-testing adjustment. 
While no haplotypes had greater significance than the individual SNPs, rs72922940 and 
rs3794885 appeared to be driving any observed haplotype association. These two SNPs 
had the strongest evidence for being functional variants. 
Rare variants present in the patient cohort and matched healthy controls were 
characterized, including 6 previously unreported rare variants which were all verified 
using a separate set of primers. These rare variants may each impact the TTR gene in a 
way that confers the same outcome of altered transcriptional control and development of 
disease in patients; conversely, the SNPs may exert a disease protection effect in controls. 
Moreover, several common variants were found to be associated with the ATTRwt 
amyloidosis clinical variables, age at disease onset and survival measured from onset of 
symptoms to death. Onset and survival were inter-dependent, and when the minor allele 
of the associated variants was present, age at onset increased while survival decreased.  
In addition, we found that genetic variation in the proximal promoter region of the 
TTR gene differed between ATTRwt and ATTRm amyloidosis cases. These findings 
may indicate differential gene regulation in these two TTR-related, but separate diseases. 
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Finally, functional predictions using online tools aided in selecting variants with 
the largest potential impact on TTR expression. The most significantly associated 
common variant, rs72922940, was predicted by both is-rSNP and JASPAR programs to 
disrupt an HNF binding site; these results strongly implicate rs72922940 as a functional 
variant. The other ATTRwt-associated variant predicted to interfere with HNF binding 
was rs3794885; this variant was also associated with age at disease onset and survival. A 
third SNP, rs3764479, found to be associated with disease onset age and survival, was 
also predicated to disrupt an HNF or AP-1 binding site. All of these variants were located 
in the proximal promoter region, an ideal location for reporter assays due to its proximity 
to the transcription start site. Although several rare variants located in the proximal 
promoter are possible functional variants, the focus of this dissertation research remained 
on the common variants, found more frequently in the general population and thus, more 
likely to impact study of disease if identified as risk variants. Our hypothesis that TTR 
expression is altered by non-coding genetic variation in ATTRwt amyloidosis was 
supported by association testing and functional predictions; further investigations in 
support of our hypothesis included a study on serum TTR concentrations (Chapter 4) 
and analysis of potential functional variants via reporter assays (Chapter 5). 
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CHAPTER 4. SERUM TRANSTHYRETIN IS A PROGNOSTIC INDICATOR IN 
WILD-TYPE TRANSTHYRETIN AMYLOIDOSIS 
4.1 Introduction 
In Chapter 3, several genetic risk factors were identified that we hypothesized might 
regulate TTR expression in ATTRwt amyloid disease (Sikora et al., 2015). Three SNPs 
located in predicted transcription factor binding sites within the TTR promoter region 
were predicted to affect transcription factor binding affinities, thus altering transcription 
control. We theorized that a change in TTR expression at the gene level in ATTRwt 
amyloidosis might lead to downstream serum concentration changes and our aim was to 
test this supposition using functional studies with reporter assays. 
In addition to providing information about the pathogenetic mechanism of 
ATTRwt amyloidosis, we believed that data from such studies had the potential to offer 
significant contributions in several other areas, including disease diagnosis and 
monitoring. An unequivocal diagnosis of ATTRwt amyloidosis currently requires biopsy 
proof of amyloid deposits by Congo red staining and identification of TTR amyloid 
fibrils by immuno-based microscopic techniques or mass spectral analysis. Disease 
course is typically monitored with two biomarkers of generalized cardiac damage, 
troponin (cTn-I) and B-type natriuretic peptide (BNP). Most recently, several reports 
have indicated nuclear imaging as a sensitive and specific method to differentiate ATTR 
forms of amyloidosis from other systemic amyloid diseases (e.g. immunoglobulin light 
chain or AL amyloidosis) without the need for tissue biopsy (Bokhari et al., 2013; 
Glaudemans et al., 2014; Maurer, 2015). However, it is clear that there is still an unmet 
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need for discovery of validated ATTRwt-specific markers of disease to improve 
diagnosis and for measuring progression. 
While it is widely held that circulating TTR is the amyloid precursor protein and 
the causative agent in ATTRwt amyloidosis, it is unclear whether the serum protein level 
has utility as a measure of disease. Low TTR concentrations have been reported in 
ATTRm amyloidosis (Buxbaum et al., 2010), but normal TTR levels were demonstrated 
in a small ATTRwt series (Buxbaum et al., 2008a). Our genetic risk findings together 
with an unclear role for circulating TTR concentration in disease and the lack of 
ATTRwt-specific biomarkers prompted us to investigate serum TTR concentrations in a 
large ATTRwt series at baseline and follow-up evaluations. In addition, we assessed the 
association of serum TTR levels with survival in ATTRwt amyloidosis and correlated 
longitudinal measurements of TTR concentrations with markers of disease progression in 
diflunisal-treated and untreated patients. 
4.2 Wild-type and inherited transthyretin amyloidosis cohort characteristics 
Baseline clinical, laboratory, and echocardiographic features in the ATTR groups are 
shown in Table 4.1. Data from 95 patients with ATTRwt disease and 29 age- and gender-
matched cases of inherited TTR (ATTRm) amyloidosis featuring cardiomyopathy were 
studied. The ATTRm group was comprised of V122I (51.7%), T60A (20.7%), V30M 
(10.3%), and other pathologic mutants (17.2%); this latter group represented individual 
cases of ATTR F64L, I68L, A81V, and E89Q (Table 4.1a). Only the non-pathologic 
mutation which encodes TTR G6S (Fitch et al., 1991) was present in the ATTRwt group, 
at a frequency of 5.3%. 
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The age of patients in the ATTRwt group was significantly higher than in 
ATTRm (75.0 vs. 68.9 years, p < 0.0001), and there was a greater percentage of 
Caucasians in the ATTRwt group (p < 0.0001). The percentage of deceased patients was 
higher in the ATTRwt group compared to ATTRm, but this difference was not significant 
(45.3% vs. 37.9%, p = 0.49). Consistent with previous reports (Connors et al., 2016; 
Haagsma et al., 2007), abdominal fat biopsy was positive in a greater percentage of 
ATTRm patients compared to ATTRwt (51.7% vs. 22.1%, p = 0.007). Body mass index 
(BMI) was slightly elevated in both groups, but not significantly different (28.1 vs. 29.4 
kg/m
2
, p = 0.986). Median values for total protein, sedimentation rate, C-reactive protein 
(CRP), sensitive CRP, and creatinine were within normal ranges in both groups (Table 
4.1b). Serum albumin was significantly higher in the ATTRwt group (p = 0.024), though 
values remained within normal range. 
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 Table 4.1. Serum study baseline clinical features and laboratory parameters 
a. Characteristic 
ATTRwt 
(N = 95) 
ATTRm 
(N = 29) 
P 
Normal 
values 
Age (years), mean (SD) 75.0 (6.3) 68.9 (5.9) < 0.0001  
Male, n (%) 95 (100) 29 (100)   
Caucasian, n (%) 93 (97.9) 15 (51.7) < 0.0001  
Deceased, n (%) 43 (45.3) 11 (37.9) 0.490  
TTR variant, n (%) 
 
   
V122I 
 
15 (51.7)   
T60A 
 
6 (20.7)   
V30M 
 
3 (10.3)   
Other
a 
5 (5.3) 5 (17.2)   
Positive abdominal fat 
biopsy, n (%) 
21 (22.1) 15 (51.7) 0.007  
BMI (kg/m
2
), median (range) 28.1 (22.0 – 36.5) 29.4 (20.3 – 40.4) 0.986 18.5 – 24.9 
b. Serological Markers, median (range)    
Total protein (g/dL) 7.1 (5.8 – 8.5) 7.2 (6.1 – 8.1) 0.662 6.0 – 8.2 
Albumin (g/dL) 4.1 (2.9 – 4.9) 4.0 (2.6 – 4.6) 0.024 3.5 – 4.8 
Sedimentation rate (mm/hr) 12 (1 – 80) 13 (2 – 81) 0.491 0 – 22 
Creatinine (mg/dL) 1.20 (0.84 – 2.72) 1.24 (0.62 – 2.50) 0.632 0.80 – 1.30 
Uric acid (mg/dL) 8.0 (3.6 – 15.1) 7.0 (3.3 – 15.7) 0.053 3.4 – 7.0 
Abnormal CRP, n (%) 24 (26.4) 6 (21.4) 0.608 
 
c. Cardiac Findings, median (range)    
NYHA functional class II or 
greater, n (%) 
84 (88.4) 24 (82.7) 0.476  
cTn-I (ng/mL) 0.121 (0.020 – 2.027) 0.126 (0.018 – 0.695) 0.825 0 – 0.049 
BNP (pg/mL) 406 (103 – 1756) 383 (118 – 2552) 0.920 0 – 72.3 
IVST (mm) 16 (12 – 25) 16 (12 – 25) 0.998 < 11 
RWT (cm) 0.74 (0.48 – 1.24) 0.66 (0.47 – 1.08) 0.148 0.22 – 0.42 
LVEF (%) 49 (20 – 70) 44 (20 – 75) 0.408 55 – 75 
LVMI (g/m
2
) 150.4 (67.0 – 308.5) 145.4 (77.2 – 240.0) 0.975 < 131 
Arrhythmia present, n (%) 67 (70.5) 14 (48.2) 0.041  
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 ATTRwt indicates wild-type transthyretin amyloidosis; ATTRm, inherited transthyretin 
amyloidosis; N, group number; SD, standard deviation; TTR, transthyretin; BMI, body mass 
index; CRP, c-reactive protein; NYHA, New York Heart Association; cTn-I, cardiac troponin; 
BNP, B-type natriuretic peptide; IVST, interventricular septal thickness; RWT, relative wall 
thickness; LVEF, left ventricular ejection fraction; and LVMI, left ventricular mass index 
a“Other” ATTRwt variants were all heterozygous for G6S. “Other” ATTRm variants consisted 
of one patient with each of the following mutations: F64L, I68L, A81V, E89Q, and one T60A 
case with G6S 
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Serologic and echocardiographic measures reflected cardiac-related amyloid 
involvement in both disease groups. Elevated serum levels of cardiac disease indicators, 
cTn-I and BNP, were measured in all ATTRwt and ATTRm cases; median values for 
echocardiographic parameters including interventricular septal thickness (IVST), relative 
wall thickness (RWT), left ventricular ejection fraction (LVEF), and left ventricular mass 
index (LVMI), were outside the normal range in both groups (Table 4.1c). A majority of 
patients exhibited symptoms of congestive heart failure; New York Heart Association 
(NYHA) functional class II or greater was evaluated in 88.4% of ATTRwt and 82.7% of 
ATTRm cases. Arrhythmia was present in 70.5% of the ATTRwt group and 48.2% of the 
ATTRm group (p = 0.041). A previous report from our laboratory established atrial 
fibrillation as the major contributor to arrhythmia in ATTRwt amyloidosis (Connors et 
al., 2016). 
Mean serum concentrations in the ATTRwt and ATTRm groups were 
significantly different (23 vs. 17 mg/dL, p < 0.0001) for TTR measured at baseline 
evaluation (Figure 4.1). In the ATTRwt group, TTR levels trended lower compared to 
healthy controls (23 vs. 24 mg/dL, p = 0.17), but average serum TTR concentration was 
within the normal range (18 – 45 mg/dL) (Ritchie, ed., 1996). Conversely, in the ATTRm 
group, serum TTR was significantly decreased compared to the control group (p < 
0.0001). In ATTRwt, lower serum TTR was moderately correlated with elevated BNP (r 
= -0.204, p = 0.048) and associated with the presence of arrhythmia (p = 0.006) (Figure 
4.2); no such correlations were found in the ATTRm group. 
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Figure 4.1. Baseline serum transthyretin concentrations. Serum TTR levels for wild-
type (ATTRwt) and mutant (ATTRm) transthyretin amyloidosis groups at baseline 
evaluation, and healthy age-matched controls are depicted in a Tukey box plot. Number 
of cases (N) and mean ± standard deviation (SD) values corresponding to each group are 
shown below the plot. 
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Figure 4.2. Transthyretin (TTR) correlations with markers of cardiac function. TTR 
was moderately correlated with marker of cardiac damage B-type natriuretic peptide 
(BNP) (a). Patients with the presence of arrhythmia had significantly lower TTR than 
patients without arrhythmia (b). Correlation coefficients (r value) and p-values are 
shown, along with a line representing the correlation in part (a), and a line representing 
mean in part (b). 
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4.3 Survival and mortality indicators 
The estimated median overall survivals (OS) for ATTRwt and ATTRm were 3.8 years 
(interquartile range [IQR], 2.7 – 5.5) and 4.3 years (IQR, 2.0 – 12.6), respectively; there 
was no significant difference (p = 0.50) in OS between the patient groups. Factors 
associated with OS were examined separately in the ATTRwt and ATTRm groups using 
Cox regression models (Table 4.2). In ATTRwt, variables associated with OS in the 
univariate analysis included TTR (p = 0.02), cTn-I (p < 0.001), BNP (p < 0.001), LVEF 
(p = 0.007), creatinine (p = 0.008), uric acid (p = 0.004), sedimentation rate (p = 0.004), 
and CRP (p = 0.04). In ATTRm, univariate analysis included three OS predictors that 
were also found in the ATTRwt group, BNP (p = 0.005), LVEF (p = 0.02), and creatinine 
(p = 0.006). No significant multicollinearity was observed between variables in either 
group. Multivariate analysis in the ATTRwt group yielded TTR (hazard ratio [HR] = 
0.89, p = 0.003), cTn-I (HR = 21.2, p < 0.001), and LVEF (HR = 0.97, p = 0.03) as 
indicators of shorter survival. 
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Table 4.2. Factors associated with survival in the transthyretin amyloidoses 
  ATTRwt (N = 92) 
 
ATTRm (N = 29) 
Variable 
Univariate Hazard 
Ratio
a
 (95% CI) 
P 
Multivariate 
Hazard Ratio 
(95% CI) 
P 
 
Univariate Hazard 
Ratio
a
 (95% CI) 
P 
TTR (mg/dL)  
0.93 
(0.87 – 0.99) 
0.02 
0.89 
(0.82 – 0.96) 
0.003 
 
  
cTn-I (ng/mL)  
10.8 
(3.82 – 30.52) 
< 0.001 
21.2 
(4.89 – 91.46) 
< 0.001 
 
  
BNP (pg/mL)  
1.002 
(1.001 – 1.003) 
< 0.001   
 
1.001 
(1.000 – 1.002) 
0.005 
LVEF (%)  
0.96 
(0.94 – 0.99) 
0.007 
0.97 
(0.94 – 1.00) 
0.03 
 
0.93 
(0.88 – 0.99) 
0.02 
Creatinine 
(mg/dL)  
2.5 
(1.27 – 4.97) 
0.008   
 
8.4 
(1.84 – 38.85) 
0.006 
Uric acid 
(mg/dL)  
1.2 
(1.06 – 1.38) 
0.004   
 
  
Sedimentation 
rate (mm/hr)  
1.04 
(1.02 – 1.07) 
< 0.001   
 
  
CRP (mg/dL) 
0.49 
(0.24 – 0.97) 
0.04   
 
  
ATTRwt indicates wild-type transthyretin amyloidosis; ATTRm, inherited transthyretin 
amyloidosis; N, group number; CI, confidence interval; TTR, transthyretin; cTn-I, cardiac 
troponin; BNP, B-type natriuretic peptide; LVEF, left ventricular ejection fraction; and CRP, c-
reactive protein. 
a
Adjusted for age, body mass index, and New York Heart Association class 
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The value of single or multiple variables in predicting 3-year survival in ATTRwt 
amyloidosis was assessed using receiver-operating characteristic (ROC) analysis (Figure 
4.3). A three-year cutoff was chosen to provide better accuracy in survival predictions as 
at least half the observations were censored before that time. The sensitivities and 
specificities for all curves are shown in Supplemental Table 2. Individually, the area 
under the curve (AUC) values indicated that sensitivity was comparable for TTR (AUC, 
0.63; 95% confidence interval [CI], 0.48 – 0.78), cTn-I (AUC, 0.64; CI, 0.49 – 0.79), and 
LVEF (AUC, 0.63; CI, 0.48 – 0.78). However, a model that included all 3 factors 
rendered the greatest sensitivity (AUC, 0.73; CI, 0.56 – 0.89).  
The impact of serum TTR levels on OS in ATTRwt amyloidosis was further 
examined using Kaplan-Meier analysis. When patients were stratified using a TTR 
threshold value at the lower normal limit of 18 mg/dL (Ritchie, ed., 1996), significant 
differences in OS were observed (p = 0.024) (Figure 4.4). Baseline serum TTR levels at 
or above 18 mg/dL corresponded to median survival time of 4.3 years (IQR, 3.1 – 5.5), 
while a poorer outcome of 2.9 years (IQR, 1.4 – 4.0) was noted in the group below the 
threshold value. After adjustments for age, BMI, and NYHA class, a near-significant 
difference in survival time between the groups was observed (p = 0.0501). 
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Figure 4.3. Receiver-operating characteristic (ROC) curves. Three-year overall 
survival predictive value was assessed for cardiac troponin (cTn-I), left ventricular 
ejection fraction (LVEF), transthyretin (TTR), and all three values combined in patients 
with wild-type transthyretin amyloidosis (ATTRwt). AUC indicates area under the curve; 
and CI, confidence interval. 
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Figure 4.4. Kaplan-Meier analysis of overall survival (OS) in ATTRwt amyloidosis. 
For survival analysis, patients were stratified using a baseline serum transthyretin (TTR) 
threshold of 18 mg/dL. Median OS time was 4.3 years (inter-quartile range [IQR], 3.1 – 
5.5) when TTR ≥ 18 mg/dL and 2.9 years (IQR, 1.4 – 4.0) when TTR < 18 mg/dL; 
survivals between the groups were significantly different (p = 0.024). 
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4.4 Longitudinal analyses in wild-type transthyretin amyloidosis 
Data available from the Amyloidosis Center clinical database included information from 
follow-up evaluations on a subset of the ATTRwt cohort included in our studies. In 
addition, serum samples obtained at post-baseline visits were available from the 
Amyloidosis Center clinical specimens repository. The group of ATTRwt patients 
included in follow-up analyses (N = 23) consisted of those treated with the TTR 
stabilizing agent, diflunisal, following baseline evaluation (N = 7) or cases that remained 
untreated with drug throughout our study interval (N =16). The treated and untreated 
subsets of ATTRwt displayed no significant differences from the entire cohort in any of 
the baseline parameters that were studied. Moreover, no significant differences in 
baseline parameters between the treated and untreated groups were noted. 
In the diflunisal-treated group, serum TTR concentrations were substantially 
increased during the first year (22 vs. 29 mg/dL, p = 0.002), and this upward trend was 
observed in 2 cases at second year evaluations (Figure 4.5a). Higher TTR levels 
corresponded to decreased BNP (330 vs. 245 pg/mL, p = 0.043) and cTn-I (0.115 vs. 
0.099 ng/mL, p = 0.422) at one year evaluation (Figure 4.5b,c). The downward trend 
continued in both patients with second year evaluations for BNP (245 vs. 168 pg/mL, p = 
0.201) and cTn-I (0.099 vs. 0.084 ng/mL, p = 0.50). 
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Figure 4.5. Longitudinal study of serum transthyretin (TTR) levels and cardiac 
markers in diflunisal-treated and untreated wild-type transthyretin amyloidosis 
(ATTRwt). Individual values obtained at baseline, 1-year and 2-year evaluations for 
serum TTR (a), B-type natriuretic peptide (BNP) (b), and cardiac troponin (cTn-I) (c) 
concentrations are shown. In each panel, values for the diflunisal-treated cases are plotted 
on the left and untreated patients are shown on the right. The number (N) and mean ± 
standard deviation (SD) values for each serum study variable are shown beneath the 
graphs.  
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In contrast, the untreated group featured significantly lower TTR concentrations 
over a two year interval (23 vs. 20 mg/dL, p = 0.014). At 1-year, cTn-I was increased 
(0.121 vs. 0.162 ng/mL, p = 0.003); BNP was significantly elevated at both 1-year (415 
vs. 524 pg/mL, p = 0.034) and 2-year (524 vs. 684 pg/mL, p = 0.031) evaluations. Mean 
serum TTR concentration was significantly higher in treated compared to untreated 
patients at first (29 vs. 21 mg/dL, p < 0.0001) and second follow-up evaluations (30 vs. 
20 mg/dL, p = 0.007). Moreover, BNP levels were higher in untreated vs. treated patients 
at 1-year visit (524 vs. 245 pg/mL, p = 0.033); similarly, the same trend was observed in 
cTn-I at both 1-year (0.162 vs. 0.099 ng/mL, p = 0.017) and 2-year evaluations (0.157 vs. 
0.084 ng/mL, p = 0.047). 
4.5 Summary and conclusions 
This chapter details the study of serum TTR concentration in a large series of patients 
with cardiac amyloidosis due to ATTRwt amyloid disease. A comparative analysis of 
ATTRwt, ATTRm, and control groups, showed that mean TTR baseline levels in 
ATTRwt (23 mg/dL) were near normal as represented in the age- and gender-matched 
healthy sera (24 mg/dL). These results validate a previously published smaller series by 
Buxbaum et al. (Buxbaum et al., 2008a). While TTR in ATTRwt and control cases were 
comparable, serum levels in an age- and gender-matched ATTRm group featuring 
cardiomyopathy were significantly lower (17.5 mg/dL, p < 0.0001). These data are 
consistent with previous reports showing depressed TTR concentrations in ATTRm 
disease associated with amyloid polyneuropathy (Buxbaum et al., 2010; Skinner et al., 
1985). We have also shown that lower concentrations of TTR in patients with ATTRwt 
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amyloidosis were associated with poor cardiac function as measured by elevated BNP 
and the presence of arrhythmia. 
TTR and other serological, as well as echocardiographic parameters, were 
examined to ascertain associations with survival. Decreased concentrations of TTR were 
found to be an independent predictor of survival in ATTRwt amyloidosis, along with 
elevated cTn-I and lowered LVEF. In ROC analysis of these significant prognostic 
determinants, an inclusive model with TTR, cTn-I, and LVEF gave the greatest 
sensitivity (AUC, 0.73) in predicting 3-year survival in ATTRwt amyloidosis. A cutoff 
value of 18 mg/dL for serum TTR level, considered to be the lower limit of the normal 
reported range (Ritchie, ed., 1996), was used to stratify ATTRwt patients at baseline 
evaluation and assess variations in survival. Significant differences in median survival (p 
= 0.024) were noted in the stratified groups. Patients with TTR in the normal range (≥ 18 
mg/dL) showed better survival compared to the group with lower levels (< 18 mg/dL), > 
4 years vs. < 3 years. 
In a longitudinal analysis comparing patients treated with diflunisal to those not 
taking drug, serum TTR levels increased significantly over a 2-year interval in the treated 
group. Increased serum TTR in the treated group was associated with improving cardiac 
status indicators. Moreover, in untreated patients, TTR concentrations progressively 
decreased over a 2-year interval; these data corresponded to rising levels of BNP and 
cTn-I, indicating worsening cardiac disease. 
This study was the first to establish the impact of serum TTR on survival in 
patients with ATTRwt amyloidosis. In addition, these data provide preliminary evidence 
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that treatment with the TTR stabilizer, diflunisal, results in elevated TTR concentrations 
and improved cardiac status; in contrast, patients not treated with diflunisal showed 
decreasing levels of serum TTR which correlated with continuous progression of 
amyloidosis as indicated by cardiac disease biomarkers. We conclude that serum TTR 
concentration is an independent predictor of survival specific to ATTRwt amyloidosis. In 
addition, TTR levels, when monitored in conjunction with the cardiac biomarker, cTn-I, 
may serve as a more sensitive measure of disease progression, particularly useful when 
assessing the impact of treatment. A cut-off value of 18 mg/dL for serum TTR 
concentration may aide in predicting survival outcome.  
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CHAPTER 5. TRANSTHYRETIN EXPRESSION IS ALTERED BY WILD-TYPE 
TRANSTHYRETIN AMYLOIDOSIS GENETIC RISK VARIANTS 
5.1 Introduction 
Evidence implicating several non-coding genetic variants as potential TTR gene 
modifiers is detailed in Chapter 3. A reporter assay was designed in HepG2 cells to 
study the functional implications of several identified risk variants. This cell line seemed 
an appropriate model for several reasons. HepG2 cells are an immortal line derived from 
hepatocelluar carcinoma cells extracted via biopsy from a Caucasian male at age 15 years 
(Aden et al., 1979); ATTRwt amyloidosis is a disease most often described in Caucasian 
males and hepatic expression of TTR is believed to be the source of the amyloidogenic 
protein. Of note, HepG2 cells display no evidence of hepatitis, but do contain several 
chromosomal abnormalities including duplications of the 2
nd
 and 14
th
 chromosomes, two 
extra copies of the 20
th
 chromosome, a deletion on the 1
st
 chromosome (p22), and 
additions of the following derived chromosomes: 6
th
 (p10) with a translocation of the 17
th
 
(q22); 16
th
 (p13.3) with a translocation of the 6
th
 (q22); and 21
st
 (q10) with a translocation 
from the 1
st
 (p22) (Wong et al., 2000). Despite the genetic abnormalities, there is general 
agreement that this is a robust and reproducible model system for interrogating plasma 
protein expression. Although the original report of this cell line did not identify TTR as a 
protein present in HepG2 cell supernatants (Knowles et al., 1980), subsequent studies 
have demonstrated TTR expression by the cell line (Bartalena et al., 1992; Bellovino et 
al., 1996; Costa and Grayson, 1991; Costa et al., 1986; Qian et al., 1995). Furthermore, 
electrophoretic mobility shift assays (EMSAs) were successfully developed using HepG2 
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cell extracts combined with elements of mouse TTR regulatory regions (Costa et al., 
1988b, 1989; Grayson et al., 1988). Collectively, these attributes make HepG2 cells a 
suitable model system for the study of TTR expression and regulation. 
5.2 Selection of key wild-type transthyretin-associated variants for functional 
analysis 
We hypothesized that sequence variations in TTR gene regulatory regions, specifically 
those SNPs identified in ATTRwt amyloidosis and detailed in Chapter 3, would cause 
functional (transcriptional) disruptions in the gene. Several key variants located in the 
proximal promoter region of the TTR gene were selected for study in HepG2 cell-based 
reporter assays. Study variants were chosen based on association with ATTRwt disease 
and/or clinical variables, and location in regions of predicted regulatory functioning, i.e. 
transcription factor binding sites (Table 5.1). Three common variants, rs3764479, 
rs72922940 and rs3794885, were chosen as candidates for functional studies. The 
rationale for selection of these variants is detailed in subsequent paragraphs. 
The single-marker association tests identified 3 SNPs (rs4799581, rs72922940, 
rs3794885) that were associated with ATTRwt, although only rs72922940 remained near 
significance after a multiple-testing adjustment (Sikora et al., 2015). While no haplotypes 
had greater significance than the individual risk variants, rs72922940 and rs3794885 
appeared to be driving any observed haplotype association. These two SNPs had the 
strongest evidence for being functional variants. 
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Table 5.1. Non-coding variants of interest located in the proximal promoter 
SNP 
Location 
Chr 18
a
 
 Base 
change 
ATTRwt 
assoc.
b 
Clinical 
variable assoc.
b 
is-rSNP
c
 predicted 
binding sites
b 
JASPAR
d
 predicted 
binding sites
b 
rs72922940 29170698 A>G 
p = 0.013, 
OR = 2.05  
HNF6, HNF-4alpha, 
HNF4, C/EBP 
HNF1A 
rs3794885 29171123 A>T 
p = 0.044, 
OR = 1.47  
AO p = 0.031, 
SFO p = 0.031 
HNF6, HNF4alpha1 
 
rs3764479 29169825 A>G 
 
AO p = 0.035, 
SFO p = 0.031 
FOXP1 
FOXA1 (HNF3A), 
FOXA2 (HNF3B), 
AP1: FOS & JUND 
rs1667246 29170013 G>A 
  
HNF4, HNF3A, ER 
 
Unreported 04 29170423 A>G 
  
HNF1, HNF6 
 
Unreported 05 29170986 C>T 
  
AP-1, C/EBP, 
C/EBPgamma, 
C/EBPdelta 
 
SNP indicates single nucleotide polymorphism; Chr, chromosome; ATTRwt, wild-type transthyretin amyloidosis; A, 
adenine; G, guanine; OR, odds ratio, HNF, T, thymine; AO, age of onset; SFO, survival from onset; and C, cytosine 
a
Assembly GRCh37.p13 
b
(Sikora et al., 2015) 
c
(Macintyre et al., 2010) 
d
(Mathelier et al., 2014) 
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Multiple analyses strongly indicated that rs72922940, located in the proximal 
promoter, could be a functional variant (Sikora et al., 2015). This SNP was the most 
significantly associated with ATTRwt disease by the allele test and the only variant to 
remain close to significance after multiple testing correction; moreover, rs72922940 
appeared to drive the haplotype and single-marker analyses. The functionality of 
rs72922940 was further implicated by the prediction of an HNF-family binding site at 
this location by is-rSNP and JASPAR analyses, where the minor allele (G) was predicted 
to preferentially bind the transcription factor and result in increased TTR expression. 
Interestingly, rs72922940 was only nearly associated (p = 0.064) with survival in 
ATTRwt amyloidosis and not associated with any other clinical measures that were tested 
(p > 0.1). 
Another variant found in the proximal promoter, rs3794885, was significantly 
associated with disease by the allele test and present in many associated haplotypes, 
providing evidence that this is a potentially functional variant (Sikora et al., 2015). This 
SNP was also found to be associated with age at disease onset and survival; functional 
analysis by is-rSNP predicted that rs3794885 could disrupt an HNF family transcription 
factor binding site. 
The common variant, rs3764479, also located in the proximal promoter, was 
found to be associated with age at disease onset and survival, but only nearly associated 
with ATTRwt disease (Sikora et al., 2015). This finding suggested that the variant could 
act as a genetic modifier of disease progression, despite having little effect on disease 
development. The minor allele (G) of rs3764479 was expected to have less affinity for 
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both HNF and AP-1 transcription factors. Since rs3764479 is located in an area targeted 
by competing transcription factors, it seemed plausible that binding disruption and/or 
differing binding affinities of both transcription factors at this site would occur when the 
SNP was present.  
Lastly, in choosing variants for functional testing, we considered three rare 
variants (rs1667246, and unreported variants 04 and 05), located in the proximal 
promoter and predicted to disrupt transcription factor binding sites by is-rSNP (Hanson et 
al., 2016). Other rare variants, identified in regions beyond the proximal promoter, were 
excluded based on the far upstream locations, recognizing that these SNPs could 
potentially be better functional candidates. It was decided that rare SNPs would not be 
investigated at this time as functional testing of common variants seemed likely to 
demonstrate the greatest genetic impact on the largest number of individuals. As 
previously discussed, the final selection of common variants, rs3764479, rs72922940 and 
rs3794885, was based on ATTRwt amyloid disease association, predicted functional 
capability, and location in the proximal promoter, a region most likely to impact TTR 
expression. 
5.3 Expression monitoring with human transthyretin promoter on pHAGE 
backbone 
HepG2 cells, transduced with pHAGE-TTR-DR1-IRES-puro and selected for 24 hours, 
expressed DR1 that was demonstrated when GFP was excited at 488 nm (Figure 5.1, 
upper panels). Each vector, containing the wild-type TTR promoter or one of the three 
risk variants, exhibited green fluorescence, while the no-virus control lacked 
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fluorescence, as expected. In the lower panels of Figure 5.1, bright field images show the 
cells transduced with virus growing robustly in culture, while the no-virus control cells 
appear to be non-viable, presumably killed by puromycin selection. Dead cells were also 
observed in the transduced cultures, indicating effective selection of uninfected cells and 
antibiotic-induced death. 
HepG2 cells were also transduced with pHAGE-TTR-luciferase, though these 
cells were not specifically collected due to the lack of a selection gene in the vector. Cells 
with this vector appeared healthy in culture following the transduction process, and no 
change in cell growth rate was observed.  
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Figure 5.1. Subset of GFP-expressing HepG2 cells transduced with pHAGE-TTR-
DR1-IRES-puro. Separate cultures of HepG2 cells were transduced with equal amounts 
of either pHAGE-TTR-WT-DR1-IRES-puro, pHAGE-TTR-rs3764479-DR1-IRES-puro, 
pHAGE-TTR-rs72922940-DR1-IRES-puro, or pHAGE-TTR-rs3794885-DR1-IRES-
puro. Images were taken with fluorescence (top) and bright field (bottom) on day 5 after 
transduction; cells were grown in the presence of 2.5 μg/mL puromycin for 24 hours. A 
no-virus control was subjected to the same conditions. Scale bars are 50 μm. WT 
indicates the wild-type promoter.   
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5.4 Transthyretin-DR1 reporter expression 
HepG2 cells transduced with the pHAGE-TTR-DR1-IRES-puro reporter vector, 
containing either wild-type or variant TTR promoters, were analyzed using fluorescence-
activated cell sorting (FACS). The viable cell percentage for each cell line was between 
85 – 92% (Figure 5.2). While each DR1-expressing cell line exhibited an increase in 
signal compared to a no-virus control, there was a subset of cells in each line that 
overlapped with the no-virus signal. These results suggested that, despite puromycin 
selection, some cells did not express a detectable amount of the reporter. The percentage 
of cells expressing GFP ranged from 20 – 30% for all vectors; there were no significant 
differences between vectors or triplicates. Specifically, promoter-driven expression 
efficiencies were 27% for wild-type and 23% consistently for the 3 risk variant 
(rs3764479, rs47922940 and rs3794885) sequences (Figure 5.3a). The mean 
fluorescence intensity (MFI) corresponding to DR1 expression was significantly 
decreased in the presence of TTR risk variants compared to the wild-type promoter 
(rs3764479, p = 0.0074; rs72922940, p = 0.016; rs3794885, p = 0.0029) (Figure 5.3b). A 
significant difference between the expression levels in the presence of rs72922940 
compared to rs3794885 (p = 0.0053) was also observed. 
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Figure 5.2. Green fluorescent (GFP) signal in HepG2 cells selected for pHAGE-
TTR-DR1-IRES-puro. HepG2 cells with no-virus (no), wild-type TTR promoter (wt), 
and TTR promoters with one of the risk variants (rs3764479, rs72922940, rs3794885) 
were measured for GFP signal by fluorescence-activated cell sorting (FACS) analysis. 
Triplicate cultures are shown in parts a, b, and c. In the tables above each graph, the 
sample color key and percent viable cells (%) are displayed. The last 3 digits of each 
variant are displayed in the tables. FL1-H is the channel that measures GFP signal.  
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Figure 5.3. Percent of GFP positive and mean fluorescence intensity (MFI) of 
HepG2 cells expressing DR1 driven by the transthyretin proximal promoter in the 
presence of risk variants. Fluorescence of HepG2 cells expressing destabilized GFP 
(DR1) driven by the TTR promoter was assessed using fluorescence-activated cell sorting 
(FACS) analysis. The percentage of cells in the culture expressing DR1 (by GFP signal) 
is shown for HepG2 cells containing the wild-type promoter compared to promoters 
containing one of three risk variants (a). The MFI is also shown for each promoter variant 
(b). A no-virus control shows the basal level of fluorescence in the cells. Error bars 
represent triplicate values, and significant p-values comparing each variant to wild-type 
are shown above the graphs. WT indicates the wild-type promoter. 
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5.5 Transthyretin-luciferase reporter expression 
HepG2 cells transduced with pHAGE-TTR-luciferase were assayed for luciferase signal. 
Cultures titrated from 1 x 10
4
 cells to one cell per well demonstrated similar transduction 
efficiencies in each line. Data were assessed in two ways; Supplemental Figure 2 shows 
each cell line graphed by cell number in the titration with 6 replicates for each line. No 
differences were observed in signal for 1,000 to 1 cell per well; at 10,000 cells, the only 
difference was between wild-type and rs3764479 lines (p = 0.018). For comparison, a 
second method was completed by generating curves of background-subtracted signal, 
where the background was calculated by averaging the 6 replicates of no-virus control 
(Supplemental Figure 3). There were no differences between the background-subtracted 
signals of the cell lines at any cell count. Consistent results obtained from the two data 
assessment methods strongly suggested that the cell lines had comparable copy numbers.  
For luciferase signal comparison between cell lines, 9 replicates of 1 x 10
5
 cells 
were assayed. Consistent with the DR1 reporter assay results, the presence of each TTR 
risk variant resulted in significantly lower luciferase signal compared to the wild-type 
promoter (rs3764479, p = 0.0075; rs72922940, p = 0.0041; rs3794885, p < 0.0001) 
(Figure 5.4). The results shown are representative of two additional identical 
experiments. 
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Figure 5.4. Luciferase signal in HepG2 cells expressing the pHAGE-TTR-luciferase 
reporter vector. The luminescent intensity is shown in HepG2 cell lines expressing 
pHAGE-TTR-luciferase driven by the wild-type TTR promoter compared to promoters 
containing one of three risk variants, rs3764479, rs72922940, and rs3794885. Error bars 
represent nine replicates; three plates run on the same day with three replicates on each 
plate, and p-values comparing each variant to wild-type are shown above the graph. 
These data are representative of three separate experiments. WT indicates the wild-type 
promoter.  
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5.6 RNA expression in reporter assays 
Quantitative PCR (qPCR) was employed to confirm results of the two reporter assays by 
measuring the expression of the two vectors at the RNA level. In cells transduced with 
either pHAGE-TTR-DR1-IRES-puro or pHAGE-TTR-luciferase vector, the TTR 
promoter containing any risk variant sequence resulted in less reporter transcription 
compared to wild-type (Table 5.2). In the DR1 reporter, DR1 expression normalized to 
GAPDH was 0.940-fold lower in the presence of rs3764479 and 0.859-fold lower in the 
presence of rs72922940 or rs3794885. In the luciferase reporter, a similar trend was 
observed, with the presence of rs3764479 in the TTR promoter again resulting in 0.940-
fold expression levels compared to wild-type, 0.864-fold expression in the presence of 
rs42922940, and 0.847-fold expression in the presence of rs3794885. The lower levels of 
transcription, measured by mRNA quantification, from risk variant vs. wild-type 
promoters were consistent with the GFP and luciferase data obtained from the DR1 and 
luciferase reporter assays. 
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Table 5.2. mRNA expression of reporter genes in HepG2 cells 
Reporter vector 
TTR promoter in 
vector 
ΔCt (SD) ΔΔCt (SD) 
Fold difference from 
WT (range) 
pHAGE-TTR-
DR1-IRES-puro 
WT 1.72 (0.23) 0 (0.23) 1 (0.855 – 1.170) 
rs3764479 1.81 (0.15) 0.09 (0.15) 0.940 (0.845 – 1.045) 
rs72922940 1.94 (0.30) 0.22 (0.30) 0.859 (0.696 – 1.060) 
rs3794885 1.94 (0.21) 0.22 (0.21) 0.859 (0.744 – 0.990) 
pHAGE-TTR-
luciferase 
WT 3.88 (0.15) 0 (0.15) 1 (0.904 – 1.106) 
rs3764479 3.97 (0.17) 0.09 (0.17) 0.940 (0.836 – 1.055) 
rs72922940 4.09 (0.11) 0.21 (0.11) 0.864 (0.803 – 0.931) 
rs3794885 4.12 (0.11) 0.24 (0.11) 0.847 (0.785 – 0.913) 
mRNA indicates messenger RNA; TTR, transthyretin; ΔCt, change in threshold cycle; SD, 
standard deviation; ΔΔCt, difference between wild-type and variant change in threshold cycle; 
and WT, wild-type 
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5.7 Transcription factor binding to risk variants 
Since the reporter assays demonstrated lowered expression levels in the presence of TTR 
risk variants, EMSAs were used to assess transcription factor binding in these promoter 
regions. Oligomeric probes containing either a wild-type or variant (rs3764479, 
rs72922940, or rs3794885) TTR promoter sequence were used to test HepG2 cell nuclear 
extracts for binding (Figure 5.5). Each wild-type/variant probe set was assayed in 
triplicate. For each analysis, an excess amount of each probe (2 μg) was tested with 
separate amounts (400 ng, 600 ng, 900 ng and 1.3 μg as quantified by BCA) of HepG2 
cell nuclear extract. In the electrophoretic system that was used for these analyses, only 
nucleic acids were visualized by staining with ethidium bromide; proteins were not 
directly detected. Two high molecular weight protein bands (upper and lower) were 
visualized on the gel by ethidium bromide staining in all wells containing nuclear extract; 
Coomassie staining of these bands during assay optimization confirmed that these bands 
were composed of protein bound to DNA (Supplemental Figure 4). Probe excess was 
demonstrated by intense staining as shown in Figure 5.5 where free probe (“oligo 
probe”) was observed at the bottom of appropriate lanes. Although some residual protein-
bound DNA from the nuclear extraction preparation was visualized in the protein-only 
wells, there was a greater signal in the presence of all 4 DNA probes, likely resulting 
from oligomer probes binding to available transcription factor binding sites. Since small 
differences between the signals of the wild-type and variant sequences were difficult to 
ascertain from staining intensities of the bands, densitometry was employed to further 
analyze the results. 
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Figure 5.5. Electrophoretic mobility shift assays (EMSA) determining HepG2 cell 
nuclear extract binding capacities to wild-type and variant TTR promoter probes. 
HepG2 cell nuclear extract amount is shown at the top as a gradient to depict wells with 
400 ng, 600 ng, 900 ng and 1.3 μg of total protein loaded. The oligomeric (oligo) probe 
present is shown as “WT” for the sequence containing the reference nucleotide at the 
variant site, and “Variant” describes the sequence containing the single nucleotide 
polymorphism (SNP). Two panels are shown for each variant, rs3764479 (a), rs72922940 
(b), and rs3794885 (c), depicting the nuclear extract (shift) in the upper panels showing 2 
bands, and excess or free probe in the lower panels representing lower electrophoretic 
migration positions on each gel. Gels were resolved using the BN-PAGE method and 
visualized with ethidium bromide. Gels shown are representative of 3 replicates.  
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The upper gel band was greater when bound to the wild-type and variant probes at 
the site of rs3764479, compared to lysate alone, though the signal intensity was similar in 
the presence of both probes (Figure 5.5, Figure 5.6a). Likewise, the presence of wild-
type and variant probes at the rs72922940 site resulted in a greater intensity than lysate 
alone, and this result was nuclear extract concentration dependent (Figure 5.5). The 
difference between the intensity of the upper band in the presence of the rs72922940 
probe was greater than wild-type at 600 ng total protein (p = 0.012), but the difference 
was not significant when all nuclear extract amounts were considered (Figure 5.6b,d). 
The signal intensity of the upper band increased in the presence of both variant and wild-
type probes at the site of rs3794885, but to a lesser degree than the other sites, indicating 
a lesser affinity of the nuclear extract to this site (Figure 5.5, Figure 5.6c). The lower 
lysate band signal was greater in the presence of all probes compared to nuclear extract 
alone, regardless of which sequence was present, and there were no observable 
differences in signal intensities for the different probes (Figure 5.5).   
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Figure 5.6. Electrophoretic mobility shift assay (EMSA) upper band signal 
intensities. Densitometric analysis yielded signal intensities of each band; the upper band 
signal intensities in the presence of each probe were normalized to the nuclear extract 
only band intensity by amount of nuclear extract loaded. Wild-type (WT) probes were 
compared to those with the variant by two-sided unpaired t-test (a-c). At 600 ng nuclear 
extract, wild-type sequence compared to variant sequence at the location of rs72922940 
displayed a significant difference (d).  
  129 
5.8 Summary and conclusions 
In studies described in this chapter, three ATTRwt risk variants identified in the TTR 
proximal promoter (rs3764479, rs72922940, and 3794885) were tested for functional 
capacity in two separate reporter assays. The variant most significantly associated with 
ATTRwt amyloidosis by the allele test was rs72922940; this was the only SNP that 
remained close to significance after multiple testing correction, appeared to drive the 
haplotype and single-marker analyses, and was predicted to disrupt an HNF-family 
transcription factor binding site. Identified as a disease risk variant by the allele test, 
rs3794885 was also found to be significantly associated with age at onset of symptoms 
and survival measured from time of onset; furthermore, functional analysis predicted 
disruption of an HNF family binding site by this SNP. While rs3764479 was found to be 
associated both with age at onset and survival, the variant was only nearly associated 
with disease which indicated that the SNP acted as a genetic modifier subsequent to 
disease development. This SNP was predicted to disrupt both HNF and AP-1 
transcription factor binding sites. 
The impact on expression of each genetic risk factor was assessed through the use 
of several reporter assays. HepG2 cells were used as a model system and transduced with 
pHAGE lentiviral constructs containing 2 Kb of the TTR promoter in the presence of the 
wild-type or one of the three risk variant sequences in addition to a reporter gene of either 
DR1 or luciferase. The individual presence of all 3 TTR promoter variant sequences 
consistently resulted in lower reporter expression compared to wild-type in both assays; 
expression was assessed in the 2 systems at both protein (GFP and luciferase) and mRNA 
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levels (qPCR). The difference observed between the variant and wild-type promoters 
were small but significant in each reporter system. 
Based on EMSA observations using HepG2 nuclear extract, a slowly migrating 
(upper) gel band contained transcription factors capable of binding to the rs3764479 site; 
no significant difference in the signals of wild-type and variant probe were noted in this 
comparison. In contrast, a transcription factor in the upper band may bind preferentially 
to the variant sequence where rs72922940 is located. Further, a transcription factor 
present in the upper band may bind at the site of rs3794885, but with a lesser affinity than 
the other probes and no preference for variant as was seen with rs3764479. Since only 
small and non-significant differences were observed in the signal intensities for variant 
vs. wild-type probes, it is likely that this method of measurement is not sensitive enough 
to detect subtle changes in transcription factor binding affinities caused by these variants. 
Moreover, non-specific interaction of each probe with a transcription factor present in the 
lower band may also be the case, since the intensity was not different from nuclear 
extract alone. 
This chapter detailed the design and use of a robust cell-based model for studies 
of TTR expression in ATTRwt. The functionality of several non-coding genetic risk 
factors was assessed and the effects of the genetic risk variants on TTR expression were 
demonstrated via overlapping and coordinating methods. In conclusion, our preliminary 
studies suggest that TTR expression is decreased in the presence of several TTR proximal 
promoter risk variants, potentially due to altered binding of hepatocyte transcription 
factors at these regulatory sites. 
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CHAPTER 6. NON-PATHOLOGIC TRANSTHYRETIN VARIANT G6S MAY BE 
PROTECTIVE IN TRANSTHYRETIN AMYLOIDOSIS 
6.1 Introduction 
Several non-pathologic variants in the TTR protein have been described which have no 
destabilizing effect on the native structure of the tetramer and do not contribute to 
inherited ATTRm amyloidosis (Rowczenio et al., 2014). The G6S variant has been 
observed in patients with ATTRm amyloidosis, though the mutant is always found in 
individuals who are compound heterozygotes for a second, amyloidogenic mutation 
(Jacobson et al., 1995). TTR G6S is widely accepted as a non-amyloidogenic variant 
(Fitch et al., 1991) and is reportedly present in 6% of the Caucasian population (Jacobson 
et al., 1995). 
While evaluating ATTRwt and control subjects in our genetic study, described in 
Chapter 3, we sequenced all 4 TTR exons to confirm that no cases had an amyloidogenic 
mutation, i.e. ATTRm amyloidosis (Sikora et al., 2015). We identified several individuals 
in both ATTRwt and control populations with the variant rs1800458, a coding SNP 
corresponding to the TTR G6S protein variant (Table 6.1). Interestingly, a nearly 
significant association (p = 0.051) and odds ratio (OR) < 1 (OR = 0.44 [0.19-1.03]) was 
found between ATTRwt and rs1800458; these data suggested that the A allele coding for 
the G6S protein variant was disease-protective. Further, the ATTRwt group had a lower 
allele frequency of 0.04 compared to 0.06 reported for Caucasians (Jacobson et al., 
1995); strikingly, the control group used in our genetic study featured a higher frequency 
of 0.08. Moreover, in the ATTRwt group with G6S, 8/8 (100%) were identified as 
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heterozygotes with mutant and wild-type alleles; no homozygotes were characterized. In 
the control group, G6S was detected in 15/118 of the samples with 11 heterozygotes and 
4 homozygotes; individuals with only variant allele (no wild-type) comprised 26.6% 
(4/15) of the group and 3% (4/118) of all controls. Lastly, rs1800458 was the only variant 
out of HWE (p = 0.001) for the control group, providing further evidence in support of 
skewed genotypes in this population (Figure 6.1). 
We also investigated the occurrence of G6S in ATTRm amyloidosis with data 
from exonic screening of groups included in the serum study (Chapter 4). In ATTRm 
amyloidosis, the G6S allele frequency was 0.017 (Table 6.1); the non-pathologic mutant 
was identified in only one patient, found to be heterozygous for G6S and the 
amyloidogenic TTR T60A. This observation was much lower than the expected 0.06 
value, but consistent with our hypothesis that G6S is a protective variant. We supposed 
that the presence of G6S in ATTRm amyloidosis would mitigate symptoms of disease; 
patients with the mutant may not have met our study selection criteria including the 
presence of cardiomyopathy, typically an indication of aggressive disease. In fact, 2 
ATTRm patients who were identified as heterozygous for G6S were excluded from our 
serum study based on low BNP values which argued against cardiac amyloid 
involvement. 
Further statistical analyses of G6S in the ATTRwt and ATTRm groups 
demonstrated that those patients with the variant had significantly lower cTn-I (p = 0.011, 
p = 0.0029) and BNP (p = 0.047, p = 0.0049) levels compared to patients without the 
variant, i.e. G6G (Figure 6.2). These data support our theory that G6S may be associated 
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with milder disease symptoms in TTR-associated pathologies, particularly in ATTRm 
amyloidosis. In order to statistically power our comparative analyses of patients with 
G6S, the ATTRm group used in the present study contained 17 patients who were not 
included in the serum study; TTR amyloidogenic mutations (n) represented in the group 
were T60A (5), L58H (5), V30M (4), S77Y (1), V122I (1), and L70N (1). The 2 patients 
with G6S in this group had pathologic TTR mutations coding for T60A and L58H. The 
results of this analysis suggested a bias of G6S against cardiac involvement. Collectively, 
these data prompted us to further examine the potential of G6S as a protective factor in 
ATTR amyloidosis. Studies included comparing the protein stability and aggregation 
potential of G6S to other amyloidogenic TTR variants.   
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Table 6.1 -Transthyretin G6S frequencies across study populations 
 
Caucasians
a
  BU Control
b
  ATTRwt
b
  ATTRm  
N 279 118 108 29 
Variant allele frequency 6% 8% 4% 3% 
Homozygous reference (GG) 246 103 100 28 
Heterozygous (GA) 33 11 8 1 
Homozygous variant (AA) 
 
4 
  
Odds ratio (95% CI)  
  
0.44 
(0.19-1.03)  
0.20 
(0.026-1.53)  
P  
  
0.051  0.086  
BU indicates Boston University; ATTRwt, wild-type transthyretin amyloidosis; ATTRm, 
inherited transthyretin amyloidosis; N, group number; G, guanine; A, adenine; and CI, 
confidence interval 
a
(Jacobson et al., 1995) 
b
(Sikora et al., 2015) 
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Figure 6.1. Hardy-Weinberg analysis of the gene variant corresponding to 
transthyretin G6S in the control group. Genotypes are depicted with the reference 
genotype, GG, on the left, and variant genotype, AA on the right, with the heterozygous 
genotype in the middle. Genotypes observed in the control group are shown in dark 
green, and expected genotypes calculated by the Hardy-Weinberg equilibrium (HWE) 
equation are shown in light green. The chi-square (χ2) and associated p-values are shown 
above the graph.   
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Figure 6.2. Cardiac troponin (cTn-I) and B-type natriuretic peptide (BNP) in 
patients with wild-type (ATTRwt) and inherited (ATTRm) transthyretin 
amyloidoses, with and without the G6S variant. cTn-I (a) and BNP (b) are shown for 
ATTRwt patients used in the serum study (N = 95), separated by the presence of glycine 
or serine at amino acid position 6 by exonic sequencing. cTn-I (c) and BNP (d) are shown 
for ATTRm patients from the serum study (N = 47), also separated based on amino acid 
at location 6. All plots are shown on a log10 scale, and p-values were determined by two-
sided unpaired t-test with Welch’s correction.   
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6.2 Stability of transthyretin G6S 
Using circular dichroism (CD) spectroscopy, the thermal stability, or the temperature 
required to unfold the G6S variant, was compared to wild-type TTR and two 
amyloidogenic variants, L55P and V122I (Figure 6.3). Wild-type TTR is an extremely 
thermodynamically stable protein (Branch et al., 1972; Hurshman Babbes et al., 2008; 
Nilsson et al., 1975), while L55P is reported to be the least stable of all amyloid-
associated TTR mutants (Hurshman Babbes et al., 2008; McCutchen et al., 1993). TTR 
V122I is a moderately unstable pathologic variant (Hurshman Babbes et al., 2008; Jiang 
et al., 2001). In the thermal unfolding analysis, TTR G6S had comparable stability to the 
wild-type protein as demonstrated by the melting temperatures, both Tm = 95 °C (Figure 
6.3a). Mixtures of the two proteins at G6S to wild-type ratios of 3:1, 1:1, and 1:3 
exhibited melting temperatures that were near equal (Tm = 95 ± 1 °C) and indicative of 
extremely stable complexes. 
In contrast, the stability of G6S was much higher than the L55P variant (Figure 
6.3c). The temperature required to unfold the L55P variant was measured at 80 °C, 
indicating a protein that is much less stable than G6S or wild-type TTR. Mixtures of 
L55P and G6S with a greater or equal portion of L55P (1:1 and 1:3) yielded melting 
temperatures similar to L55P alone; these data suggested that the amyloidogenic L55P 
variant destabilized the G6S protein. In a mixture of 3:1 G6S to L55P, a melting 
temperature of 86 °C was obtained, indicating that one subunit of L55P in the tetramer 
was enough to destabilize the G6S protein. 
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Figure 6.3. Thermal unfolding curves of G6S in comparison and in complex with 
other transthyretin variants. TTR G6S (green squares) was unfolded using circular 
dichroism spectroscopy (CD) alone and in complex with wild-type (wt) TTR (a; blue 
squares), V122I (b; yellow squares), and L55P (c; red squares). Each variant, including 
wild-type, was mixed with G6S in 1:3, 1:1, and 3:1 ratios with G6S, as indicated by the 
key and associated diagram on each graph. Melting temperature is indicated by an arrow. 
mdeg indicated millidegree. 
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The G6S variant was also more stable than the V122I pathologic variant, which 
had a melting temperature of 87 °C. However, mixtures of the two proteins yielded 
melting curves that were different than those observed in the experiments with L55P. 
Figure 6.3c shows the results obtained on the mixtures of G6S and V122I. The melting 
temperatures for all G6S and V122I samples were more similar to G6S, indicating that 
the presence of a G6S variant likely stabilized the tetramer in complex with V122I. 
6.3 Transthyretin G6S aggregation 
An in vitro aggregation assay designed to create insoluble high molecular weight (HMW) 
oligomers on pathway to amyloid fibrils was used to analyze the aggregation propensity 
of TTR G6S. As with the thermal stability study, results for G6S were compared to data 
obtained on wild-type and the pathologic variants, L55P and V122I (Figure 6.4). In 
general, HMW oligomers were observed in the gels by 48 hours, while tetrameric TTR 
was the dominant form (Figure 6.4a). Lower molecular weight bands were observed in 
wild-type, G6S, and V122I; these were possibly dimers and other intermediates formed 
subsequent to tetramer dissociation. The monomer was only observed after 4 hours for 
V122I, and was not observed in any of the other TTR variants or wild-type. There were 
no lower molecular weight forms observed for L55P. The same HMW aggregates were 
observed for each TTR type, located at approximately 100, 150, and 200 kDa; these data 
suggested an ordered oligomerization process. For each TTR type, the loss of protein was 
observed over the time course of the experiment, likely due to insoluble oligomer 
precipitation. 
  140 
Wild-type TTR aggregated most slowly, resulting in approximately 50% soluble 
protein remaining after 48 hours (Figure 6.4b). G6S appeared to aggregate at a slightly 
faster rate compared to the wild-type protein; soluble forms of G6S remaining at 24 hours 
were approximately 75% vs. 90% for wild-type. However, both G6S and wild-type 
proteins showed approximately 50% soluble forms remaining at 48 hours, indicating that 
the stabilities of G6S and wild-type TTR are near equal over an extended time interval. 
In highest contrast, the least stable L55P variant rapidly precipitated out of 
solution; 70% soluble protein remained at 4 hours and by 24 hours, the amount had 
decreased to 40%. The V122I variant seemed to be slightly less stable than G6S as HMW 
oligomers appeared to form more rapidly; 65% of the V122I protein was soluble at 24 
hours compared to 75% of G6S. At 48 hours, there was still slightly more soluble G6S 
than V122I (50 vs. 40%). 
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Figure 6.4. Aggregation of transthyretin G6S in comparison to wild-type (WT) and 
variants V122I, L55P. Aggregation curves (a) are shown for each variant, derived as % 
soluble protein from densitometric evaluation of polyacrylamide gels (b) with time points 
under aggregation conditions. Wild-type TTR is shown in blue, G6S in green, V122I in 
yellow, and L55P in red. HMW indicates high molecular weight oligomers; T, tetramer; 
M, monomer; hr, hours of incubation; and kDa, kilodaltons. 
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6.4 Structural modeling of transthyretin G6S 
In order to shed light on the contribution of amino acid replacement to the observed 
stability of TTR G6S, we compared the structure of the protein to that of wild-type and 
the amyloidogenic variants L55P and V122I using the Chimera program (Pettersen et al., 
2004). Overall, the structural model of TTR G6S did not differ from the wild-type protein 
(Figure 6.5a). The N-terminal fragment containing the first 9 amino acids showed an 
unstructured region of the protein located on the outer surface (Hörnberg et al., 2000; 
Schormann et al., 1998) and proximal to the thyroxine binding pocket (Figure 6.5b). The 
presence of the serine residue on G6S did allow for the possibility of an additional 
hydrogen bond (length 3.428 Å) and additional stabilizing interactions not available in 
the wild-type structure (Figure 6.5d); however, no major changes in structure were 
observed in these analyses. Separate complexes of TTR G6S with amyloidogenic 
variants, V122I and L55P, each at a 1:1 ratio of G6S and amyloid protein, demonstrated 
that the G6S residue likely does not directly interact with the other variants. The V122I 
and L55P residues are buried within the protein and found at locations quite distant from 
G6S residues on the tetramer, making interactions likely insignificant (Figure 6.5c). 
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Figure 6.5. Transthyretin G6S structure analysis. TTR G6S (PDB # 1BZD 
[Schormann et al., 1998)]) in tan (residue shown in green) and wild-type (PDB # 1TTA 
[Hamilton et al., 1993]) in blue (residue shown in navy) are shown aligned in tetrameric 
form (a). TTR G6S is also shown aligned with wild-type in complex with diflunisal 
(PDB# 3D2T [Adamski-Werner et al., 2004]), showing the binding pocket proximity to 
the residue (b). An example of 1:1 complexes formed by G6S with L55P (PDB # 3DJZ 
[Cendron et al., 2009]; shown in salmon with the residue in red) and V122I TTR (PDB 
#1TTR [Damas et al., 1996]; shown in yellow with the residue in gold) are shown to 
depict relative residue locations in the tetramer (c). A close-up of the residue and binding 
site on one subunit is displayed along with the added H-bond at 3.428 Å (d). 
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6.5 Summary and conclusions 
In this chapter, we detail the use of several methods to evaluate the stability of TTR G6S. 
Comparative studies of G6S with the wild-type and two amyloidogenic variants, V122I 
and L55P are described. Collectively, the results of these experiments suggest that TTR 
G6S is a structurally stable protein (Tm = 95 °C) with a stability that is equivalent to wild-
type TTR, and the protein exhibits a lower propensity to aggregate compared to 
amyloidogenic variants, L55P and V122I. 
Thermal unfolding by CD demonstrated that, while individually G6S is a very 
stable protein, mixtures with pathologic variants V122I and L55P can destabilize G6S. 
As most patients are heterozygous for the variants, we tested whether G6S could stabilize 
the pathologic variants in heterotetramer complexes. Our experiments showed melting 
temperature shifts from 95 °C for G6S alone to 87 °C and 80 °C in mixtures of the 
protein with V122I and L55P, respectively. TTR G6S stabilized V122I in all ratios, but 
any tetramer containing L55P was destabilized compared to G6S alone, indicating that 
the stabilizing effect of G6S is dependent on the other mutations present. TTR G6S was 
also most stable, along with wild-type, in the aggregation assay. While aggregation of 
L55P and V122I was more rapid with each, yielding only 40% soluble protein after 48 
hours, G6S and wild-type aggregated less slowly and showed 50% soluble protein at 48 
hours. 
One limitation of these studies is that both thermal unfolding and aggregation 
assay results describe only one experiment using each method. Further studies and 
repeated experiments are required to confirm the results. Nevertheless, these data 
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showing the instability and aggregation-prone characteristics of the V122I and L55P TTR 
variants are consistent with results from other studies and suggest that these are valid 
methods to measure the comparative stability of G6S. 
Our modeling of the TTR G6S tetramer suggests that the location and 
biochemical nature of the amino acid replacement in this variant may contribute to a 
stabilizing effect on the tetramer. The N-terminal region where G6S is located is an 
unstructured region of the protein (Hörnberg et al., 2000; Schormann et al., 1998), with a 
low propensity for aggregation by prediction methods (Polimanti et al., 2014). Further 
investigation is warranted to fully understand the effect of G6S on misfolding and 
aggregation, and to determine whether there is an in vivo protective effect on the wild-
type TTR protein. 
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CHAPTER 7. DISCUSSION 
7.1 Non-coding genetic variation may affect transthyretin expression in wild-type 
transthyretin amyloidosis 
7.1.1 Identification of genetic risk factors and functional predictions 
Our genetic study was the first to analyze non-coding genetic variation of the 
transthyretin gene in ATTRwt amyloidosis, and to identify genetic risk factors for disease 
(Sikora et al., 2015). We found 11 common and 20 additional novel variants in the 
ATTRwt population that we studied. Of the common variants, 3 were associated with 
ATTRwt amyloidosis by allele test (rs4799581, rs72922940, and rs3794885), and 4 were 
associated with clinical variables age at onset and survival (rs4799581, rs3764479, 
rs3764478, and rs3794885). Despite the homogeneous nature of the population studied, a 
large number of rare variants were identified, each with a very small occurrence in 1 – 3 
individuals (Hanson et al., 2016). Interestingly, most rare variants were identified in the 
control group. Six of the rare variants were previously unreported. 
Disease association and transcription factor binding predictions implicated 3 
variants located in the proximal promoter region as most likely to affect TTR expression; 
the ATTRwt amyloid-associated mutations identified were rs3764479, rs72922940, and 
rs3794885. The minor allele for rs3764479 (G) was associated with older age at onset 
and shorter survival; this allele was predicted to have less affinity for both HNF and AP-1 
transcription factors. Since the two transcription factors compete for binding at this site, 
the impact of this nucleotide alteration on TTR expression, as suggested by prediction 
methods, was unclear. The non-coding mutation, rs72922940, was strongly implicated as 
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a functional variant; this SNP displayed the strongest association with ATTRwt disease 
by the allele test (p = 0.013) and a near significant (p = 0.083) result after multiple testing 
correction. Furthermore, rs72922940 appeared to drive the haplotype and single-marker 
analyses of all variants identified in the ATTRwt amyloidosis group, indicating a high 
degree of LD in the region and further implicating this particular SNP as the causal SNP. 
These results suggest that rs72922940 is most likely to contribute to ATTRwt disease risk 
through direct interaction with transcription factors. The minor allele (G) was predicted 
to preferentially bind an HNF-family transcription factor, possibly resulting in increased 
TTR expression. The rs3794885 variant demonstrated significant disease association by 
the allele test (p = 0.044), was present in many associated haplotypes, and found to be 
associated with older age at onset of symptoms and decreased survival measured from 
onset to death. Functional analysis predicted that rs3794885 disrupts an HNF family 
transcription factor binding site and may cause decreased TTR expression in individuals 
with this mutation. We posit that for rs3794885 and other variants with similar 
associations (rs4799581, rs3764479, and rs3764478), the development of ATTRwt 
amyloidosis may be later in individuals with these SNPs; however, once disease onset 
occurs, there is a rapid progression of symptoms.  
Additionally, rs3794885 and rs4799581 (located in enhancer region 1) appeared 
to be in moderate LD with rs72922940, but in higher LD with one another. These results 
along with the conditional analyses indicate that there may be two loci of interest, one 
driven by rs72922940 which confers a disease risk and another driven by rs3794885 
which impacts the clinical variables age at onset and survival. However, the LD in the 
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region, along with the strength of the association data, made it difficult to determine 
which (if any) of these SNPs were causal, since none seemed to have an effect 
independent of the others. 
In addition to rs3764479, three other variants (rs2420813, rs3764478, rs1791228) 
were predicted to disrupt transcription factor binding sites even though they failed to 
associate with ATTRwt amyloidosis by the allele test. C/EBP, a known liver transcription 
factor with recognition sites upstream of the TTR gene (Costa and Grayson, 1991; Costa 
et al., 1989) was predicted to preferentially bind the minor allele (C) of rs2420813, which 
could increase TTR expression. An HNF site was predicted to be disrupted by rs3764478, 
potentially causing lowered TTR production. TEAD1, a transcription factor expressed in 
cardiac tissue, was predicted to preferentially bind to the minor allele (C) of rs1791228, 
as was reported by Polimanti and colleagues (Polimanti et al., 2013). This might result in 
TTR expression by the cardiac cells, though TTR expression in cardiac tissue has not 
been demonstrated experimentally. 
There are several limitations to our genetic study which restrict interpretation of 
results. First, our sample groups were modestly sized at 108 ATTRwt patients and 118 
controls, and the reported associations are only nominally (p < 0.05) significant. Using 
the genetic power calculator, we estimate that patient and control groups, each with N = 
261 (more than double the size in each of our groups) would yield 80% power to detect 
an effect similar to that observed for rs72922940 based on a Bonferroni corrected 
significance threshold (p < 0.01 correcting for 5 SNPs). Therefore, data from larger 
sample sets are necessary to confirm the disease associations of the SNPs that we have 
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reported. Unfortunately, achieving these sample sizes is difficult due to the limited 
number of patients diagnosed with ATTRwt amyloid disease at this time. Moreover, there 
is moderate LD across the TTR gene region that we have examined, making it possible 
that the group of variants highlighted in our study may be acting as a proxy for some 
other functional SNP in high LD. However, the possibility that the causal SNP is in LD 
with, but located outside the regions tested in this study, is unlikely since we carefully 
selected our targets for their functional capacity. There is also the chance that one (or 
more) underlying loci exist which is directly linked to ATTRwt pathogenesis; there may 
be more than one causal SNP, and it is also possible that these functional variants affect 
disease by interacting in concert with one another. Therefore, the data presented in our 
genetic analysis offer insight, but do not unequivocally demonstrate which genetic 
variants may be responsible for observed associations. In vitro follow-up studies aimed at 
investigating the functional implications of the identified SNPs were necessary to 
delineate the role of genetic variation in ATTRwt amyloidosis. 
7.1.2 Rare variants and potential implications in wild-type transthyretin amyloid disease 
development 
In our genetic studies, we identified several rare variants located in regulatory regions of 
the TTR gene that were predicted to affect the binding affinities of both hepatic and sex 
hormone receptor transcription factors (Hanson et al., 2016). From our data, we conclude 
that ATTRwt amyloidosis is a disease impacted by non-coding genetic variation in 
multiple ways. The most direct inference is that common variants associated with disease 
may lead to pathogenesis in some individuals, whereas others may be impacted by rare 
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variants. As greater levels of genetic variation are found in non-coding regions 
(Hrdlickova et al., 2014), it is possible that any number of variants could lead to the same 
disease-causing effect of altered TTR expression. Interestingly, the patient with rare 
variant Unreported 05 was heterozygous for the common variants associated with 
ATTRwt amyloidosis (rs72922940 and rs3794885), as well as the common variants 
associated with age at onset and survival (rs3764479 and rs4799581) (Hanson et al., 
2016; Sikora et al., 2015). Unreported 05 was predicted to disrupt androgen receptor 
(AR), AP-1, and C/EBP binding sites. Three individuals with Unreported 06 were found 
to also have both homozygous and heterozygous mutations for several of the common 
variants associated with ATTRwt amyloidosis, disease onset, and survival; this variant 
possibly disrupts an estrogen receptor (ER) binding site which might result in decreased 
TTR expression. It is unclear whether these rare variants are silently inherited along with 
the common risk allele, or whether they contribute to the disease phenotype. 
Furthermore, both common and rare variants may interact together in a complex manner 
of expression regulatory control with some variants increasing expression, others 
decreasing expression, and disease risk resulting only when the SNPs are considered in 
combination. Alternatively, since more rare variants were identified in the control group 
and predicted to affect transcription factor binding, it is possible that some rare variants 
convey a protective effect. 
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7.1.3 Sex hormone responsive elements binding to the transthyretin promoter may be 
impacted by genetic risk variants 
A high degree of sexual dimorphism has been described in ATTRwt amyloidosis, 
indicating that there may be sex-related factors which confer either risk of, or protection 
against, disease (Coelho et al., 2013; Connors et al., 2016; Grogan et al., 2016; Rapezzi et 
al., 2008). Studies have demonstrated an impact of sex hormones on TTR expression 
(Goncalves et al., 2008; Quintela et al., 2008, 2009, 2011) and in our genetic analysis, we 
found that transcription factor binding predictions support these hypotheses. We not only 
found that some sex hormone responsive sites were predicted to be disrupted by some of 
the variants described, particularly the rare variants, but there are also reported 
interactions of sex hormones with liver transcription factors which were predicted to be 
disturbed by our identified variants. Transcription factor interactions and impact on the 
TTR gene are complex and sex hormone responsive elements may impact TTR 
expression in a number of ways. 
A large number of the predicted affected binding sites for rare variants found in 
our ATTRwt group were for sex hormone receptors themselves (Hanson et al., 2016); 
this is in contrast to the common variants, which mostly were predicted to affect hepatic 
transcription factor binding sites (Sikora et al., 2015). This finding is particularly 
interesting in that it supports the hypothesis that females may have a protective factor(s) 
shielding them from developing ATTRwt amyloidosis (Falk et al., 1997; Rapezzi et al., 
2008). Several sex hormone responsive elements have been identified upstream of the 
TTR gene (Meyer et al., 2013), including a distal estrogen responsive element which 
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functions as an enhancer (Martinho et al., 2013). Furthermore, several studies have 
provided evidence to support a role of sex hormones in TTR expression. Exposure to 
testosterone was shown to increase TTR expression to a greater degree than estrogen in 
mouse liver and these data corresponded to an increase in serum TTR levels (Goncalves 
et al., 2008). Testosterone, estrogen, and progesterone were shown to upregulate TTR 
expression in the mouse and rat choroid plexus (Quintela et al., 2008, 2009, 2011). Given 
our finding that many sex hormone responsive elements may be disrupted by rare 
variants, it seems likely that sex hormones could play a role in either disease risk or 
protection.  
Moreover, hepatic transcription factors c-jun and C/EBP, which have binding 
sites upstream of the TTR gene, have been shown to interact with AR (Boruk et al., 1998; 
Bubulya et al., 1996; Kallio et al., 1995; Sato et al., 1997; Shemshedini et al., 1991). Both 
common and rare risk variants identified in our patient group were predicted to disrupt 
binding of these transcription factors. Further, AR inhibits c-jun DNA-binding activity, 
though it is unclear whether c-jun affects AR-DNA affinity (Kallio et al., 1995; Sato et 
al., 1997). Thus, it is possible that AR activity in the liver affects TTR expression either 
through direct interaction with DNA in an androgen responsive element or indirectly by 
binding to other transcription factors. The implication that sex hormones may be involved 
in ATTRwt amyloidosis is exciting given the reported male prevalence of disease; our 
findings suggest genetic complexity in patients with ATTRwt amyloidosis and provide 
numerous avenues for future investigations. 
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7.1.4 Presence of risk variants results in decreased reporter expression 
We chose to focus on defining the effects of common risk variants located in the TTR 
proximal promoter, as these regulatory region mutations seemed most likely to cause 
measurable changes in TTR production. Our reporter studies in HepG2 cells indicated 
that TTR expression decreased in the separate presence of each of the 3 risk variants, 
rs3764479, rs72922940, and rs3794885. Consistent results were obtained in 2 separate 
assays which used reporter vectors to monitor GFP or luciferase expression driven by the 
TTR promoter test sequence; data from the reporter assays were confirmed by qPCR 
analysis. Our results demonstrated that a small, but significant, decrease in TTR 
expression occurred when each promoter variant sequence was present; however, the near 
equal results from the variant testing prevented us from establishing a rank order of SNP 
impact level. 
One complication that arose was our inability to establish a titer for transduction 
of the lentivirus into the HepG2 cells. The FG293 cells typically used in the protocol for 
establishing the pHAGE lentivirus titer (Wilson et al., 2008) did not express any of the 
vectors produced, including a positive control driven by the EF2α promoter. It is likely 
that the cells did not express the reporter driven by the TTR promoter because the 
promoter is specific to liver cells; however, it is unclear why the constitutively active 
promoter did not produce an abundance of signal. Our method for troubleshooting this 
problem included transduction of HepG2 cells with increasing amounts of lentivirus 
containing wild-type TTR promoter. Results from these experiments showed sufficient 
signal from transduced cells. Since all lentivirus were produced concurrently, and thus 
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were likely of similar virulence, we decided to use the same amount of each lentivirus for 
our transduction. 
In the DR1 reporter assay, a minor complication arose when it was observed that 
the signal for transduced and selected cells overlapped with the no virus signal by FACS 
detection. These results indicated that a subset of the selected cell population was not 
expressing DR1. One possible reason for this finding could lie in the design of the 
protein. The destabilized version of GFP attenuates signal by targeting the protein to the 
lysosome for degradation. It is possible that, in some cells, increased trafficking to the 
lysosome caused reduction of signal to undetectable levels. Another possibility is gene 
silencing; a subset of cells may have retained the puromycin resistance while 
downregulating DR1 expression, potentially due to an added stress on the cells caused by 
the lysosome degradation. Nonetheless, MFI evaluation yielded significant results that 
were consistent with the other assays. 
Of note, a limitation in our reporter studies was the use of an immortal cell line 
with chromosomal abnormalities. Although there is widespread acceptance of HepG2 
cells as an experimental model, and several reports have detailed TTR expression and 
promoter studies in these cells, this is an artificial system which cannot truly replicate 
ATTRwt disease conditions. It is possible that transcription factor concentrations may be 
altered in HepG2 cells due to the inherent chromosomal abnormalities, and this may 
affect assay results. One way to address this limitation would be to repeat the reporter 
assays in a disease model of ATTRwt patient-derived induced pluripotent stem cells 
(iPSCs). Using a method developed in Dr. George Murphy’s laboratory, a cell-based 
  155 
system of TTR-producing hepatocytes derived from reprogrammed ATTRwt blood 
mononuclear cells could be designed and used to study TTR expression levels within the 
exact genetic context of the disease (Leung et al., 2013; Sommer et al., 2012). The use of 
iPSC-derived hepatocytes, a truer ATTRwt disease model, would allow clarification of 
results obtained from HepG2 cells related to differences in genetic profiles, and 
potentially facilitate discovery of other genetic or protein factors important in ATTRwt 
amyloidosis pathobiology. 
7.1.5 Risk variants cause subtle changes in transcription factor affinities 
In our structure-function studies using EMSA analysis, no significant differences in the 
binding affinities of the variants and wild-type sequences were noted. This was an 
unexpected finding given our observations from the reporter assays of consistently lower 
TTR expression levels when disease-associated variant sequences were present in the 
proximal promoter. The EMSA results may be reflective of very subtle changes in 
transcription factor binding affinities which are undetectable by the method employed. 
Although a standard ladder was not electrophoresed with these samples, the separation of 
protein/DNA complexes was expected to occur within an appropriately chosen size range 
and compatible in the system that was employed. Based on the BN-PAGE method 
instruction manual by Life Technologies, a protein band occurring at 83% (approximately 
5 cm) of the total gel length (measured from the bottom of the loading well to the bottom 
of the gel) should correspond to 66 kDa; likewise, an electrophoretic migration endpoint 
at 18% from the bottom of the loading well (approximately 1 cm) should approximately 
indicate a 1236 kDa sized protein(s). The upper band observed in our nuclear extract 
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samples electrophoresed to approximately 3% the length of the gel (approximately 2 
mm), corresponding to the reported estimated size > 1200 kDa. As the molecular weights 
of HNF proteins range from 50 – 60 kDa, the substantially higher weight of our observed 
band suggests that this is a complex of transcription factors. This finding increases the 
likelihood that multimeric forms of a single transcription factor or protein complex 
present in this band could have varying affinities for the probes; AP-1 and HNF would 
represent examples of this situation. However, collectively, a complexed group of 
proteins may not show observable differences in affinity. Several transcription factor 
binding sites are reported to be overlapping, and individual transcription factors impact 
expression levels to varying degrees (Qian et al., 1995). Thus, changes in regulatory 
region sequence may allow one factor to bind with greater affinity over another at one 
site, which could have an effect on expression despite the lack of an apparent change in 
signal for the EMSA shifted bands. This may also explain why a possible increase in 
EMSA signal for the rs72922940 variant sequence could result in decreased expression 
levels observed in the reporter assays. 
Since all variants were predicted to disrupt HNF binding sites, it is possible that 
HNF is present in the upper EMSA gel band, and available to interact with all the probes. 
The rs72922940 variant probe showed the greatest difference in binding affinity to 
protein in the top gel band (> 1200 kDa), but further confirmation of this study is 
necessary as results were not overwhelmingly significant. Interestingly, in our functional 
predictions, HNF had a greater affinity for the variant allele of rs72922940, and our 
EMSA observations were consistent with this prediction.  
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Further studies will be required to precisely define the impact of these variants on 
transcription factor binding and expression of TTR. One limitation of our method was the 
non-specific nature of ethidium bromide binding to DNA. Using biotin-labeled probes for 
detection may yield more interpretable results by eliminating background DNA from the 
nuclear extract preparation. We observed a basal level of nucleotide signal in the nuclear 
extract only wells, indicating that the transcription factors retained bound DNA during 
the isolation process. Another advantage of using biotin-labeled probes would be the 
ability to perform competition assays, where specific binding is confirmed with the use of 
unlabeled probe. Since we did not observe significant differences between wild-type and 
variant probe shift signals, we cannot rule out that these were non-specific interactions. 
The shifted band which electrophoresed just below the upper band (~1200 kDa) most 
likely also interacted non-specifically with the probes used in the assay. The use of a 
biotin-labeled probe in the assay would eliminate non-specific interactions; the addition 
of non-specific DNA sequences should restrict interactions with the labeled probes to 
only those that are due to specific binding.  
7.2 Serum transthyretin may be a prognostic indicator in wild-type transthyretin 
amyloidosis 
7.2.1 Serum transthyretin level is a survival predictor 
Although ATTRwt baseline concentrations averaged in the lower range of normal, we 
found decreased serum TTR to be an independent predictor of overall survival (OS) in 
patients with this amyloid disease, along with elevated cTn-I and lowered LVEF. ROC 
analysis demonstrated that TTR and cTn-I had similar individual survival prediction 
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power (AUC, 0.63 vs. 0.64), and an inclusive model combining TTR, cTn-I, and LVEF 
yielded the highest prognostic accuracy (AUC, 0.73). Moreover, we found that patients 
stratified by a TTR baseline concentration of 18 mg/dL (lower normal limit) showed 
significant differences in median OS; patients with TTR levels within the normal range 
(≥ 18 mg/dL) showed better OS (> 4 years) compared to those with decreased levels (< 
18 mg/dL, OS < 3 years). These data suggest that TTR concentration may be a useful 
prognostic indicator, and longitudinal monitoring of TTR concentration may provide 
some indication of disease progression. 
It should be noted that in our survival model, the HR of predictors varied from 
0.89 for TTR to 21.2 for cTn-I. The much larger HR for cTn-I likely reflected the greater 
test sensitivity and smaller unit values (ranging from 0.02 to 2.0 ng/mL) of this metric, 
and accurately indicated the degree of cardiac damage associated with a one unit increase 
in Tn-I. Likewise, the wide CI observed for cTn-I may be indicative of the broad range of 
values reported in our cohort (0.020 – 2.027 ng/mL). When log-transformed, the cTn-I 
HR and CI values were more precise (multivariate HR, 2.57; CI, 1.44-4.56); however, 
interpretation of the transformed data in the context of other variables in the model is 
unclear.  
7.2.2 Serum transthyretin concentration correlates with markers of disease progression 
as demonstrated by diflunisal treatment study 
Our longitudinal data provide supporting evidence for the use of TTR as a prognostic 
indicator in ATTRwt amyloidosis. A subset of ATTRwt patients treated with the TTR 
tetramer stabilizer, diflunisal, exhibited increased serum TTR levels concomitant with 
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decreased BNP and no change in cTn-I over a two year period. These findings indicate a 
potential improvement or delay in progression of ATTRwt cardiac amyloid symptoms 
with diflunisal treatment. In contrast, TTR concentration decreased significantly in an 
untreated group of patients that were not significantly different from the treated group at 
baseline evaluation with respect to age, laboratory, or echocardiographic features. In 
addition, the untreated patients showed increasing BNP and cTn-I over the 2-year 
interval, signs of worsening cardiac function and thus, progression of disease. These 
observations further corroborate the results of our survival analysis, which showed that 
lower TTR concentrations were associated with increased mortality, i.e. shorter survival.  
Despite small group numbers, our results indicate that diflunisal treatment has an 
overall effect of increasing serum TTR concentration, and that this may lead to improved 
survival. The observed increase in serum TTR concentration with treatment fits a model 
in which diflunisal stabilizes tetrameric TTR thereby preventing amyloid fibril formation 
deposition (Adamski-Werner et al., 2004). Conversely, lack of treatment allows for TTR 
misfolding, oligomerization, and cardiac tissue deposition of the protein resulting in 
overall decreased serum concentrations and worsening of disease. As all mechanistic 
actions of the drug have yet to be precisely determined, it cannot be ruled out that there 
may be toxic oligomeric forms of TTR accumulating in the circulation that do not deposit 
in the tissue; however, this is unlikely as serum TTR increases coincided with 
improvement of disease observed via BNP and cTn-I. In addition, it is possible that our 
serum TTR concentrations do not accurately reflect total circulating levels of the protein 
as there may be non-native forms (monomeric or aggregated) not measured in the 
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immuno-based nephelometric assay. Moreover, diflunisal is a non-steroidal anti-
inflammatory drug (NSAID), and in addition to stabilizing tetrameric TTR, the 
therapeutic agent may exert some indirect influence in the disease process related to 
inflammation; of note, TTR is a negative acute phase protein (Johnson et al., 2007). 
It remains to be determined whether total TTR concentrations or tetramer 
stabilization is specifically the link to better prognosis, or whether any increase in TTR 
concentration and/or initially higher TTR levels at disease onset are beneficial. 
Furthermore, although low serum concentrations are associated with poorer outcomes 
and diflunisal treatment results in both higher serum TTR and improved cardiac function, 
it is unclear whether low serum TTR is a cause or effect of ATTRwt amyloidosis. 
Additional studies of expanded patient group numbers should clarify the relationship 
between serum TTR concentrations and survival, and larger follow-up group numbers 
would strengthen conclusions from our longitudinal analysis. 
7.2.3 Low serum transthyretin in wild-type transthyretin amyloidosis may result from 
altered gene expression triggered by genetic risk factors 
Our serological findings indicated that ATTRwt patients with lower serum TTR 
concentrations had significantly shorter overall survival compared to those with normal 
serum TTR concentrations. Furthermore, lowered TTR reporter expression in the 
presence of ATTRwt genetic risk factors supported our proposition that lower levels of 
TTR may confer a risk for disease. However, when the genetic risk factors were assessed 
in patients stratified using the serum TTR concentration threshold of 18 mg/dL, no 
significant differences were observed between the patients with serum above or below 
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this level (Supplemental Table 2). Further investigation is necessary to fully define the 
impact of TTR risk variants on expression levels, whether these sequence alterations 
result in lowered serum concentrations, and whether lower levels of serum circulating 
TTR in ATTRwt patients with worsening disease is a causal factor or an effect of TTR 
amyloid deposition. 
7.2.4 Utility of serum transthyretin as a prognostic metric in wild-type transthyretin 
amyloidosis  
While our data suggest that TTR is a plausible measure of disease progression and 
outcome in ATTRwt amyloidosis, the potential of this plasma protein as a sole biomarker 
of disease is likely low. TTR serum levels can be impacted by a variety of factors 
including age, race, sex (Buxbaum et al., 2008a), and nutritional status due to its short 
half-life of less than 2 days (Oppenheimer et al., 1965), as well as the presence of 
inflammation since TTR can function as a negative acute-phase reactant (Johnson et al., 
2007). These additional features are challenging and must be considered, but the clinical 
use of serum TTR in ATTRwt amyloidosis, a disease mainly described in elder 
Caucasian males, seems reasonable especially if used in combination with other measures 
identified as disease-specific survival risk factors, including cTn-I and LVEF. 
The investigations of ATTRwt serum concentrations detailed in this thesis were 
designed to build upon a recent report from our group describing a prospective, 
observational ATTRwt cohort study which documented the natural history of disease in a 
large series (Connors et al., 2016). While there was some overlap of the patients included 
in the previous and current studies, the two series were not identical and likely contribute 
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to some reported differences. First, the initial report included a larger cohort of ATTRwt 
patients collected between 1994 through 2014, while our study was restricted to patients 
evaluated at the Amyloidosis Center clinic in the interval from 2009 to 2016 for whom 
serum samples were stored and available for TTR quantification. Secondly, our survival 
analysis included TTR values, but excluded other serological and echocardiographic 
markers deemed less significant in the previous report. Therefore, the differences in 
factors associated with survival (BNP, RWT, LVEF, and uric acid) reported by Connors, 
et al. (Connors et al., 2016) and those found in the present study (TTR, cTn-I, and LVEF) 
may be attributed to the variability in patient populations, sample size, or number of 
parameters included in the analyses. Importantly, in both studies, decreased LVEF was 
consistently identified as a predictor of shorter survival and while, in the present work, 
uric acid and BNP did not reach significance in construction of a multivariate model, we 
did find each variable to be an independent indicator of survival by univariate analysis. 
As cTn-I and BNP are both well-recognized and widely used clinical indicators of 
cardiac damage, it is not surprising that one of the two was present in each of the reported 
models of survival risk in an amyloid disease that features mainly heart failure. It is 
probable that both metrics cannot be present in the predicted model due to statistical 
overlap and if analyzed collectively, contribute to a decreased overall significance in the 
model. 
A recent report determined a staging system for ATTRwt amyloidosis based on 
serological measurements of cardiac troponin T (cTn-T) and N-terminal pro B-type 
natriuretic peptide (NT-proBNP) (Grogan et al., 2016), two markers of cardiac function 
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which our center does not routinely measure at the present time. Selection of these 
markers was based on a survival analysis similar to ours, in which the authors identified 
age, LVEF, NT-proBNP and cTn-T as multivariate risk factors in ATTRwt amyloidosis. 
Differences among the studies may stem from the relationship of the markers tested. The 
report by Grogan and colleagues did not include TTR or cTn-I, while our analyses did not 
include cTn-T and NT-proBNP. The troponin proteins, cTn-I used by our group and cTn-
T reported by Grogan, et al., are different forms of a troponin complex which controls 
calcium-mediated actin-myosin interactions, and are measured by different assays 
(Sharma et al., 2004). Similarly, BNP (used by our group) and NT-proBNP (reported by 
Grogan, et al.) are related, as they are two cleaved portions of the proBNP protein, but 
cleared from the serum via separate mechanisms; thus, the two forms of BNP exist at 
different concentrations in the bloodstream and are also measured by different assays 
(Weber and Hamm, 2006). Importantly, at least one of these markers of cardiac damage, 
as well as LVEF, were consistently identified as disease-associated risk factors in all 
studies. Thus, it seems likely that some combination of LVEF with cTn-I, cTn-T, BNP, 
and NT-proBNP may yield the most accurate survival prediction model in ATTRwt 
amyloidosis. It may also be pertinent to determine if any of these cardiac damage markers 
are more predictive, specifically in ATTRwt amyloidosis. Since the current study was the 
only one to consider serum TTR concentration, it may be pertinent to further investigate 
the possible utility of serum TTR as a specific marker of ATTRwt amyloidosis. 
Several limitations of our serum study should be considered. The quantification of 
serum TTR concentrations was performed by immunoturbidity and it is unknown which 
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forms of TTR are recognized by the antibody used in the assay. As ATTRwt amyloidosis 
is a disease characterized by the dissociation, misfolding, and oligomerization of TTR 
(Azevedo et al., 2013), it is unclear which, if any, of these intermediates are 
immunoreactive in the TTR measurement assay. It is possible that the sensitivity and 
specificity of the antibody used in the nephelometric quantification of TTR allows 
accurate assessment of tetrameric and possibly monomeric forms of the protein, but do 
not permit the precise measurement of oligomers present in the serum. Our expression 
studies suggest that TTR production is altered in the presence of genetic risk variants; 
however, several issues have yet to be resolved. It is unclear whether TTR expression is 
uniformly altered in ATTRwt patients; likewise, we have not determined if our 
observation of lowered patient serum TTR levels reflects changes in expression or 
changes due to fibril deposition. Differential TTR expression levels may explain the 
broad range of values (11 – 39 mg/dL) observed at baseline in the ATTRwt group; 
alternatively, it is possible that TTR concentration variability reflects differences in 
stages of disease at baseline evaluation. While studies have shown that TTR amyloid 
fibril formation and deposition are concentration-dependent processes (Johnson et al., 
2012), it is not known whether a continuous decrease in total serum circulating levels of 
the protein occurs during disease progression. Further studies using ATTRwt patient 
samples may help to elucidate the mechanistic contributions of TTR gene expression, 
serum concentration, and fibril deposition in this disease. Lastly, our study lacks the 
inclusion of echocardiographic strain, cardiac MRI, and nuclear imaging data, 
measurements currently considered to be important in monitoring patients with ATTRwt 
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amyloidosis (Gertz et al., 2015b; Maurer, 2015). This study was a retrospective analysis 
and many of the aforementioned metrics were unavailable on patients included in this 
series; furthermore, in those patients with data, the number was small and precluded 
inclusion in our analysis. 
7.3 Wild-type and inherited transthyretin cardiac amyloidoses are related, but 
distinct diseases 
7.3.1 Wild-type and inherited transthyretin amyloidosis patients exhibit differences in 
non-coding genetic variation 
We chose to expand our initial ATTRwt genetic analysis by investigating nucleotide 
variation in the proximal promoter region of a small, age and gender-matched ATTRm 
group with cardiac amyloid disease. The aim was to investigate the presence of sequence 
variants, identified as ATTRwt risk factors, in the inherited form of TTR-associated 
cardiac amyloidosis and to test for associations with disease risk in this cohort. 
Unexpectedly, we found that the opposite allele in 2 of our ATTRwt risk variants, 
rs3764479 and rs3794885, was associated with greater risk for ATTRm amyloid disease 
(Table 7.1). Likewise, the greatest risk factor for ATTRwt, rs72922940, was not 
associated with ATTRm disease. The genetic variation was reversed in ATTRwt and 
ATTRm, suggesting that the non-coding genetic variants impact the diseases differently. 
 
  
1
6
6
 
1
6
6
 
Table 7.1. Comparison of genetic variation in wild-type (ATTRwt) to inherited (ATTRm) transthyretin 
amyloidosis (Olsson et al., 2010; Sikora et al., 2015; Soares et al., 2004) 
SNP 
BU ATTRwt, 
risk allele, 
OR (p) 
Sikora, et al. 
BU ATTRm, 
risk allele, 
OR (p) 
ATTR V30M, risk allele, OR (p) 
Soares, et al. 
 
Olsson, et al. 
Portuguese 
Early onset, 
< 40 y 
Swedish  
Late onset, 
> 60 y 
 
Swedish 
Late onset, 
> 60 y  
rs4799581 
C, 1.56 
(p = 0.019)
a 
 
    
rs3764479 
G, 1.45 
(p = 0.057) 
A, 3.87 
(p = 0.004) 
A, 2.94 
(p < 0.0001) 
A, 1.74 
(p = 0.287)   
rs71383038 
(CA)
9, 1.39 
(p = 0.084) 
 
   
(CA)
10, 2.19 
(p = 0.0034) 
rs72922940 
G, 2.05 
(p = 0.013) 
A, 1.07 
(p = n/s)    
A, 1.43 (p = n/s) 
rs3794885 
T, 1.47 
(p = 0.044) 
A, 2.37 
(p = 0.014)    
T, 2.14 
(p = 0.0041)  
rs62093482 
T, 1.09 
(p = 0.887) 
 C, 3.71 
(p = n/s)   
T, 26 
(p < 0.0001) 
rs1791228 
T, 1.29 
(p = 0.179) 
 C, 3.65 
(p < 0.0001) 
C, 1.18 
(p = 0.828)   
BU indicates Boston University; ATTRwt, wild-type transthyretin amyloidosis; ATTRm, ATTR V30M, inherited 
transthyretin amyloidosis; SNP, single nucleotide polymorphism; OR, odds ratio; C, cytosine; G, guanine; A, adenine; and 
T, thymine 
a
For each study, the associated allele is listed followed by the odds ratio and significance. P-values were determined in the 
current study by chi-square test for independence, in the ATTRm studies by Fisher’s exact test; unreported p-values are 
represented by “n/s”. Blank spaces indicate the SNP was not tested. 
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Literature reports of non-coding genetic variation in ATTRm amyloidosis (Olsson 
et al., 2010; Polimanti et al., 2014; Soares et al., 2004) and our findings of differing 
genetic variants in ATTRwt and ATTRm patients, suggest that these are distinct diseases 
with unique genetic variation, driven by different loci. The non-coding variants 
associated with ATTRwt amyloidosis in our study (Sikora et al., 2015) were not the same 
as, or in LD with, the risk variants reported in ATTR V30M (Table 7.1). The most 
notable difference was for rs62093482, located in the 3’ UTR, where the T allele (freq = 
0.52) was associated with ATTRm and predicted to preferentially bind to miRNA-643 
(Olsson et al., 2010). The C allele (freq = 0.98) was more prevalent in our ATTRwt 
group. Although this SNP was not significantly associated with ATTRwt disease, our 
findings are consistent with the hypothesis presented by Olsson et al.; the authors 
proposed that the T allele of rs62093482 protects against early age development of 
amyloidosis by miRNA regulation and this contributes to the observed late-onset of 
disease in the Swedish ATTR V30M population. Further investigation is required to 
confirm a functional role for this SNP in ATTRwt amyloidosis, since the suggested 
implication for ATTR V30M in the Swedish population (Olsson et al., 2010) was not 
verified in functional studies (Norgren et al., 2012). In our study, this allele was not 
identified in any of the ATTRwt patients and consequently, miRNA control of TTR 
expression may be less important. While the contribution of rs62093482 in ATTRwt 
disease may be small, the SNP may be in LD with other genetic variants that also affect 
TTR regulation in ATTRwt patients. Our sample size was not sufficient to establish an 
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association between ATTRwt amyloidosis and rs62093482 due to the low frequency of 
the T allele. 
Our ATTRm cardiac amyloidosis study predicted the same disease risk allele for 
rs3764479 as the Soares report (Soares et al., 2004) (Table 7.1). In addition, our results 
indicating rs72922940 as an ATTRm disease-associated variant were similar to data from 
the Olsson report (Olsson et al., 2010), though disease risk was not significant in either 
study. The only difference in predictions of ATTRm disease risk factors between our 
study and the others was with respect to rs3794885; the A allele was predicted to have 
significant disease risk (p = 0.014) in our group, while Olsson and colleagues found the T 
allele to be significant (p = 0.0041). One reason for this difference may be that the Olsson 
study was performed exclusively in a cohort of ATTR V30M, while we analyzed patients 
with a variety of ATTR-associated coding mutations in which V30M represented only 
10% of the group. It is possible that these risk alleles are specific to ATTRm amyloid 
disease type as determined by the inherited pathologic mutant. Another explanation for 
the differences in study results may lie in the possibility that these non-coding variants 
are linked to specific coding variants on individual haplotypes, due to the high degree of 
LD in the region. In further studies with larger patient group numbers and separate 
ATTRm disease populations, examining the functions of these variants may parse out 
which scenario is most likely. 
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7.3.2 Serum transthyretin level differentiates wild-type and inherited transthyretin 
amyloidoses 
In comparing ATTRwt and ATTRm patient groups, we found that the two TTR-
associated forms of cardiac amyloidosis exhibited differing serological and survival 
characteristics. While matched for age ≥ 60, male gender and elevated cardiac 
biomarkers, the two groups featured significantly different (p < 0.0001) average serum 
TTR concentrations at baseline evaluation; TTR levels were in the lower normal range 
(23 mg/dL) in patients with ATTRwt amyloidosis and below normal (17 mg/dL) in the 
ATTRm group. In ATTRwt patients, lower TTR concentration at baseline was associated 
with poor cardiac function as measured by elevated BNP and the presence of arrhythmia; 
however, no such associations were found in the ATTRm group. BNP, LVEF, and 
creatinine were associated with survival by univariate analysis in both ATTRwt and 
ATTRm amyloidoses, likely stemming from the selection of study patients featuring 
cardiac involvement. However, lower serum TTR levels were associated with poorer 
survival exclusively in ATTRwt amyloidosis, along with other risk factors including cTn-
I, uric acid, sedimentation rate, and CRP. These differences may indicate pathobiological 
differences in the two TTR-associated diseases and provide evidence to support the utility 
of serum TTR as a prognostic indicator in ATTRwt amyloidosis. However, it is important 
to note that definitive conclusions regarding ATTRm disease predictors cannot be 
gleaned from this study since the patient group was too small to conduct multivariate 
analysis. 
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One concern with the conclusion that the two ATTR diseases are distinct lies in 
the constituency of the ATTRm group used for comparison to ATTRwt. While the 
ATTRwt and ATTRm groups were matched for age ≥ 60 years, male gender and cardiac 
involvement, 13/29 (44%) of the ATTRm group self-identified as African American with 
the V122I variant (the 2 others with V122I self-identified as Caucasian and mixed-race), 
and 93/95 (98%) of the ATTRwt group self-identified as Caucasian. Since serum TTR is 
reportedly lower in African Americans males, aged ≥ 60 years compared to gender- and 
age-matched Caucasians (254 vs. 262, p = 0.004) (Buxbaum et al., 2008a), this may 
contribute to the lower serum TTR concentrations observed in our ATTRm group. We 
cannot completely rule out that ethnic variability between the ATTRwt and ATTRm 
groups contributed to dissimilar results from the Cox analyses; however, data from 
studies reported in this dissertation and other investigations in our laboratory strongly 
suggest that the ATTRwt and ATTRm cardiac amyloidosis are TTR-related diseases, but 
distinct pathologies impacted by different factors and separate mechanisms. 
7.4 Transthyretin G6S may be protective in transthyretin-related amyloidosis 
7.4.1 G6S allele prevalence suggests genetic selection 
An unexpected finding from our initial genetic analyses indicated that TTR G6S may be a 
protective variant in ATTRwt amyloidosis. Further data that supported this finding 
included: 1) the skewed HWE exhibited by the healthy control group, suggesting allele 
selection; 2) a lower frequency of G6S in both ATTRwt and ATTRm groups compared to 
healthy controls and the reported general population level (Jacobson et al., 1995); and 3) 
  171 
a correlation of G6S with lower cTn-I and BNP values in ATTR patients, indicating 
lesser disease severity. 
Importantly, the small numbers of patients (ATTRwt, N = 108; ATTRm, N = 29 
selected, N = 47 unselected) and controls (N = 118) in our comparison groups were a 
limitation in the genetic studies of TTR G6S. Assigning significance in the occurrence of 
G6S in groups of 29 to 118 was challenging given the reported frequency of 6% for the 
variant (Jacobson et al., 1995), and statistical interpretation was complicated. Although 
we did reach significance in many of our tests, the small group numbers leave some 
uncertainty in the results. Only larger groups can validate our findings. However, we 
found the lower than expected frequency of TTR G6S in both patient groups compelling 
and further investigated the impact of this amino acid replacement on TTR protein 
stability and aggregation. Our aim in these additional studies was to provide further 
evidence in support of our genetic prediction that G6S is a disease protective mutant. 
7.4.2 G6S presence stabilizes tetrameric transthyretin and slows aggregation of the 
protein 
The structural studies corroborated our genetic findings and indicated that G6S is a stable 
TTR variant that may function to protect against tetramer dissociation and misfolding in 
complex with some pathologic variants. In the thermal unfolding studies, G6S had 
comparable stability to the highly stable wild-type TTR. In complex with V122I, G6S 
had an overall stabilizing effect on the heterotetramer; conversely, when complexed with 
L55P, the least stable TTR variant, the protective effect of G6S was diminished. Thus, 
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results from these studies suggested that the tetramer stabilizing capacity of G6S is 
dependent on variant structure and stoichiometry in the complex. 
It is unlikely that G6S stabilizes the amyloidogenic mutant TTR in complex by 
direct residue interaction, due to the lack of proximity of the mutant residues to the N-
terminus. Therefore, it is more probable that overall structural changes contribute to a 
tetramer stabilization effect. The V122I mutant destabilizes the protein (Hurshman 
Babbes et al., 2008; Jiang et al., 2001) at the tetramer disassociation or rate-limiting step; 
this is consistent with our CD data showing G6S in complex with V122I exerting a 
greater overall stabilizing effect on the tetramer. In contrast, the L55P variant is reported 
to cause the most destabilizing effect on the TTR monomer (Hurshman Babbes et al., 
2008); this was in agreement with our finding that G6S was less able to stabilize 
tetrameric complexes formed with the L55P variant. 
The results of the aggregation assay provide further evidence that G6S is a stable 
form of TTR, more resistant to aggregation than the unstable variants V122I and L55P. 
Differences in the amounts of lower molecular weight species formed by each TTR 
variant and the wild-type protein, assessed by electrophoretic monitoring, likely stem 
from tetramer and monomer stabilities; the tetramer is stable in wild-type and G6S forms, 
and the monomer is stable in V122I. This may explain why we only observed monomer 
for V122I, as it may exist as an intermediate for a longer period of time; conversely, in 
amyloid fibril formation with wild-type, G6S and L55P, monomeric TTR may be a more 
transient reaction species. Particularly for L55P, all lower molecular weight intermediates 
may be extremely short-lived and this may explain why we observed no lower molecular 
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weight protein bands. Further studies probing mixtures of these unstable variants with 
G6S, as in the thermal unfolding assay, may yield more insight into the potential 
stabilizing effect of G6S. 
The N-terminus may be an important stability-affecting component of TTR and 
the location of serine at residue 6 in this region may be more than coincidental. The first 
9 N-terminal residues of TTR exhibit no defined conformation (Hörnberg et al., 2000; 
Schormann et al., 1998); thus, the positioning of the unstructured N-terminus could affect 
the surface accessibility of lysine 48, a potential site for proteolytic cleavage leading to 
fragments found in amyloid fibrils (Dwulet and Benson, 1986; Gustavsson et al., 1991; 
Schormann et al., 1998; Thylén et al., 1993; Wallace et al., 1986). The G6S amino acid 
substitution could allow for more hydrogen bonding, potentially with the backbone 
between glycine 57 and leucine 58, which would create a more stabilized structure and 
thus, a plausible explanation of how G6S protects from amyloidosis. Furthermore, the N-
terminal region has a lower propensity for interactions that lead to self-aggregation by 
prediction methods (Polimanti et al., 2014) and experiments have demonstrated that the 
N-terminus is an unstructured region resistant to protein aggregation (Wilce et al., 2002). 
Crystallographic analyses of the TTR tetramer have shown that the N-termini of 
the subunits extend near to the entrance of the central channel where the thyroxine 
binding pockets are located (Hamilton et al., 1993). Although the overall TTR structure 
and amino acid sequence of the thyroxine binding pocket are highly conserved (Schreiber 
and Richardson, 1997), most evolutionary sequence changes have occurred in the N-
terminal region, particularly as a shortening of the polypeptide chain in this region 
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(Aldred et al., 1997; Manzon et al., 2007). Both the length and hydrophobicity of the N-
termini were shown to influence thyroid hormone binding affinity (Morgado et al., 2008; 
Prapunpoj et al., 2002, 2006). Specifically, a loss of the 6 N-terminal residues decreases 
sea bream TTR tetramer (highly conserved with human TTR) binding affinity for T4 
(Morgado et al., 2008). Interestingly, this loss also decreases the acid-mediated 
aggregation propensity of the protein (Morgado et al., 2008). 
Moreover, the binding affinity of RBP4 has been shown to be influenced by 
amino acid changes in the TTR N-terminal region; specifically, the strongest binding of 
RBP4 was observed for longer, more hydrophobic N-terminal chains on TTR, and 
weaker binding for shorter, less hydrophobic chains (Leelawatwattana et al., 2011). As 
G6S confers a shift to a less hydrophobic N-terminal chain, it would seem that this 
variant might exhibit a weaker binding affinity to RBP4, but this has not been 
demonstrated experimentally. It is important to note that RBP4 reportedly binds TTR 
through interactions with the C-terminus, and there is no evidence to indicate that the 
unstructured 10 N-terminal amino acids of TTR are directly involved in binding 
(Monaco, 2000, 2002), despite their close proximity to the C-terminus. While it is likely 
that N-terminal changes have no direct effect on RBP4 binding, the impact of amino acid 
changes in this region of TTR may lead to slight structural perturbations which would 
indirectly result in changes of binding affinity between the two proteins 
(Leelawatwattana et al., 2011).  
Although our studies suggest that serine 6 may be an important structural residue 
which stabilizes tetrameric TTR and protects against the aggregation cascade, the greatest 
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limitation to our study is the lack of repetition. Our results represent just one set of data 
points. In order to fully conclude that G6S is an important stabilizing and protective 
residue, experimental confirmation of these data in repeated and expanded studies is 
required. Furthermore, the CD examination of TTR thermal unfolding could be analyzed 
more accurately with a more complete set of melting curve data points. We never 
achieved complete thermal unfolding as indicated by a plateau at the top of the melt 
curve, making accurate calculation of the melting temperature a challenge. TTR 
denaturation was studied in the presence of urea in an attempt to achieve complete 
unfolding as the native protein is extremely stable with a reported Tm beyond the limits of 
instrumentation. A true thermal melting curve should be conducted in the absence of 
urea, though it is not clear that CD analysis is appropriate for achieving the temperatures 
required to completely unfold wild-type and G6S forms of TTR. To avoid evaporation, 
oil can be used to cover the protein solution during melting. Another, possibly more 
viable strategy would be to conduct a chemical denaturation curve with urea, by 
increasing amounts of urea over time to induce denaturation. 
7.5 Future directions 
7.5.1 Expansion of genetic studies 
Although we were able to achieve significance in our genetic study, expanding the group 
sizes would strengthen our results. Typical group sizes for genetic studies range from 
several hundred to thousands of participants, and required group numbers increase with 
the size of the genetic regions and number of variants being tested. Another way to 
confirm our findings would be through the use of a validation cohort of ATTRwt 
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patients. This would entail enrollment of the same number of patients in a new study of 
the same gene regions, and testing of the same risk variants to check for consistency. A 
larger group size would also benefit our rare variant study. The extremely low rate of 
these variants made analysis difficult; enlarging group sizes would allow more accurate 
assessment of the rarely occurring and common variants. Lastly, though this possibility is 
currently unrealistic, a genome-wide association study (GWAS) could be especially 
beneficial to the field. Unfortunately, these studies require much larger group numbers 
than would be possible to attain, even in collaboration with other research groups. A 
more targeted approach may be possible with studies of alternative genes and encoded 
proteins linked to the TTR-associated amyloidoses, such as RBP4, clusterin, and serum 
amyloid P; such investigations would still require a large group and likely not be feasible 
until disease recognition improves and study groups can be expanded. 
Due to the highly complex nature of transcription factor binding effects on 
expression, further studies investigating the functionality of these variants in vitro would 
help to define exactly how rare variants impact disease. The intricate interactions of rare 
variants and the balance of positive and negative consequences on TTR expression was 
beyond the scope of our aims; while complex, this would be an intriguing avenue for 
future studies. Our studies suggest rare variants may have an impact on ATTRwt disease, 
but large sample sizes are required to establish an effect via genetic association testing. 
The number of patients in our study (N = 108) precluded an accurate assessment of rare 
variant impact on gene function; moreover, functional studies on any of these rare 
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variants would only yield data on a small percentage of patients afflicted with ATTRwt 
amyloidosis. 
7.5.2 Performance of more in-depth reporter expression studies 
It would be interesting to further investigate the role of non-coding variants in reporter 
assays. More risk variants could be tested in the assays employed in our studies, such as 
those located in the enhancer regions. Further, it may be pertinent to explore interactions 
between risk variants by adding mixtures of the variants into the vector for comparison to 
the single variants. This strategy would be more biologically relevant as most patients 
have more than one risk variant in TTR upstream regions, though results from such 
studies may be more complicated to interpret. It may also be interesting to test rare 
variants in the reporter assays to see if these SNPs do, in fact, impact TTR expression. 
Testing many variants may help to determine whether there is an overall effect of altered 
TTR expression that can be achieved by multiple non-coding variants; this possible 
complexity, at the gene level, may explain why no genetic predisposition has been 
identified in ATTRwt amyloidosis. An alternative scenario may be that some non-coding 
variants confer a certain, likely small, level of risk only when present in a specifically 
arranged order that favors disease development. 
Further studies might also include experiments using the iPSC-derived patient 
hepatocytes. We designed our reporter assays on the pHAGE lentiviral background in 
order to be able to utilize these patient-specific models in future studies. There are a 
multitude of directions in which the expression studies should proceed utilizing these 
cells; for example, many lines could be created to test whether a patient’s genetic 
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background uniquely affects expression. In addition, variants could be tested in more than 
one patient cell line to see if effects are consistent, and thus entirely dependent on the 
variant. Another possible strategy using these cells could be to insert desired risk variants 
into the genomic DNA and measure actual TTR expression compared to the endogenous 
levels.  
It would also be interesting to investigate the role of sex hormones and sex 
hormone receptors in TTR gene regulation. This would be pertinent since there is a clear 
gender disparity in ATTRwt amyloidosis, and our genetic study identified many rare risk 
variants that potentially disrupt sex hormone receptor binding sites. Given the 
interactions between AR and liver transcription factors, studying the common risk 
variants may be pertinent as well. 
Our EMSA studies suggest that a transcription factor in the slowly migrating, 
upper gel band (> 1200 kDa) binds to probes containing the tested SNP sequences with 
varying affinities, though significance was not achieved in these analyses. Now that a 
“proof of concept” has been established, follow-up studies with labeled probes would 
help to parse out the small differences in binding affinity among the variants that were 
initially tested and possibly uncover significant impact affects. As mentioned previously, 
use of labeled probes would also allow for competition assays which would aid in 
confirmation of binding specificity. Future strategies to identify proteins present in the 
top gel band would include the use of mass spectrometry and immuno-based techniques; 
it is likely that numerous transcription factors and/or complexed proteins are present and 
will require extensive study. Once identified, key proteins in the group that associate with 
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the mutant sequences could be further tested with the use of recombinant replicates to 
confirm binding by EMSA. These proposed studies would constitute a comprehensive 
analysis of the genetic factors associated with ATTRwt amyloidosis. 
7.5.3 Extension of serum transthyretin study 
The greatest limitation to our exciting longitudinal serum findings was the small number 
of patients who returned for evaluation partly due to the lack of treatment and also 
because of the short time interval between diagnosis and death. It would be beneficial to 
expand these group sizes by including more follow-up sera in our analysis. 
Unfortunately, we rely on patient longitudinal evaluations for these results, and some 
time may pass before we can accrue a larger sample size. Any expansion of our small 
numbers would be beneficial and we are hopeful that as diagnosis improves and 
treatment options become available, the sample size will continue to increase. As in the 
genetic study, a validation cohort could confirm our findings, and would offer an 
opportunity to stratify risk factors, possibly with the intent of developing a disease 
staging system. Although the Mayo Clinic recently reported a stratification schema for 
ATTRwt amyloidosis based on cTn-T and NT-proBNP (Grogan et al., 2016), many 
centers, including our own, use alternative biomarkers which could be equally predictive. 
7.5.4 Follow-up studies of G6S stability 
Our stability studies require more data and additional assays to support our hypothesis 
that G6S is an ATTR disease-protective variant protein. Since our studies suggest that 
G6S and wild-type TTR have comparable structural stabilities, it would be interesting to 
study mixtures of V122I and L55P with wild-type to compare to the G6S mixtures. As 
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the aggregation assay results represented only one experiment, further studies would be 
required to draw conclusions from these data. It may also be interesting to examine 
mixtures, used in the CD analyses, in the aggregation assay to see if the G6S stabilizing 
effect in heterotetramer complexes protects against aggregation. Finally, our stability 
studies could be supported by other methods; appropriate testing might include 
determination of an aggregation index by light spectroscopy during unfolding and 
temporal quantitation of Congo red or Sypro orange binding to aggregates and/or 
unfolded TTR in an amyloid fibril formation assay.  
7.6 Summary and significance 
This body of work demonstrates that ATTRwt amyloidosis is a unique disease, separate 
from the related ATTRm amyloidosis, which can be impacted by serum TTR 
concentrations, possibly as a result of expression changes driven by non-coding genetic 
variation of the TTR gene. This dissertation details identification of genetic risk factors 
for ATTRwt amyloid disease, demonstration that genetic variation differs from that in 
ATTRm patients, confirmation that reporter expression driven by the TTR promoter 
decreases in the presence of genetic risk factors, a connection of low serum TTR levels to 
worse survival and prognosis, and shows that the presence of the G6S variant may protect 
against destabilization and aggregation of TTR. Based on these data, a model of ATTRwt 
amyloidosis is presented which incorporates our findings and hypotheses into the TTR 
amyloid hypothesis (Figure 7.1). We propose that the genetic risk factors identified in 
our study decrease TTR expression and contribute to the amyloid cascade, possibly by 
triggering further dissociation of the tetramer due to already decreased serum 
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concentrations (Figure 7.1b). We also hypothesize that G6S confers protection by halting 
or stalling the amyloid cascade at both the tetramer and oligomer stages by stabilizing the 
native structure and slowing aggregation (Figure 7.1c). 
The potential clinical implications of this work are the inclusion of TTR in 
clinical work-ups and verification that stabilizing treatments improve disease. 
Mechanistically, this thesis provides evidence of a genetic predisposition for ATTRwt 
amyloidosis, which may impact disease through altered TTR expression. We showed 
experimentally that expression levels do change in the presence of these genetic risk 
variants, and we demonstrated that G6S-TTR does stabilize the tetramer and reduce 
aggregation rates. This work advances the field by providing mechanistic 
characterization, identifying risk factors of disease, and contributing evidence in support 
of biomarkers which may have utility in disease diagnosis and monitoring. Moreover, our 
hypotheses are consistent with current ideologies. 
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Figure 7.1. Changes to the transthyretin amyloid cascade that occur with risk and 
protective factors identified in our studies. The normal state of TTR expression, known 
to be driven by hepatocyte nuclear factors is shown (a). Acceleration of the amyloid 
cascade in disease state is depicted in response to genetic risk factors and lowered serum 
TTR (b); and deceleration of the cascade is depicted in the presence of protective variant 
G6S (c). 
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Supplemental Table 1. Eleven common variants identified 
in wild-type transthyretin amyloidosis (ATTRwt) and 
control subjects 
SNP 
Location, 
Chr 18a 
Minor 
(Common) 
Alleles 
ATTRwt, 
MAF 
Control, 
MAF 
rs2420813 29161365 C (T) 0.44 0.35 
rs4799581 29161511 C (T)  0.49 0.38 
rs34047090 29169213 
A duplication 
(no duplication) 
0.47 0.40 
rs3764479 29169825 G (A)  0.43 0.34 
rs3764478 29170483 T (G)  0.12 0.13 
rs71383038 29170616 (CA)9 ((CA)10) 0.44 0.36 
rs72922940 29170698 G (A)  0.17 0.09 
rs3794885 29171123 T (A)  0.44 0.35 
rs1800458 29172865 A (G) 0.04 0.08 
rs1791228 29179040 C (T) 0.45 0.52 
rs75032823 29179228 A (G) 0.12 0.13 
ATTRwt indicates wild-type transthyretin amyloidosis; SNP, single 
nucleotide polymorphism; Chr, chromosome; MAF, minor allele 
frequency; C, cytocine; T, thymine; A, adenine; and G, guanine  
aAssembly GRCh37.p13 
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Supplemental Table 2. Sensitivity and 
specificity for 3-year mortality  
Threshold Sensitivity Specificity 
TTR 
<33 100% 8% 
<31 99% 10% 
<29 93% 20% 
<26 88% 36% 
<24 66% 44% 
<22 53% 62% 
<21 44% 72% 
<20 33% 81% 
<18 28% 87% 
<17 19% 94% 
<14 6% 99% 
cTn-I 
>0.020 99% 1% 
>0.042 94% 10% 
>0.060 83% 20% 
>0.075 77% 29% 
>0.097 73% 45% 
>0.130 62% 63% 
>0.172 53% 76% 
>0.202 40% 83% 
>0.289 22% 90% 
>0.550 11% 97% 
>0.674 9% 99% 
LVEF 
<65% 99% 8% 
<60% 89% 22% 
<50% 77% 55% 
<45% 49% 66% 
<40% 31% 75% 
<35% 16% 87% 
<30% 7% 94% 
<25% 2% 98% 
TTR indicates transthyretin; cTn-I, cardiac troponin; 
LVEF, left ventricular ejection fraction 
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Supplemental Table 3. Chi-square (χ2) analysis of risk variants in wild-type 
(ATTRwt) and inherited (ATTRm) transthyretin amyloidosis stratified by 18 mg/dL 
cutoff 
Variant 
< 18 mg/dL 
MAF 
≥ 18 mg/dL 
MAF 
χ2 P 
rs3764479 0.25 0.35 1.27 0.259 
rs72922940 0.12 0.18 0.528 0.468 
rs3794885 0.38 0.46 0.760 0.383 
MAF indicates minor allele frequency 
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Supplemental Figure 1. Box plots showing remaining variants significantly 
associated with age at onset and survival from onset. Both associations are shown for 
rs4799581 (a), rs3764479 (b), and rs3764478 (c). 
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Supplemental Figure 2. pHAGE-TTR-luciferase HepG2 cell titration. HepG2 cells 
transduced with pHAGE-TTR-luciferase with the wild-type TTR promoter (WT), or one 
of the risk variants (rs3764479, rs72922940, rs3794885) and a no virus control were 
titrated from 10,000 cells per well to 1 cell per well in 96 well plates and luciferase signal 
was quantified. No major differences in signal are observed between cell lines, 
particularly at lower cell numbers. Variants are denoted by the last 3 digits in each plot.  
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Supplemental Figure 3. Luciferase signal in HepG2 cell titration. HepG2 cells 
transduced with pHAGE-TTR-luciferase were titrated from 10,000 cells to 1 cell per 
well, and the average signal for 6 replicates is graphed for each cell line: no virus control 
in pink, wild-type TTR promoter in yellow, variant rs3764479 in gold, variant 
rs72922940 in green, and variant rs3794885 in blue (a). The no virus signal was used to 
subtract background luciferase signal from the transduced variants (b). Comparable 
signals were observed for the variants at each cell number. Variants are denoted by the 
last 3 digits in each plot. 
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Supplemental Figure 4. Coomassie staining of HepG2 cell nuclear extract for 
electrophoretic mobility shift assay (EMSA) analysis. Upper and lower bands stained 
with Coomassie substitute (Gelcode Blue). The Coomassie G-250 dye front was run to ~1 
cm from the bottom of the gel. 
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